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Mammalian skeletal muscle has a major impact on whole-body metabolic homeostasis. 
Hence, maintenance of a metabolically active muscle mass is key for optimal health. 
Notably, both muscle function and mass are profoundly negatively affected by 
environmental factors such as chronic smoking and physical inactivity. 
 
RNA abundance integrates genetic, epigenetic and environmental influences. Therefore, 
while true understanding of physiological adaptation likely require the integration 
between muli-level datasets, the transcriptome represents a powerful investigative tool in 
determining the underlying molecular mechanisms behind complex phenotypic traits. 
 
The overarching aim of this thesis was to evaluate, using omics-based systems biology 
approaches, the global regulation of RNAs during exogenous modulation of mammalian 
muscle phenotype in order to characterize local homeostatic processes as well as identify 
robust biomarker signatures. 
 
The first part of this thesis deals with smoke-induced peripheral muscle wasting. 
Initially, biological domain knowledge is used to validate a pre-clinical smoking model. 
Then, specific cytokines are statistically linked to limb muscle energy metabolism; a 
testable hypothesis supported by both animal and human data. 
 
The second part deals with the development of ‘molecular predictors’ of endurance 
training adaptability. Two complex clinically relevant traits are considered, namely 
whole-body insulin sensitivity and plasma triglyceride content. Promisingly, quantitative 
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1 General Introduction 
	  
1.1 Mammalian skeletal muscle tissue 
Skeletal muscle, as a consequence of its mass and great metabolic capacity, has a major 
impact on whole-body metabolic homeostasis [1, 2]. Besides the obvious role in 
locomotion, breathing, and postural maintenance, skeletal muscle is an important 
thermogenic tissue as well as a significant determinant of the body’s overall basal 
metabolic rate (a reflection of the body’s ‘idling speed’) [3, 4]. As a consequence of this, 
the maintenance of a metabolically active muscle mass is key for optimal health. In line 
with this notion, previous epidemiological studies have shown an association between 
peripheral skeletal muscle weakness and all-cause mortality [5–7]. 
More recently, less intuitive skeletal muscle functions such as endocrine and possible 
immune effects have been reported in the literature [1]. 
 
1.1.1 Skeletal muscle fibre types and properties 
Skeletal muscles are made up of bundles of long aligned myofibers (aka fascicles). The 
myofibers usually extend the entire length of the muscle. Each myofiber is a 
multinucleated, terminal differentiated cell formed by the fusion of multiple myoblasts. 
There are about 600 different muscles in the human body, ranging in size depending on 
anatomical location; the smallest only contain a few hundred myofibers whereas the 
powerful thigh muscles contain several hundred thousand myofibers [8]. 
 
Myofibers can develop tension and shorten (i.e. contract) by moving specialized cellular 
components; so-called cross-bridge interactions between actin and myosin molecule 
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complexes leading to a conformational change. The muscle cross-bridge cycling is 
heavily dependent on ATP, however this energy-rich molecule is only immediately 
available in tiny amounts (enough to sustain contractions for a few seconds only). As a 
result, the myofibers rely on several intracellular pathways to supply additional ATP 
when needed: creatine phosphate (phosphocreatine), oxidative phosphorylation (OxPhos) 
and glycolysis. 
OxPhos, which takes place within the mitochondria (a self-replicating organelle), is a 
multi-step pathway that effectively harnesses energy from the breakdown of nutrient 
molecules such as glucose and fatty acids (32 ATP molecules/glucose molecule). 
Notably, oxygen is required to support the mitochondrial respiration. If the delivery of O2 
from the vasculature to the mitochondria is impaired, whatever the reason might be, the 
anaerobic glycolytic pathway will immediately take over. Further, glycolysis will also 
kick in if OxPhos is not able to meet the muscle’s demand during intense physical 
activity. During glycolysis, sugars are chemically broken down to pyruvate aerobically or 
lactate anaerobically, yielding two ATP for each glucose metabolized. Pyruvate is then 
further degraded by OxPhos to yield more ATP. 
 
Histochemistry (e.g. anti-myosin adenosine triphosphatase staining) has shown 
that mammalian myofibers can have different physiological/biochemical properties. 
Based on such properties fibers are defined as ‘Type I’ or ‘Type II’ [9]. Notably, the 
latter term is further sub-classified into Type IIa and Type IIx based on ATP-synthesizing 
ability. 
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Because of the different properties highlighted in Table 1-1, myofibers have distinct 
‘tasks’: Type I fibers are responsible for postural support and prolonged low-intensity 
activities as a result of the high mitochondrial density. In contrast, Type II fibers are key 
players during mechanical loading. 











MHC1 MHC2A MHC2X 
Contractility Slow twitch Fast twitch Fast twitch 
Colour of fiber Red Red White 
Resistance to fatigue High Intermediate Low 
Recruitment 
threshold 
All intensities >40% VO2max >75% VO2max 
Morphological properties 











High Moderate-High Low 










Table 1-1 | Characteristics of the different human skeletal muscle fibre types. 
Adapted from Egan & Zierath [10]. 
 
Adult mammalian skeletal muscles contain different proportions of myofiber types 
depending on the anatomical location. As a result of this diversity, individual muscles 
overall have different contractile speed, strength and resistance of fatigue (Table 1-1). 
 
Noteworthy, adult skeletal muscles have the capacity to adapt at the myofiber level to 
various exogenous stimuli such as alterations in hormonal milieu, chronic systemic 
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disease or long-term exercise training. Adaptations include growing or shrinking as well 
as switching the expression of myosin heavy chains genes [11, 12]. 
 
The vastus lateralis thigh muscle, the human muscle tissue of interest throughout the 
thesis, is composed of ~50% slow-twitch type I fibres in healthy sedentary subjects [13]. 
However, as extreme examples of the potential for adaptation, in elite sprinters the vastus 
can be made up of >70% fast fibres [14], whereas world-class cyclists and marathon 
runners can have less than 40% [12]. 
 
1.1.2 Skeletal muscle adaptation 
Skeletal muscle is a highly plastic organ⎯2nd to the nervous tissue only⎯that readily 
changes its phenotype in response to various repeated stimuli (or lack of stimuli due to 
inactivity or denervation) [15]. Such stimuli include among others changes in mechanical 
loading (e.g. strength training, microgravity) [16], neuromuscular activity (e.g. endurance 
exercise training) [10], and metabolic perturbations (e.g. nutrient availability, tissue 
hypoxia) [17, 18]. This adaptability is an important feature of skeletal muscle tissue as it 
allows for its economic ‘design’ by maximizing intracellular biochemical processes.  
 
From a molecular perspective, any adaptation can ultimately be viewed as the accretion 
or loss of key proteins induced by a given stimulus. Accordingly, the altered gene 
expression response that initiates changes in intracellular protein concentrations⎯by 
making more mRNA available for ribosomal translation⎯is of significant importance. 
Currently, much of our understanding of skeletal muscle gene expression (as reflected by 
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mRNA abundance) is focused at the level of transcription, orchestrated by a complex 
network of transcription factors and their co-regulators. 
Theoretically, muscle gene expression can be controlled by i) regulating the number of 
myonuclei (i.e. DNA content), ii) gene transcription rate, iii) post-transcriptional control, 
iv) mRNA translation and v) muscle protein degradation, with each of these molecular 
events being susceptible targets of regulatory influences triggered by the stimulus (e.g. a 
bout of exercise). 
The involvement of cell signaling pathways in the transduction of various stimuli into the 
activation of specific gene expression events is widely recognized [19]. Such changes in 
muscular gene expression ultimately result in an incremental adaptation in protein level 
as well as activity (e.g. enzymatic activity), thus modifying the structural composition 
and/or functional properties [10]. Hence, gene expression is an important layer of 
processing for the integration of various exogenous stimuli into the adjustments of 
‘muscle makeup’ necessary to match muscle function to alterations in demand. 
Although considerable progress has been made in understanding the functional 
adaptations of skeletal muscle at the cellular level, the underlying molecular pathways 
remain obscure, especially those related to translational regulation. In fact, the abundance 
of a particular mRNA does not necessarily reflect the level of the corresponding protein. 
This is because the complex mechanisms that regulate protein expression are not 
dependent on mRNA alone [20]. Finally, the majority of molecular mechanism suggested 
to govern muscular adaptation in humans, originate from in vitro cell models and animal 
studies (e.g. knock-out mice). Hence, more clinical studies are currently needed to help 
shed more light at the molecular level. 
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1.1.2.1 Skeletal muscle protein turnover 
Skeletal muscle plasticity is, at least in part, due to a dynamic balance between protein 
synthesis and degradation. Any shift in this balance will lead to qualitative and 
quantitative alterations in myofibers and associated structures. The muscle protein 
turnover is known to be influenced by a numerous of extrinsic (e.g. feeding, fasting, 
mechanical loading, immobilization) and intrinsic factors (e.g. hormones, disease). 
Notably, an imbalance between protein synthesis and breakdown (i.e. higher degradation 
or reduced synthesis rates) has been reported to be a key mechanism for the loss of 
skeletal muscle mass and function [21]. Of particular interest to this thesis are two 
factors: i) chronic obstructive pulmonary disease (COPD)-induced peripheral muscle 
dysfunction, and ii) progressive endurance exercise training. 
 
1.1.3 Interindividual variability in skeletal muscle adaptability 
A large variability in the responsiveness and degree of peripheral skeletal muscle 
adaptation is observed among individuals ⎯ despite using carefully controlled exercise 
training regiments as stimuli [22, 23]. A number of factors have been reported to 
affect⎯although only to a minor degree⎯this adaptive response such as age, nutritional 
support and genetic predisposition. 
Notably, Timmons and co-workers have demonstrated that specific genes might 
determine, at least in part, how much aerobic fitness increases (i.e. gain in VO2max) 
following progressive endurance exercise [24]. They demonstrated that a group of 29 
genes could categorize individuals into low, medium, and high responders to endurance 
exercise based on three independent data sets. Similar approaches are also required to be 
applied to other important clinical endpoints in order to provide initial clues as to what 
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causes the observed inter-individual variation. In continuation of this, the latter part of 
this thesis sets out to develop predictive multivariate models of key phenotypic traits 
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1.2 Application of systems biology approaches to human health 
It is now clear that much of the complex mammalian muscle physiology or pathophysiology 
cannot be understood in sufficient detail through a traditional hypothesis-driven reductionist 
approach alone. Although this approach has proved valuable in explaining broader phenomena 
and individual mechanisms, linking multiple mechanisms and effects has proved challenging, 
e.g. a disease phenotype is very rarely caused by a single dysfunctional gene or protein [25]. 
Instead, genetic variability, epigenetic modifications, and post-transcriptional regulation 
mechanisms etc. all act in concert to determine a specific high-level phenotypic 
response/adaptation [26]. The potential for such complex interaction makes data interpretation 
much more complicated than originally envisioned, highlighting the need to move away from 
the widespread  ‘candidate gene approach’ [27]. 
 
Triggered by the advent of genome sequencing, inspired by the Human Genome Project [28, 
29], dramatic technological advances within the last two decades have led to increased 
throughput in genome-wide molecular analyses (i.e. genomics, epigenomics, transcriptomics, 
proteomics, and metabolomics). The dense accumulation of data from these tools allows for 
unbiased and hypothesis-free analysis approaches. 
As this thesis revolves around the use of such omics approaches, I will now describe some of 





	   9	  
1.2.1 High Density Data Acquisition 
	  
1.2.1.1 GWAS SNP genotyping 
Many smaller DNA regions across the entire human genome vary between individuals due to 
insertions/deletions (indels), copy number variation among others [30, 31]. On average each 
individual has between 3 and 4 million polymorphic loci within their genome [32]. This genetic 
variation is what makes you and I unique. 
Single nucleotide polymorphisms (SNPs) by far exert the biggest contribution, constituting 
>85% of the total genetic variation [33]. SNPs are randomly distributed throughout the genome, 
occurring every 500-1,000 base pair on average [34]. These single base DNA variants may fall 
within the gene-coding region or in the intergenic regions (i.e. regions between genes). Many 
SNPs outside the protein-coding regions have no effect on gene expression or gene products 
and thus appear to be phenotypically silent. However, those SNPs that are not silent provide a 
molecular basis for genetic variation that encompasses susceptibility to diseases and responses 
to exogenous exposures. 
The number of reported common1 human SNPs, which are deposited in publicly available 
databases such as the National Center for Biotechnology Information (NCBI) dbSNP, currently 
exceeds 15 millions (and still growing) [35]. 
However, today the workflow for SNP-based studies has shifted away from their discovery 
toward SNP genotype selection ⎯ serving as landmarks in the search for genes associated with 
disease and complex traits. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Minor allele frequency 5% or more in the broader population. 
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The small size of SNPs, as well as their evolutionary stability, has facilitated high-throughput 
genotyping by use of high-density oligonucleotide array technology (i.e. SNP chips/arrays). In 
addition, as specific combinations of neighboring alleles from different SNPs tend to be 
inherited together (loci not easily separable by genetic recombination due to their close physical 
proximity), SNP-chips are in fact able to survey a large portion of the human genetic variation 
in the form of SNPs [36]. 
Commercial probe-based SNP-chips are mainly manufactured by two providers: Affymetrix 
(Santa Clara, CA, USA) and Illumina (San Diego, CA, USA) [36]. Both rely on the Watson-
Crick base pairing rules [37]. Notably, the basic principles behind SNP chips are the same as 
for mRNA microarrays, which is discussed in great detail in the next section. In brief, each 
surface-immobilized oligonucleotide probe on the array has been designed to target a specific 
DNA sequence. The signal intensity from the attached fluorescent dye is dependent upon the 
hybridization affinity between DNA target and capture probe (Figure 1-1). Impeded 
hybridization⎯due to a mismatch at the SNP site⎯will lead to a dimmer signal from the 
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Figure 1-1 | Overview of the Affymetrix SNP chip technology. 
Figure adapted from [38]. 
 
1.2.1.2 Transcriptome expression profiling 
Messenger RNA is far less redundant compared to that of DNA as only 5-10% of the human 
genome is actively transcribed (of which only around 2% is translated into proteins) [39]. 
However, mRNA is more dynamic as it integrates genetic [40–42], epigenetic [43, 44] and 
environmental [45–47] influences, thereby capturing substantially more variance than genomic 
DNA. In addition, the transcriptome is cell-type specific and time/context dependent. 
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Consequently, the transcriptome, as an intermediate molecular phenotype, is substantially more 
complex than the genome and allows for interpreting the functional elements in the genome. 
 
The development of whole-genome microarrays has made it possible to interrogate the entire 
transcriptome of a cell or tissue (i.e. the complete set of transcripts expressed). The proven track 
record of this technology, which spans nearly two decades [48], has helped improve our 
understanding of molecular processes underlying phenotypes by dissecting natural variation in 
mRNA abundance. 
 
Differences in commercial microarray technology solutions: 
Despite the gaining popularity of next-generation sequencing (see next section), microarrays 
still remain the most popular technology for transcript profiling as they can be readily afforded 
by most laboratories worldwide; since 2010 ~250,000 arrays have yearly been indexed by the 
ArrayExpress database [49]. In addition, the short turn-around time and ease of data generation 
add to the continued popularity of microarrays. 
Today commercial microarrays are mainly manufactured by three providers: Affymetrix, 
Agilent and Illumina. Affymetrix creates high-density short oligonucleotide sequence arrays by 
use of a photolithographic synthesis process [50]. Each target transcript is represented by a 
number of ‘probes’ (i.e. specific 25-nucleotide sequences) that match to different exonic gene 
regions, which together make up a ‘probe-set’. Notably, each probe is actually a ‘probe pair’ (at 
least for the older 3’-based arrays), as it consists of a perfect match and a mismatch (MM) oligo 
(Figure 1-2). The rationale for the MM oligos is to gauge the level of non-specific cDNA 
binding (see Section 1.2.2 below for more information on this issue). 
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Figure 1-2 | Probe design on the older 3’-based Affymetrix microarrays. 
For each probe pair, the mismatch oligo has a central base altered (see red square) to measure 
background. The brighter the colour the more cRNA has hybridized. Figure adapted from [51]. 
Such a probe design not only allows for unspecific binding estimation, but also evaluation of 
RNA quality [52]. The latter is particular important when analyzing data from the public 
domain, as will be evident from several chapters within this thesis (see Section 3.3.6). 
Noteworthy, the newer Affymetrix exon arrays only contain 25 nt-long perfect match oligos 
designed to target individual exons in a given transcript (Figure 1-3). On average each ‘exon 
probeset’ includes four probes. Due to the lack of MM oligos, Affymetrix instead added ~1,000 
Background Intensity Probes, which are designed not to target any expressed sequences in the 
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Figure 1-3 | Schematic overview of the difference in Affymetrix probeset design between 
their newer exon arrays and the older 3’-based arrays. 
Yellow regions represent exons, whereas grey regions represent introns. The short dashes 
underneath the exon regions indicate individual probes of 25 nt in length – each representing a 
probe-set. Figure taken from [53]. 
 
Agilent, an offshoot of Hewlett-Packard, on the other hand uses a DNA synthesis 
method based upon inkjet printing technology. This innovative approach provides customers 
with the ability to quickly order custom designed microarrays at no extra cost. This is 
particularly useful when working with species for which no commercially available microarrays 
exists (e.g. non-model organisms). In Chapter 3, we take advantage of this when developing the 
first genome-wide microarray platform for the guinea pig model species. 
 
As data generated by mRNA microarrays represent a central part of most chapters 
throughout this thesis, I will briefly describe a typical sample-to-data workflow using Agilent 
technology (other technologies will differ slightly). 
As depicted in Figure 1-4 below, RNA is first extracted from the biological sample of interest 
(tissue or cells) using either a spin column-based method or the more traditional phenol-
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chloroform based one [54, 55]. Next, excess oligo-dT primers (bearing a T7 promoter) are 
added which will hybridize to the poly(A) tail of all mRNAs once the temperature is raised to 
65˚C. Then reverse transcriptase enzyme and deoxynucleotides are added to the mixture 
allowing the creation of cDNA molecules. Notably, due to this initial linear mRNA 
amplification step, as little as 25ng of total RNA is sufficient as input. 
In order to incorporate fluorescence dye (Cyanine-5 or Cyanine-3), the cDNA is then converted 
to complementary/copy RNA (cRNA) by a T7 promoter-specific RNA polymerase. The 
resulting labeled cRNA is fragmented into shorter, less structured fragments before 
hybridization to the surface-bound capture probes over night. The fragmentation step is 
imperative in order to reduce structural effects, as secondary and tertiary structures can 
significantly decrease hybridization efficiency [56, 57]. 
After washing off remaining unbound cRNA, a high-resolution laser-scanning machine captures 
the fluorescence signal from labeled cRNA bound to each microarray probe. The amount of 
fluorescence signal is proportional to the amount of bound cRNA, which obviously is 
dependent on the transcript abundance within the cells/tissue. Finally, an image analysis 
procedure, which recognizes the two dimensional position of each spot in the scanned image, is 
used to extract a numeric representation of each probe on the array based on pixel intensities. 
These intensity values are representative of the relative amounts of mRNA. The relative 
quantification has to do with microarray intensities being prone to background noise arising 
from non-specific binding of mRNA species that are only partially complementary to the probe 
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Figure 1-4 | Individual web-lab steps of a microarray experiment. 
Figure taken from [59]. 
 
1.2.1.3 Next Generation Sequencing (NGS) 
As compared to the hybridization-based array technologies presented so far, NGS does not rely 
on existing knowledge on genome sequence. Here RNA or DNA is sequenced by reading each 
base/nucleotide, which enables the reconstruction of the genome or transcriptome (depending 
on biological starting material). 
 
In addition, RNA sequencing (RNA-Seq) provides a more detailed examination of the 
transcriptome due to its ability to characterize different splice isoforms and broader dynamic 
range (i.e. able to quantify even very lowly expressed transcripts due to a very low background 
signal) [60]. For the reasons mentioned above, RNA-Seq has a strong potential to replace 
microarrays for whole-genome transcriptome profiling. The latter statement is supported by the 
immense number of peer-reviewed research papers citing NGS technologies. Further, RNA-Seq 
is able to capture both common and rare genetic variants, making this technology a strong 
alternative to array-based SNP assays mentioned earlier. 
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Similar to microarrays, RNAs are initially reverse-transcribed to cDNA. This is then 
fragmented and platform-specific ‘adaptor’ sequences are attached to one or both ends of the 
cDNA fragments. Notably, an additional size- and type-selection step (e.g. ribosomal RNA 
depletion) is often included in order to increase read depth. 
Next, each modified cDNA molecule is sequenced by use of high-throughput sequencing 
technology. Finally, all of the resulting short sequences (so-called ‘reads’) are assembled into 
longer fragments and, most often, aligned to a reference transcriptome. Alternatively, all reads 
can be assembled de novo to produce a genome-scale map [60]. 
The number of reads sequenced per gene sequence is used as a reliable proxy of mRNA 
abundance (once corrected for the sequence length). 
1.2.2 Microarray data analysis 
1.2.2.1 Raw data pre-processing 
The overall aim of microarray data processing is to remove noise and systematic variability 
while preserving the biological heterogeneity. In this context, ‘systematic’ refers to effects that 
affect all data points on the array in the same way (e.g. an overall higher or lower background 
intensity). The main sources of unwanted interarray variability originate from dye bias (specific 
to multichannel experiments), differences in sample labeling efficiency as well as differing 
yields during purification. 
 
Data transformation (usually log2): 
As highlighted in Figure 1-5, the distribution of raw signal intensity values is heavily skewed 
towards the low signal intensity side. Hence, a data transformation procedure, often logarithm 
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base two (log2), is normally applied in order to force the spread of features more evenly across 
the intensity range. In addition, most statistical tests developed for microarray analysis are 
parametric and hence assume the data follow a normal distribution. 
In brief, the logarithm function will squeeze together larger intensity values (i.e. genes 
abundantly expressed in the tissue of interest) and stretch out those in the low intensity area, 
thereby causing an overall distributional right-shift (Figure 1-5). 
 
	  
Figure 1-5 | Histogram showing the distribution of signal intensities before (left panel) and 
after (right panel) log2 data transformation. 
 
Inter-array normalization: 
In an ideal microarray experiment normalization would not be required. However, as 
highlighted in Section 1.2.1.2 below, the microarray experimentation process is fairly complex. 
As a result of this, systematic errors are frequently introduced during RNA extraction, labeling, 
hybridization and scanning, which can result in artificial differences between replicated 
samples. Importantly, such differences may likely confound the biological differences between 
sample groups in a given experimental setup. Hence, the overall aim of normalization is to 
remove as much of this unwanted experimental and technical variation while maintaining true 
biological variability (as much as possible). 
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Multiple global normalization methods have been developed during the last decade, see [61] for 
a comprehensive review on this topic. Notably, the choice of method is dependent on the design 
of array capture probes (i.e. 3’-based versus the newer whole transcript based chips), number of 
channels, as well as manufacturer. 
Quantile normalization proposed by Bolstad et al. [62], used throughout this thesis, is a popular 
method likely due to it being mathematically simple (Figure 1-6), fast and easy to implement 
(needs no user interaction/parameter tuning). 
This normalization procedure forces each array in a set of arrays to have the same empirical 
distribution, as it is assumed that the distributions of intensity values on the slides have the 
same overall shape. Plotting histograms of the raw probe intensities on a single plot can help 
establish whether such an assumption is in fact valid. The latter point is important, yet often 
ignored by researchers (in my experience at least), as the normalization procedure by design 
always ‘works’, even if data are bad. 
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Figure 1-6 | Details of the quantile normalization procedure for expression arrays. 
 
 
Gene/Probe-set summarization:  
Due to their dense nature commercial microarrays often have several million features spotted, 
which allows for multiple features per target gene. The goal of the summarization step is to 
produce a unique measure for every gene as close to the ‘true’ gene expression as possible. 
Although optional, two approaches are commonly preferred: 
1. Selecting a single, most representative probe-set from a set of probe-sets (e.g. one with 
the highest expression). 
2. Taking the average expression value of all gene specific probe-sets 
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Noteworthy, Li et al. recently published a probe-set scoring method that exploits the unique 
properties of the older 3’-based2 Affymetrix arrays [63]. In brief, this method assesses each 




Modern commercial mRNA microarray platforms allow the simultaneous profiling of over 
20,000 unique genes (the human genome contains around 21,000 protein-coding genes [64, 
65]). However, not all of the profiled transcripts are expected to be expressed in a given 
experimental condition, as most mammalian tissues only express ~10,000-15,000 protein-
coding genes at biologically meaningful levels [66, 67] (and likely even fewer). The recorded 
signal intensity values from probesets targeting non-expressed transcripts simply represent 
noise due to non-specific binding ⎯ particularly from abundantly expressed RNA species [68]. 
Hence, in order to increase sensitivity (e.g. in finding differentially expressed genes) it is 
common practice to remove all probesets below or close to the detection limit (i.e. background). 
However, the definition of ‘background’ is a non-trivial issue, as highlighted by the many 
different approaches put forward in the literature. To mention a few: signal from anti-genomic 
probesets (i.e. negative controls included on the array by the manufacturer), average intensity 




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 Probes are designed to target sequences near the 3’-end of an mRNA transcript to minimize 
loss of fluorescence signal caused of non-specific RNA degradation.	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MAS 5.0 absent/present calls (specific for Affymetrix chips): 
Throughout this thesis I take advantage of the Affymetrix Human Genome U133 Plus 2.0 
GeneChip®. Probes on this array are selected to interrogate the 3’-end of an mRNA species 
(Figure 1-3). In addition, this platform contains ‘mismatch’ probes intended to quantify the 
amount of unspecific binding (Figure 1-2). 
A probeset is termed detected/expressed (i.e. ‘present’) by the Affymetrix MAS5 software 
when the signal intensity of the perfect match oligos is statistically higher (p<0.04) than the 
corresponding mismatch oligos based on a Wilcoxon signed-rank test (a non-parametric 
alternative to a paired Student’s t-test) [71]. 
Notably, it has been demonstrated that such a filtering approach increases the correlation to 
quantitative PCR expression measurements [72]. 
 
1.2.2.2 Exploratory analyses to assess data quality 
It is important to realize that effects of degraded RNA, etc. cannot be removed by any 
normalization procedure. 
Exploratory data analysis techniques are vital for outlier detection, identification of sample and 
gene similarity/dissimilarity and dimension reduction. 
 
The very high dimensionality of microarray data makes direct visualization impossible as the 
human eye only can handle a maximum of 3 dimensions. Hence, dimensionality reduction 
techniques are very popular when analyzing omics datasets. 
Worth mentioning is principal component analysis (PCA), an unsupervised dimensionality 
reduction technique, that is widely used within the community to find dominating patterns in 
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multidimensional data sets [73, 74]. In brief, this well-established mathematical technique 
exploits that complex data usually is not uniformly distributed, but show strong correlations 
among groups of measured variables. Such correlation highlights a certain degree of 
redundancy within a data set. Hence, the number of underlying factors accounting for most of 
the variation with the data is much smaller that the dimensions of the data itself. 
PCA reduces data dimensionality by creating new ‘artificial’ variables (i.e. orthogonal axes of 
best fit), referred to as principal components (PCs). Each of these PCs is a linear combination of 
the observed variables. Importantly, the different PCs are uncorrelated to each other thereby 
ensuring that they represent different characteristics of the original dataset [73]. By default, the 
first PC accounts for as much of the variability in the dataset as possible (and the last PC the 
least variance). Typically, the first handful of PCs explains the vast majority (>80%) of the 
variability.  Conversely, two points (each represent a biological sample) that are visually 
separated in a PCA plot by one of the first PCs will have different overall expression profiles. 
Other common tools used for exploratory analysis include tree-based visualization and 
clustering algorithms. Such methods can reveal the similarity between genes and/or samples 
[75]. Genes with a similar expression profile will cluster together, suggesting that they may 




Batch effects have been defined as “sub-groups of measurements that have qualitatively 
different behavior across conditions and unrelated to the biological or scientific variables in a 
study” [76]. As highlighted in Figure 1-7, many independent factors can contribute to the 
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creation of batch effects. Particularly, non-biological sources of variation among microarrays 
tend to arises when they are processed in separate independent batches (e.g. on different days, 
which is common in larger clinical studies) [76]. Thus, it is important to apply data 
visualization in order to check for such batch effects. PCA plots are particularly suited as the 
biggest source of gene expression variability very often associate to technical variables rather 
than biological groups [76]. In addition, commercial providers add exogenous controls (also 
known as ‘spike-ins’), which can be useful for checking the quality of the different array 
processing steps [77]. 
If ignored, batch effects will likely lead to increased technical noise (which decreases detection 
power) and number of false positives. To illustrate the latter, if all control samples were 
processed on day 1 and all treated samples the following day, certain genes might appear 
differentially expressed by treatment, while this in fact is only due to the confounding batch 
effect. 
Due to the frequent occurrences of batch effects in high-throughput data [76], the development 
of in silico removal methods is a very active research area. Hence, many different adjustment 
methods now exist based on different statistical models (for a recent review see [78]). One very 
popular algorithm based on an empirical Bayes framework, which I also take advantage of in 
Chapters 4 and 5, is ComBat [79]. Notably, a fairly recent systematic evaluation on simulated 
data identified ComBat as the best performing algorithm [80].  
However, it must be acknowledged that some of the true biological signal will also be removed 
by any correction procedure (i.e. loss of intra-group biological heterogeneity), due to the 
difficulty in discerning unwanted variation from the experimental variation of interest [53]. 
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Hence, it is key to reduce the effect of batches by careful experimental design [81, 82], 
particularly when only subtle differences are expected. 
 
	  
Figure 1-7 | Flowchart highlighting potential batch effect sources (grey boxes) during data 
generation. 




1.2.2.3 Defining transcriptional signatures of perturbations 
With the advent of omics technologies, also surfaced the challenge of interpreting the high 
volume of data. 
A popular approach is to identify genes that are differentially expressed between experimental 
conditions based on a user-defined preselected probability cutoff. However, such singular 
enrichment-based analyses have been criticized for not considering the biological knowledge 
(i.e. genes known to be biologically associated are scored individually) [83]. 
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Hence, novel statistical methods were developed that relies on the principle that genes do not 
work in isolation, but in an intricate network of interactions.  
 
Gene Set Enrichment Analysis (GSEA): 
GSEA [84] differs from other overrepresentation analysis tools in that this does not require the 
user to set an arbitrary probability threshold beforehand. For this reason, the GSEA procedure 
should potentially uncover additional biological data trends (idea is to ‘borrow’ strength), and 
hence well suited for complex polygenic phenotypes. 
In brief, an Enrichment Score (ES) is calculated for each gene set by ranking all genes in the 
transcriptome based on their association with the phenotype of interest (Figure 1-8). Next, the 
statistical significance of the observed ES is assessed by permuting phenotype labels many 
times (i.e. the observed ES is the distribution of permuted enrichment scores). Finally, 
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Figure 1-8 | Schematic overview of the Gene Set Enrichment Analysis procedure. 
Figure adapted from [84]. All genes are ranked according to the fold-change difference in 
mRNA expression between Phenotype class A and class B (see colour bar at the top of the 
heatmap in Panel A). Panel B: For a given target gene-set (e.g. a KEGG pathway): every 
present gene (black vertical bar) gives a positive contribution, whereas every absent gene in the 
ranked list gives a negative contribution to the GSEA enrichment score (ES) as the algorithm 
walks down the ranked gene list (see red trace in the ES profile at the bottom). The cumulative 
ES with the biggest deviation from zero proves the final ES (so a high absolute ES denotes a 
high local enrichment). Distributions of random ES scores from N permutations is then 
generated (i.e. null-hypothesis distributions) in order to estimate a p-value for every tested 
gene-set. Finally, probability values are adjusted for multiple hypothesis testing.
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1.3 Aims and outline of the thesis 
 
Overarching aim 
The overall aim of the thesis was to improve the current understanding of the molecular 
basis for lower limb skeletal muscle adaptation/dysfunction under two key conditions 
known to affect its phenotype, namely long-term endurance exercise training and chronic 
obstructive pulmonary disease (COPD) characterized by peripheral skeletal muscle 
wasting. 
 
Rationale and specific objectives: 
Despite decades of intense investigation, our understanding of the regulatory molecular 
mechanisms controlling skeletal muscle homeostasis is still limited. Moreover, 
biomarkers to support the development of new therapeutic interventions to improve 
muscle-skeletal functionality in chronic degenerative diseases (e.g. COPD and T2DM) 
are very much needed. 
 
The development of genomics and functional genomics have provided an unprecedented 
amount of data characterizing the molecular state of skeletal muscles in physiological and 
pathological conditions. Recently, it has also become apparent that computational 
approaches to integrate and model omics datasets are fundamental to formulate more 
robust testable hypotheses. 
The current thesis represents a pioneering effort in this direction. More precisely, the 
current work is based on the hypothesis that genetic variants and abnormal or altered 
expression status/pattern of mRNAs, in lower limb muscles, can be linked to physiology 
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and that such molecular signatures⎯when combined with biological domain 
knowledge⎯can be exploited to develop robust quantitative predictors. 
 
I have approached the challenge of improving biological understanding of the gene-
networks that underlie response to physical exercise and muscle pathophysiology by 
applying a data-driven computational approach to both animal models and human 
intervention studies. 
 
This highlights three main challenges for this thesis: 
1) Develop an initial proof of concept to validate the application of data-driven 
biological network inference in understanding lower limb muscle maladaptation 
(addressed in Chapter 2). 
2) By using a rodent chronic smoking model, identify and validate candidate 
inflammatory signals underlying peripheral skeletal muscle wasting in COPD 
patients (addressed in Chapter 3). 
3) Utilise pre-intervention omics profiling to subsequently build response-predictors 
of systemic physiological traits (i.e. whole-body insulin sensitivity and serum 
triglyceride content) using one of the biggest exercise training trials to date. 
Importantly, such quantitative predictors will have to be validated in independent 
clinical studies to avoid model overfitting (addressed in Chapters 4 & 5).  
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2 Multi-level functional genomics data integration as a tool for 
understanding physiology: A network biology perspective 
	  
	  
The	  work	  presented	  in	  this	  chapter	  represents	  a	  collaborative	  project	  between	  the	  labs	  
of	  Francesco	  Falciani	  and	  Stuart	  Egginton	  (University	  of	  Leeds).	  Prof.	  Egginton	  helped	  
conduct	  the	  in	  vivo	  animal	  exposure	  experiment	  while	  him	  and	  I	  were	  both	  physically	  
situated	   in	   Birmingham.	   Josep	   Roca	   (University	   of	   Barcelona)	   provided	   the	  
anthropometric	  characteristics	  related	  to	  the	  clinical	  COPD	  cohort.	  
I	   independently	   conducted	   all	   the	   murine	   wet	   lab	   work	   (RNA	   extraction	   +	   array	  
generation)	  as	  well	  as	  in	  silico	  analyses	  presented	  in	  the	  case	  study.	  
This	  chapter	  (in	   its	  current	  state)	   is	  currently	  under	  2nd	  review	   in	   Journal	  of	  Applied	  
Physiology.  
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2.1 ABSTRACT 
The overall aim of physiological research is to understand how living systems function in 
an integrative manner. Consequently, the discipline of physiology has since its infancy 
attempted to link multiple levels of biological organization. Increasingly this has involved 
mathematical and computational approaches, typically to model a small number of 
components spanning several levels of biological organization. With the advent of omics 
technologies, which can characterise the molecular state of a cell or tissue, the number of 
molecular components we can quantify has increased exponentially. Paradoxically, the 
unprecedented amount of experimental data has made it more difficult to derive 
conceptual models underlying essential mechanisms regulating mammalian physiology.  
 In this chapter I present an overview of state-of-the-art methods currently used for 
identifying biological networks underlying genome-wide responses. These are based on a 
data-driven approach that relies on advanced computational methods designed to ‘learn’ 
biology from observational data. Furthermore, I illustrate an application of these 
computational methodologies using a case study (proof of concept) integrating an in vivo 
model representing the transcriptional state of hypoxic skeletal muscle with a clinical 
study representing muscle wasting in COPD patients. The broader application of these 
approaches to modelling multiple levels of biological data in the context of modern 
physiology is discussed. 
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2.2 INTRODUCTION 
 
2.2.1 Modelling in physiological sciences 
Physiology has evolved as a series of sub-disciplines attempting to understand 
organismal function as a combination of interacting components and systems. The last 
decade or so has witnessed the development of Systems Biology as an investigative 
approach, and its application in different areas of biology, ranging from 
engineering/synthetic biology (e.g. design of bacterial strains with improved properties) 
to health sciences (e.g. disease biomarker identification). Despite the lack of a concise 
definition acceptable to the majority of the community [85, 86], Systems Biology is 
frequently understood to be the study of complex regulatory interactions in biological 
systems using a holistic approach. This is often achieved by integrating different 
experimental approaches within the conceptual framework of a computational model (i.e. 
a mathematical representation of a system that allows simulation of its behaviour). 
Physiology is probably one of the few research areas in biological sciences that have 
traditionally adopted such an approach. It has long sought to understand the behaviour of 
complex biological processes and cellular systems using an integrative approach, and has 
extensively adopted mathematical modelling in its tool set. Classical examples include 
August Krogh’s tissue cylinder model of oxygen transport to skeletal muscle [87], and 
Huxley’s two-state cross-bridge model of muscle contraction [88], which are still used by 
investigators today. Indeed, physiology can be considered a precursor of Systems 
Biology. 
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As often happens when a distinct discipline branches out of another, there developed over 
time a separation of ideas based in part on confusion arising from use of esoteric 
terminology – similar concepts masked by unfamiliar language. There is therefore a need 
for an overview of this relatively new discipline, to both emphasise the essential links 
with basic physiological principles and de-mystify the approach such that the available 
tools may become more widely adopted in physiological research. The overall aim of this 
opinion-based review is to describe, using concepts that will be intuitive to physiology 
researchers, different key methodologies available from the Systems Biology community. 
In addition, I provide a practical step-by-step guide for integrating multi-level data within 
an analysis pipeline based around inferred interactions of variables, modelled as a 
network based on statistical correlations, using a worked example in the field of 
physiological sciences. 
 
2.2.2 The advent of Functional Genomics: a challenge for physiological modelling 
It appears that the function of living mammalian organisms cannot be addressed in 
satisfactory detail through a traditional hypothesis-driven approach alone. For many 
years, the attention of molecular biosciences was directed to specific rate-limiting 
enzymes and key genes with a high impact on physiological trait. However, a disease 
phenotype is very rarely caused by a single dysfunctional or dysregulated gene or protein. 
Instead, genetic variability, epigenetic modifications, post-transcriptional regulation 
mechanisms etc. all act in concert to determine a specific complex phenotypic response 
[26]. The potential for such complex multi-level interaction makes data interpretation 
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much more complicated than originally envisioned, highlighting the need to move away 
from the widespread  ‘candidate gene’ approach [27]. 
The advent of DNA sequencing [28, 29] has enabled the development of 
technological advances, which have led to increased throughput in genome-wide 
molecular analyses. These technological advances have made it possible to measure gene, 
protein or metabolite concentration in single experiments at a genome-wide level. 
The comprehensive data acquisition tools developed to cope with large datasets have 
allowed investigators to determine the molecular state of cells, tissues or even entire 
organs in a single experiment. Such cost-effective omics approaches are now becoming 
prevalent in biological and medical research, and consequently have been responsible for 
the generation of an incredibly large amount of multivariate molecular data. A large 
proportion of this data is available in the public domain via different online databases 
(e.g. NCBI Gene Expression Omnibus [89], EBI ArrayExpress [90], and PRIDE [91]).  
For example, mRNA microarray technology and more recently mRNA 
sequencing, has provided insight into the transcriptional response of skeletal muscle to 
prolonged endurance exercise training, highlighting a pronounced inter-individual 
variation [19, 24]. The transcriptional signatures identified in such studies likely explain, 
at least in part, why some people show great improvements in aerobic capacity (VO2max) 
whereas others only experience smaller benefits, despite completing the same supervised 
exercise training program. Another example of applying omics technology to better 
understand human physiology concerns the quantification of individual levels of different 
proteins in health and disease; by use of proteomics methodology, Holloway et al. [92] 
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were the first to investigate adaptations in human muscle protein content to long-term 
exercise training on a large scale. 
While such omics-based studies hint at the potential of a data-driven approach, 
they also illustrate the difficulty in deriving conceptual models underlying the essential 
mechanisms regulating physiology, as most are restricted to only one aspect of 
regulation. Perhaps surprisingly, the exponential growth in publicly available omics data 
[93, 94] has not resulted in a paradigm shift in our understanding of biology. The main 
reason is the continuing challenge of integrating multivariate datasets spanning multiple 
organization levels in a way that allows the identification of discrete, small biomolecular 
networks that are truly important in the context of a specific biological response [95]. 
Such a task cannot be achieved simply using unaided human interpretation. Rather, 
complex computational techniques are needed that are able to integrate and automatically 
‘learn’ the structure of a biological system. Such a modelling framework is very different 
from what physiological sciences have traditionally employed. 
 
2.2.3 Towards data-driven predictive biology 
Although the modelling approach traditionally used by physiologists has been extremely 
successful, it suffers from severe limitations when challenged with extensive omics data. 
For example, physiological modelling relies to various degrees on a mechanistic 
understanding of the biological system of interest [96], which automatically limits the 
number of components that can be included due to gaps in our current knowledge [95, 
97]. Moreover, estimation of model parameters, which is usually a challenging task 
because of experimental limitations (e.g. due to limited amount and quality of data), 
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makes the approach difficult to scale up to a larger number of components and their 
interactions. Perhaps the most comprehensive example to date is modelling the cardiac 
cycle based on ion channel kinetics [98]. 
With such large multivariate datasets, and little knowledge about the way 
biomolecules are connected with each other and to key phenotypic switches, the 
fundamental question is whether or not we can ‘learn’ the structure of biological 
interaction networks from high-throughput data. Clearly, there is a need for sophisticated 
computational tools that are able to i) integrate genome-wide measurements spanning 
multiple levels of biological organization (ranging from subcellular to organ level), ii) 
identify key biomolecular components of the system, and finally iii) statistically infer the 
way that these biomolecules interact in a pairwise manner to generate an observed 
biological response.  
Central to these approaches is the concept of interaction networks, a mathematical 
representation of a system of biomolecules. Networks are commonly used to describe 
biological systems at different levels of complexity (e.g. metabolic and signal 
transduction networks). They can be descriptive models built using a wide spectrum of 
qualitative data (e.g. biological knowledge of protein-protein interactions, transcription 
factor binding, etc.) or they can be inferred from quantitative measurements using 
complex computational models. In this case they can be used to predict the behaviour of 
the system when perturbed.   
In the following section, we summarise specific methodologies that can be 
applied to achieve such tasks. 
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2.2.4 COMPUATIONAL APPROACHES FOR THE ANALYSIS OF COMPLEX 
DATASETS 
The process of modelling a biological system from complex multi-level datasets can, for 
the sake of convenience, be divided into four conceptually distinct yet interconnected 
approaches (Figure 2-1).
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Figure 2-1 | Schematic representation of the process involved in modelling a biological 
system by integrating knowledge from various sources, and complex multi-level datasets. 
The process can be conceptually subdivided into four distinct yet interconnected approaches (A-
D). The experimental data used can either be novel multivariate data generated in your own (wet) 
laboratory or taken from a public repository. These may then be used to identify predictive 
biomarkers, i.e. variables that are predictive of a defined outcome (e.g. response to exercise 
training), and also to inform development of important networks that infer such outcomes; 
experimental data and other source of biological knowledge may also be useful in refining these 
representation of complex interactions. Such networks may in turn aid biomarker discovery, but 
are an essential precursor to computational models that are able to explore underlying molecular 
mechanisms; again, knowledge of specific biological issues may help in their refinement. Finally, 
incorporation of these models into larger scale analyses offer the potential for in silico 
experimentation, whereby e.g. the effect of different therapeutic interventions on disease outcome 
may be tested. 
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The first approach is biomarker discovery (Figure 2-1A), which perhaps is most 
widely used in the analysis of functional genomics datasets. Here the objective is to 
identify measurable variables that are predictive of a given outcome (e.g. the response to 
physical training in a population of individuals). Such measurements can be molecular 
(e.g. gene expression, protein levels, metabolite concentrations, genetic variants) and/or 
more traditional physiological endpoints (e.g. endurance, VO2max). 
The identification of predictive biomarkers can be achieved by use of univariate and 
multivariate variable selection strategies that aim to identify the most relevant 
explanatory measurement(s), while developing a computational model that can accurately 
predict an outcome [99]. Univariate methods will test every variable (e.g. expression of a 
given gene) on its own, whereas multivariate methods test combinations of variables for 
their ability to explain a given outcome. Clearly, multivariate approaches better resemble 
the complex nature of biological networks, and therefore are more likely to provide 
insights into the mechanisms underlying a complex phenotypic trait. Consistent with this 
notion, multi-gene biomarkers are often required for robust predictions in independent 
datasets.  
The second approach (Figure 2-1B) consists of ‘reverse engineering’ biomolecular 
networks from observational data (i.e. infer regulatory interactions between quantified 
biomolecules based on mathematical principles). Here the overall aim is to reconstruct 
the underlying structure of interactions between biological molecules profiled using 
omics tools (ideally from multiple data sources) and rigorous statistics. Such a network 
inference framework can be achieved by applying a multitude of approaches with varying 
underlying data assumptions and modelling principles, including ordinary differential-
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equation (ODE)-based methods [100], probabilistic modelling techniques (e.g. Bayesian 
theory models) [101, 102], state-space representation models [103], and correlation-based 
methods. Note, while the first three approaches are able to infer directed networks, their 
capability is currently limited to inferring smaller networks with few variables due to 
increased computational complexity than possible with correlation approaches. 
 Importantly, this network inference part may potentially benefit from a biomarker 
discovery phase, since it has been shown that identified predictive variables are more 
likely to be directly controlling important physiological processes, and therefore are good 
candidates to include in a network [95]. Similarly, whole networks can be used as an 
input for biomarker discovery procedures. It has been shown that often the overall 
‘activity’ of a biological network (e.g. a specific signalling pathway) is a better predictor 
than a few key individual genes, proteins and/or metabolites. This implies that in the 
coming years predictive biomarkers are more likely to consist of a relatively large panel 
of measurements, possibly spanning multiple levels of complexity within a pathway. 
Current omics platforms are experiencing a rapid development as well as drop in costs, 
making routine collection of large datasets a feasible option. Once a robust biological 
network has been inferred this may serve as a good basis for developing a more 
conventional modelling approach to provide explanations for observed phenomena that 
requires a mechanistic understanding of the system (Figure 2-1C).  
Finally, multiple computational models that initially were developed independently can 
be integrated into a larger and more complex models, which allow responses to 
physiological/pathological challenges to be simulated, thus integrating effects across 
multiple organs and/or pathways. These complex models are often referred to as decision 
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support systems because of their potential to provide information about the expected 
outcome of a therapeutic intervention (Figure 2-1D). 
Several large international projects aiming at the development of such technology 
into Systems Medicine integrated frameworks have been established so far, e.g. the 
Virtual Physiological Human (VPH) project funded by the European Commission 7th 
Framework Programme, which aims to aid clinically relevant research by establishing a 
framework for handling and integrating various mechanistic models spanning different 
levels of organizational complexity (ranging from molecular components to organ 
function). By unifying the modelling languages employed across the different 
mathematical models included, parameters of a particular model in the hierarchy can be 
processed by other appropriate models at a lower hierarchical level. These global 
initiatives should be considered long-term goals, aiming at understanding human 
physiology quantitatively as a dynamic system.  
Developing a comprehensive model of a biological system requires integrating 
mechanistic and probabilistic inferences. The mathematics for performing such a task is 
in its infancy, and more development is needed. However, a successful example is 
illustrated by the anatomically based model of human heart ventricles [98]. In the 
following sections we aim to provide an overview of some of the methodologies that can 
be used to infer biomolecular networks, as well as introduce one particular approach we 
have found useful in our research. 
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2.2.5 Inference of biological networks from observational data 
Reverse engineering is an evolving field within network-based Systems Biology. The 
rapid accumulation of omics data in the post-genomic era has made it possible to infer 
(aka ‘reverse engineer’) models of cellular systems with the overall aim of deducing the 
regulatory structure at a sub-cellular level. Most of the network-based approaches that 
have been developed are in fact general and can be applied to any type of experimental 
data. However, because the mRNA expression profiling technology is the most mature 
omics discipline, most applications have been developed to reconstruct transcriptional 
networks (i.e. decode the mechanisms of transcriptional control). However, recently it 
has become apparent that, irrespective of the methodology used to generate data, in order 
to be able to recapitulate the complex behaviour of a biological system it is essential to 
integrate multiple types and scales of experimental data (e.g. transcriptomic, proteomic, 
metabolomic).  
 
2.2.6 Static vs. dynamic networks 
Biological networks can be reconstructed from two different types of experimental 
studies: either cross-sectional, e.g. representing a population of individuals at a given 
time (i.e. steady-state measurements following an experimental perturbation), or 
prospective, where the experimental data is available across a defined time-course. In 
reverse engineering, statistical inference of biological causality is an important goal 
[104]. A simple example of causality could, for example, be a transcription factor 
regulating the expression of several target genes. Since determining cause and effects 
implies a direction (i.e. the cause precedes the effect), inference of causality from cross-
sectional studies presents a challenge due to their static nature, one that is less difficult 
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when a time-course is available. However, it must be stressed that both approaches are 
often used in combination to, for example, integrate clinical cross-sectional studies 
(thereby providing the researcher with a static network representation) and experimental 
intervention studies that can provide dynamic (prospective) models of the process being 
studied. At present, most of the developed techniques infer regulatory networks without 
any causality information (likely due to the scarcity of time-course datasets due to their 
higher costs). However, a small number of causality detection techniques have been 
proposed in the literature such as dynamic Bayesian networks [105] and Granger 
causality [106]. It is also important to point out that true time-course datasets can only be 
developed when the sequence of events is measured within the same cells/tissues. This is 
for example achieved with imaging techniques that require complex molecular probes, 
and can typically be only applied to measure a relatively small number of system 
components [107]. Omics technologies unfortunately are disruptive, so time-course data 
derived using these approaches are in fact a sequence of independent snapshots, which 
clearly limits the potential use of dynamical modelling tools. 
2.2.7 A primer for network inference methods 
The simplest method for inferring statistical relationships between experimental variables 
is computing the pairwise correlation coefficient across a large collection of 
heterogeneous samples [108]. Usually such an approach is not able to identify complex 
non-linear dependencies, and does not discriminate between direct and indirect 
connections. More complex methods, such as the mutual information (MI) based 
Algorithm for the Reconstruction of Accurate Cellular Networks (ARACNE) [109], also 
aim at establishing a statistical relationship between pairs of variables but have a stronger 
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theoretical foundation. Because of the added mathematical complexity they can capture a 
broader range of biologically relevant dependencies between variables including non-
linear, non-monotonic relationships; importantly, they can distinguish between direct and 
indirect relationships. ARACNE is a free tool for which a Java-based graphical user 
interface (GUI) exists; hence investigators do not need any programming skills in order 
to use the software. 
 ARACNE relies on estimating the probability that a variable (e.g. the expression 
of a gene or a protein) assumes a certain ‘state’ (i.e. abundance) given the state of another 
biomolecule (conditional probability). A number of alternative MI-based 
implementations have been proposed during the last decade (e.g. Context Likelihood 
Relatedness (CLR) [110], Minimum Redundancy/Maximum Relevance Networks 
(MRNET) [111]), which mainly differ by the way inferred indirect relationships (so-
called ‘edges’) are removed once the dependencies between all pairs of variables have 
been mathematically formulated. In such analyses, unwanted indirect interactions occur 
by default if there is strong correlation between biomolecule 1 and biomolecule 2, and 
between biomolecule 1 and biomolecule 3 in a three-node clique (i.e. a triplet of 
connected variables). 
 An MI value of zero means that there is no dependency (i.e. no information flow) 
between two variables, whereas an MI value of 1 indicates a perfect association between 
them, and therefore, a likely strong regulatory interaction between them. For each 
inferred dependency, a P-value is calculated based on the distribution of MI values 
between random permutations of the original dataset, thereby allowing the elimination of 
all non-statistically relevant dependencies by thresholding using an appropriate (user-
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defined) cut-off level. Importantly, the quality of the inferred interaction network 
depends on the arbitrarily selected probability cut-off. A small threshold (e.g. P=0.05) 
gives a high recall (i.e. fraction of true dependencies that could be inferred) but low 
precision, whereas a higher threshold (e.g. P=10-6) yields better precision (i.e. fraction of 
inferred dependencies that really are in the network) while suffering from a low recall. A 
further advantage of MI as an information-theoretical measure of dependency between 
variables concerns its relatively low computational requirements for building an 
interaction network. Hence, MI is able to handle very large data matrices with thousands 
of experimental variables, whereas most of the other more advanced techniques 
mentioned (e.g. Bayesian methods) can only deal with much smaller numbers of 
variables (<100) because of the high computational complexity.  However, in order to 
infer robust statistical associations based on MI a fairly large sample size is required (> 
50-100 biological replicates), due to the required estimation of the (joint) frequency 
distribution of the connectivity. Interaction networks derived from such reverse 
engineering methodologies can be visualized and further analysed using various freeware 
software tools such as Cytoscape [112], Pajak [113], and BioLayout [114]. A 
comprehensive list of visualization tools focused on interaction networks and their web-
links has recently been reviewed [115]. 
Up to now, these information-theoretic approaches have usually been employed 
on gene expression data only, due to the wealth of such data available. However, as 
physiologists have known for many decades, biological systems are usually more 
complex and multi-layered. Indeed, despite some popularist science writing to the 
contrary, genes on their own are merely permissive elements within biological systems 
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[26]. Further, it has been shown that when multiple types of data (e.g. copy number 
variants, protein or microRNA expression levels) are incorporated in the network 
inference pipeline, the accuracy of the learned network topology increases [116]. Hence, 
at present there is a call for methodologies that can embed multiple data sources in a 
single computational framework. Our recent work has focused on methods that are able 
to handle large-scale, multi-dimensional genomic datasets [117, 118]. 
 
Topological analysis of inferred biological networks provides useful biological 
insight 
Up to now we have described some of the most widely used methodologies for inferring 
regulatory networks. However, an immediate challenge arises in interpreting these often 
large, complex networks that visually present as a ‘hairball’ (i.e. too dense a collection of 
connections to comprehend as a whole) [119]. A simple solution, although not very 
objective, is to focus the analysis around a favourite gene(s). In this scenario, the 
investigator typically examines the manually selected sub-network in order to identify 
unknown or unexpected biological relationships, which in turn may be used to formulate 
new hypotheses. Such ‘discovery-led’ science may be useful when there is insufficient 
data to justify an hypothesis-driven approach. 
 Alternatively, the topological properties of the network can be used to identify 
interesting genes and sub-networks that can be interpreted. We and others have 
demonstrated the existence of a higher-level, modular organization in biological networks 
[95, 120, 121], i.e. components of biological systems that act in collaboration to carry out 
specific biological processes. Consequently, several modularization approaches have now 
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been developed to help group subsets of cellular components based on a given property, 
such as topological structure or functional role. Such decomposition of a large complex 
network into relatively independent sub-networks (or ‘modules’) has been shown to be an 
effective way to deduce the underlying structure of the fully connected network 
containing many hundred variables (so-called ‘nodes’), as each module can then be 
analysed independently. In addition, studies have demonstrated that such identified 
network modules can serve as better predictors of a physiological response than the 
classic biomarker discovery approach  (see Figure 2-1). 
In biomolecular interaction networks, as well as sub-networks, nodes have 
different levels of connectivity (i.e. number of interactions with other nodes). It has been 
shown that such interaction networks have so-called ‘scale-free’ structure properties, as 
their node connectivity distribution fits a power law [122]. Such a power law degree 
distribution implies that most of the connections between biomolecules is linked to a 
small number of highly connected nodes, such that a large proportion of the molecular 
state of a cell can be explained by a small subset of biomolecules (so-called ‘hub’ nodes; 
e.g. a transcription factor that regulates many more genes than average). Hence, in 
biological networks a hub is often assumed to be a key component of a regulatory 
networks, hence important for the function of a cell/tissue under investigation. This 
assumption is supported by the fact that random node disruption does not significantly 
affect the network architecture, whereas deletion of hub nodes leads to a complete 
breakdown of the network structure [123]. Hence, adjusting the spatial position of each 
node according to its interconnectivity has been shown to be a simple, yet effective way 
of visualizing large complex interaction networks [124]. 
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More advanced methods to extract information from complex networks exist that 
aim to identify functional modules (i.e. sub-networks of biomolecules that are linked to 
the same biological function), e.g. by integrating both physical interactions (i.e. 
experimentally validated protein-protein interactions) and mRNA expression data [125]. 
In this context, an identified functional module represents a putative multi-protein 
complex that is transcriptionally regulated in a specific experimental condition (e.g. 
treatment vs. control). Hence, by considering additional data on a different level of 
organization, one can potentially infer a clearer composite picture of the underlying 
biological function.  
Finally, in order to generate objective hypotheses about biological processes 
controlled by a specific hub node or sub-network, functional enrichment analysis can be 
performed on all its direct neighbours (i.e. all the adjacent nodes that are directly 
connected to the hub) [126]. Such enrichment analysis aims at reducing complexity by 
defining groups of molecules (represented by gene sets) that share similar biological 
functions (e.g. a class of adhesion molecules). To accommodate latest advances in 
knowledge, the different annotation databases used for this purpose (e.g. Gene Ontology 
[127] and KEGG [128]) are frequently updated by curators. Using software tools like the 
web-based application DAVID [129] or applications such as BiNGO [130] developed 
specifically for use with software visualization tools like Cytoscape, one can quickly 
determine whether any gene sets are statistically over-represented, thus generating 
hypotheses on the biological processes controlled by those factors outlined above. 
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2.3 CASE STUDY: INFERENCE OF OXYGEN-DEPENDENT PATHWAYS IN 
LIMB SKELETAL MUSCLE 
The main purpose of this case study is to illustrate in a step-by-step manner the 
application of reverse engineering to integrate supra-cellular physiological measures and 
genome-wide expression profiling. From a more biological perspective we aim to identify 
a clinically relevant signature of skeletal muscle tissue hypoxia. 
This analysis uses two different datasets. The first is a publicly available dataset 
(GSE27536) representing a cohort of COPD patients and healthy controls matched for 
age and smoking history [131] (see Table 2-1 for subject characteristics), which includes 
gene expression profiling in vastus lateralis limb muscle and whole-body physiological 
variables (e.g. VO2max, minute ventilation, PaO2) [132][133]. 
	  







Gender (M/F) 10/2 9/0 6/0 
Age (years) 65.3±2.9 69.4±1.5 69.2±4.6 
BMI (kg/m2) 26.3±1.1 27.4±1.4 19.7±1.0**,†† 
FFMI (kg/m2) 21.0±0.8 21.5±0.7 16.7±0.9**,†† 
VE (L/min) 71.2±5.6 40.5±3.6*** 33.0±3.8*** 
FEV1 (L) 3.46±0.2 1.41±0.09*** 1.21±0.21*** 
FEV1/FVC (%) 75.9±2.4 44.0±2.7*** 39.5±4.5*** 
RV (% of pred.) 103.9±5.2 145.0±13.3 160.0±28.6* 
VO2max (l•min-1•kg-1) 22.3±1.4 13.9±1.7** 14.4±1.5** 
Peak power (W) 117±8 60±7*** 47±9*** 
6MWD (m) 584±24 469±30* 367±59*** 
BODE index 0.1±0.1 2.3±0.4** 4.0±1.0***,† 
    
    
Data are presented as mean±SEM. 
*: p<0.05; ** p<0.01; *** p<0.001 versus controls. †: p<0.05; †† p<0.01; ††† p<0.001 
versus COPD patients with a normal BMI. Comparisons were analysed using one-way 
ANOVA and Tukey’s post hoc test. 
Abbreviations: BMI: body mass index; FFMI: fat-free mass index; VE: lung ventilation; 
FEV1: forced expiratory volume in 1 sec; 6MWD: 6-min walking distance;  
Table 2-1 | Anthropometric characteristics defining the COPD cohort used in the 
case study. 
The second dataset represents an unpublished, genome-wide transcriptional response of 
mouse soleus muscle to a gradual decline in atmospheric oxygen concentration 
(GSE64076; data will be released upon publication). 
Using the first dataset, representing the basal transcriptional state of skeletal muscle in a 
COPD cohort (Figure 2-2), I first show how to infer statistical connections between 
oxygen availability (e.g. VO2max), oxidative stress (protein carbonylation) and gene 
expression signatures (Figure 2-2A-C). 
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Figure 2-2 | Schematic representation of the analysis strategy used in the case study, 
highlighting how the inferred static multi-scale network from the clinical COPD 
cohort (Fig. 2-2A-C) can be bridged to the inference of a dynamical network 
representing the temporal progression of events following an experimental challenge 
(hypoxic exposure) in a murine animal model (Fig 2-2D-G). 
[figure legend continues on next page] 
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Having identified a clinical condition with known outcome (exercise intolerance in 
patients with respiratory disease), we could target unknown mechanisms by focussing on 
one likely source of functional limitation  (skeletal muscle dysfunction ± central 
limitation on O2 supply), and generate data characterising the phenotype. Both genomic 
and physiological readouts were used to construct a network of inferred interactions, 
which was then interrogated to identify statistically robust linkages among broad 
biological functions. While very useful in providing a list of useful biomarkers, there 
remains a potential limitation with single point associations. The dynamic nature of 
relationships is captured by repeated measures across a suitable time scale (which will 
vary for different molecular, physiological and structural responses) using an animal 
model of respiratory distress, where the transcriptome-based model demonstrated the 
central importance of oxygen in the response. 
 
Having defined an oxygen-related signature in the disease setting, we then transpose 
these findings in a mouse model of gradual hypoxia (second dataset, Figure 2-2D-E). 
Here we use a different computational approach to develop a hierarchical dynamical 
model explaining the transcriptional response of oxidative leg muscles to a prolonged 
gradual reduction in blood oxygenation (hypoxaemia) (Figure 2-2F-G). The model we 
describe below validates the notion that the signature identified using the clinical study 
may be truly triggered by changes in oxygen availability. Moreover, the model 
contributes to the understanding of the transient events following oxygen depletion that 
cannot be observed using a cross-sectional clinical study. 
 
 
2.3.1 Step 1. Linking physiological measurements and gene expression data in the 
COPD cohort 
In order to reconstruct an interaction network spanning multiple levels of organization, 
we have utilised the following strategy that the Falciani lab developed earlier [133]. 
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1. Combining measurements from different data sources 
In order to combine gene expression data with whole-body physiological readouts, all 
variables need to have the same units of measurement (as the range of e.g. VEGF mRNA 
expression values is very different from that of VO2max). All such raw scale units can be 
unified by simply ‘transforming’ each experimental variable to have the same dynamic 
range, e.g. this can be achieved by standardising measurements across samples to have a 
mean of 0 with a standard deviation of 1. Such an established approach, called z-scoring, 
enables us to treat the physiological indicators as individual ‘nodes’ in the inferred 
interaction network with states (just as each gene on the array is treated). 
Definition of a biological framework for data-driven network inference   
The outcome of data-driven reverse engineering of biological networks, in the absence of 
any biological assumption(s), often provides results that are difficult to interpret due to 
the large number of inferred significant interactions. Thus, to reduce complexity of the 
problem, we decided to focus the analysis on the set of physiological parameters and 
genes encoding for enzymes in the central bioenergetic pathways (i.e. TCA cycle, 
oxidative phosphorylation, glycolysis). The latter choice is reasonable considering the 
paramount importance of these molecular pathways in skeletal muscle adaptation. The 
overall strategy is therefore to identify biomolecules that are highly correlated (based on 
MI) with biologically important experimental variables. Such a focused analysis will 
generate multiple network modules of interacting biomolecules, each with a bioenergetic 
hub gene or physiological measurement at its centre. Two modules will be linked 
together if a specific gene is statistically linked to both hubs. 
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2. Reverse engineering. 
In order to infer robust regulatory relationships between variables in the integrated multi-
level dataset, we used the ARACNE algorithm. This choice was based on the large 
number of measured variables to be considered by the mathematical framework. By 
combining all genes expressed in human skeletal muscle (>10,000 mRNAs) with the list 
of physiological variables we far exceed the number of variables that can be handled by 
more advanced network inference methods (e.g. Bayesian methods). Hence, we infer a 
static network without any obvious hierarchical organization. The result of an ARACNE 
run is an ‘adjacency matrix’ containing MI values for all pairwise interactions above the 
specified MI threshold, which can be visualized automatically in Cytoscape. 
 After calculating MI-based dependencies between all the different variables in our 
multi-level data matrix, all those inferred regulatory interactions with an MI value below 
0.22 (corresponding to a P-value cut-off of 10-6) were removed. Such filtering of weaker 
statistical dependencies is an important step in the generation of a more sparse interaction 
network, which can more easily be interpreted by the investigator. The stringent P-value 
cut-off means that the remaining associations have been inferred with high precision at 
the cost of a lower recall rate. 
 
3. Network visualization  
Data visualized as a network are often easier to interpret than long lists of biomolecules 
and their associated statistical dependencies. Hence, the numeric output of ARACNE, 
which contains MI values for all pairwise associations, was imported into Cytoscape for 
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visualization, a conventional way of analysing interaction networks. Briefly, we 
reconstruct the network neighbourhood of each of the bioenergetic ‘seed’ genes (i.e. all 
variables directly connected to them). The neighbouring variables can either be genes 
expressed in skeletal muscle and/or physiological variables. Figure 2-3 summaries key 
regulatory associations (based on MI) between this seed set of genes and their immediate 
neighbours.
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Figure 2-3 | Graphical representation highlighting putative regulatory associations 
(significant correlation between two factors is shown as a dotted line) that likely 
represent robust interactions, based on high mutual information values. 
The focus is on central metabolism pathways (i.e. glycolysis, TCA and OXPHOS, 
respectively) and their immediate neighbours. The grey boxes define functional 
enrichment of the different bioenergetic compartments based on direct neighbours. 
Individual genes of relevance are grouped into modules with others of related function, as 
are physiological readouts that may be treated in a similar manner for statistical analysis. 
C1-5: the different complexes in the electron transport chain. The value of such an 
approach is in providing a detailed overview of a complex interaction network, reducing 
the huge number of potential factors into groups of defined function, and offering a 
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4. Functional analysis of the network hubs 
We further explored whether the direct interacting neighbours of each central metabolism 
pathway mapped to functional categories (i.e. GO terms) as well as KEGG pathways. 
Notably, a marked enrichment of the different bioenergetic compartments was observed 
(Figure 2-3, boxes A-C) that clearly highlights the interconnected nature of the 
bioenergetic machinery, i.e. functionally related genes appear to be co-expressed. 
 
5. Biological interpretation 
The most important finding of the current analysis is that among the direct neighbours to 
each bioenergetic pathway, particularly the two oxidative ones, we noted a statistical 
over-representation of genes encoding histone deacetylase enzymes (i.e. HDAC and 
SIRT mRNAs). This observation is consistent with previous studies that have highlighted 
the importance of sirtuins in regulating metabolism [134–136]. Further, the protein 
deacetylase SIRT3 that primarily is localized in the mitochondrial matrix was also 
significantly positively correlated to both arterial oxygen tension (PaO2) and oxygen 
uptake (VO2max). In support of deacetylation being an important control point, it was 
recently shown that Sirt3 knockout mice exhibit decreased oxygen consumption, thus 
affecting cellular respiration [135]. Hence, besides the obvious oxygen-driven effect on 
aerobic pathways (as indirect measures of oxygen availability such as VO2max are linked 
to key genes in oxidative phosphorylation), the present network-based Systems Biology 
approach points to tissue hypoxia as being a potential important player in modifying 
expression of deacetylase modifying enzymes in severe COPD patients with a muscle 
wasting phenotype. Our Systems Biology approach also negatively links protein 
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carbonylation (an established proxy measure for oxidative stress; [137]) to Complex 1 
and 3 in the electron transport chain (Figure 2-3, bottom left part). The validity of such an 
association is further strengthened via functional enrichment analysis using DAVID, as a 
significant fraction of direct neighbouring genes to protein carbonylation is statistically 
associated to gene ontology (GO) terms representing cellular respiration. 
If we then focus on the genes in the glycolytic pathway (Figure 2-3, top right 
part), a high proportion of pro-inflammatory mediators/receptors (e.g. IL1B, IL1R1 and 
TNFRSF21) are among the direct neighbours, as indicated by the enrichment of the 
‘inflammatory response’ GO term (Figure 2-3, box A). Hence, hypoxia is pro-
inflammatory, as seen by more traditional observation methods [138]. 
 Multi-scale network inference approaches, similar to that illustrated in Figure 3, 
have proven very effective in generating robust hypotheses (e.g. 45). However, statistical 
associations may not represent causality, particularly when the inferred associations stem 
from steady-state measures. Thus, in order to validate our hypothesis that varying oxygen 
levels (represented by VO2max and PaO2) control the expression of epigenetic modifiers, 
we used a more sophisticated network inference algorithm that can learn the structure of 
networks from time-course data. We applied this dynamic inference approach to a murine 
model of hypoxia (Step 2).  
 
2.3.2 Step 2. Gene expression dynamics in response to tissue hypoxia 
Animal models are commonly used for studying the in vivo effects of hypoxia, for ethical 
reasons, where severe or prolonged hypoxaemia is induced and invasive samples are 
required to explore mechanisms. Importantly, hindlimb skeletal muscles have been 
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reported to alter metabolic phenotype and reduce fibre size in response to prolonged 
hypoxic stress in mice [139, 140], highlighting their potential relevance as a pre-clinical 
model of muscle wasting in COPD patients. In order to experimentally test the hypothesis 
derived from the clinical COPD network presented in Figure 2-3, we therefore exposed 
adult male C57/Bl6 mice to chronic systemic hypoxia for up to 2 weeks, in order to 
simulate levels of hypoxaemia reported in COPD patients with advanced respiratory 
insufficiency. To capture the temporal effect of reduced oxygen tension on gene 
regulation, we sampled and gene profiled the soleus muscle (n=4) at 3 different time-
points (day 3, 7 and 14) following initiation of the gradual hypoxic insult (i.e. the O2 
level was gradually lowered to 10% over the first week and kept stable during the second 
week) (Figure 2-2, bottom part). 
First, a high-level representation of the temporal transcriptional changes was 
performed using a variable reduction technique called principal component analysis 
(PCA) (Figure 2-4B). When plotting replicates of two variables against each other, it is 
relatively easy to see which is a better discriminating factor; visual inspection becomes 
increasingly difficult as the number of variables increase, hence the need for PCA. In 
essence, this method aims at ‘tilting’ the axes through the multidimensional data space, 
such that the first principal component accounts for as much of the variation in the 
original dataset as possible (the assumption is that the most important dynamics in the 
dataset are the ones with the largest variation). Our PCA revealed that the early dynamics 
of hypoxia is captured by the first principal component whereas the 2nd most important 
principal component (in terms of variance captured) separated the later time-points. 
Further, functional enrichment analysis of the differentially expressed genes (ANOVA, 
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P<0.05) using DAVID (Figure 2-4A), highlighted several important pathways/ontologies. 
Most striking was the enrichment of protein catabolic process and ubiquitin-mediated 
proteolysis among genes up-regulated at day 7 and 14, clearly suggestive of a 
transcriptionally regulated muscle wasting phenotype driven by the experimentally 
induced hypoxaemic state. 
	  
Figure 2-4 | High-level representation of temporal transcriptional changes in the 
murine model of hypoxia. 
A) Graphical representation of the pre-clinical experimental design. The O2 level was 
gradually decreased from 21% to 10% during the first week and mice were housed for 
another week at this O2 concentration. B) PCA plot highlighting the transcriptional 
dynamics caused by the hypoxic challenge. C) Hierarchical clustering using mRNA 
expression levels of genes modulated by hypoxia (P<0.05). Each row represents a 
transcript and each column represents a sample. Red and green colours indicate 
expression levels above and below the median value of the distribution of signal, 
respectively. Using solid yellow lines we have subdivided genes into overall trends in 
order to help the reader. Enriched functional terms within these are listed next to the 
heatmap. 
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State space models (SSMs) are a class of probabilistic graphical models. SSM 
provides a general framework for analyzing deterministic and stochastic dynamical 
systems that can be measured/observed through a stochastic process. The SSM 
framework has been successfully used for the analysis of gene expression data [103, 
141]. In its simpler application the model formalises the effect of hidden, unmeasurable 
factors in specifying observed gene expression changes over time. The inclusion of these 
hidden factors is important since we cannot hope to measure all possible factors 
contributing to genetic regulatory interactions (e.g. levels of regulatory proteins as well as 
effects of mRNA and protein degradation).  
The next step was to apply state-space modelling to reverse engineer transcriptional 
network modules (i.e. representing discrete temporal dimensions) from our replicated 
murine time-course dataset. Such module-based reduction in complexity allows analysis 
of hundreds or even thousands of genes, as those with a similar temporal expression 
profile are aggregated into a transcriptional module. To allow construction of a near 
genome-level model, we took advantage of a newer approach that incorporates this 
concept of modularization [103]. 
A SSM can reconstruct the topology of a network representing the systems 
dynamics, despite a relatively small number of time-points, by using biological replicates 
for each time-point [103]. In order to reduce complexity, variables that do not change 
significantly are excluded from the modelling process. In this case study, genes deemed 
to be significant by ANOVA at a 1% significance level, as well as all hub genes, were 
included (931 variables in total). The hub genes were chosen to represent the different 
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components in our interpretative model derived from the clinical COPD dataset (Figure 
2-3). Finally, the experimentally set oxygen level was used as an independent variable. 
	  
Figure 2-5 | The hierarchical dynamic state-space model identified 4 modules (x-
axes define length of hypoxic exposure), each characterised by two separate 
transcriptional profiles: plus and minus, representing up- and down-regulation, 
respectively. 
The hierarchical position of the modules represents the estimated temporal structure of 
the network. Functionally enriched GO terms  (regular text) as well as key genes (italics) 
are identified next to the relevant module. Blue arrows represent temporal repression 
whereas red arrows represent temporal induction. The numeric value next to each arrow 
represents the estimated coefficient. 
 
 Based on unsupervised clustering using HOPACH within the software 
programming environment R [142], we identified 8 distinct gene clusters with similar 
expression profiles. Hence, to model the effect of hypoxaemia on the skeletal muscle 
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transcriptome the hidden state dimension was set to 4, as each inferred module contains 
both a positive (+) and a negative (-) component.  
The hierarchical dynamic model in 4 temporal dimensions shows that modules 1 
and 2, which sit on the highest level of hierarchy (i.e. precede others in time), were 
enriched in GO terms related to muscle contraction, bioenergetic pathways, and 
inflammation among others (Figure 2-5). Interestingly, the experimental oxygen 
concentration was represented in module 1(-) whereas two deacetylases SIRT3 and SIRT5 
were found in module 2(-). A negative influence is observed of module 1 on module 3, 
which is located further down the temporal hierarchy. Module 3(+) is highly enriched in 
inflammatory processes whereas its negative counterpart mainly represents two key 
signalling pathways (mTOR and insulin). At the lowest temporal level we find module 4, 
which is enriched in GO terms related to muscle differentiation, tissue remodelling and 
blood vessel development. Interestingly, three HDACs are represented in module 4(+) 
(Figure 2-5). Figure 2-6 represents a more focused version of Figure 2-5, highlighting the 
most significant interactions between components in the four inferred modules from 
Figure 2-5. 
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Figure 2-6 | A higher resolution representation of Figure 2-5, highlighting the most 
significant gene interactions between components in the four inferred modules. 
Lines represent factor interactions based on mutual information (blue represents temporal 
repression, red represents temporal induction). Genes are colour coded for broad 
functional categories (red=cytokines; blue=epigenetic modifiers; green=aerobic 
metabolism; purple=muscle differentiation; yellow=cell-interaction). 
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 We therefore conclude that the inferred dynamic model using a state space 
modelling approach appropriately recapitulates the interpretative model advanced in 
Figure 2-3. In addition, it identifies oxygen at the highest level of hierarchy, whereas key 
effector functions controlled by oxygen such as inflammation and muscle differentiation 
are downstream in the temporal hierarchy. 
 
2.4 CONCLUSIONS 
The aim of this brief review is to provide an intuitive overview on data-driven ‘learning’ 
of biological pathways, linking molecular and physiological readouts. We used a case 
study to make it easier for experimental biologists to see the potential of computational 
biology to provide interpretative models of complex patterns, and stress that the 
identification of general properties of a system from a genome wide analysis of a 
molecular state of a system is a very powerful approach. We also explain that it is 
complementary, rather than an alternative to hypothesis-driven science.  The importance 
of a robust characterization of the physiological parameters of the biological system, 
which must be integrated in the model to provide useful testable hypothesis, is 
emphasised. In support of this concept, we demonstrate the development of an integrative 
workflow that incorporates measurements from different levels of cellular and molecular 
organization using a case study representing muscle wasting in COPD. The outline 
provides an exemplar where individual steps can be modified according to the type of 
data at hand and addition data types added. For example, in contrast to established gene 
expression microarrays, techniques for proteomics and especially metabolomics are still 
under development. Once it is possible to measure the whole proteome and metabolome 
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of a sample, systems identification pipelines will clearly benefit from these omics 
techniques. 
The specific findings in the case study relate to the definition of an oxygen dependent 
signature in COPD. Such signature (exemplified in Figure 2-3) is static and entirely based 
on statistical inference. The model is therefore based only on correlation between a series 
of patient biopsie snapshots, and therefore does not allow any inference of causality. The 
use of a mouse model of gradual hypoxia allowed us to demonstrate that a signature 
inferred from the clinical cohort is indeed modulated by experimental reduction in 
oxygen levels. Moreover, the development of a mathematical model identifies oxygen as 
the most upstream event as an emergent property. This may appear an obvious finding 
but, from a methodological perspective, validates the analytical approach. 
The data we have used in this case study is gene expression profiling, and as such is 
representative of available datasets. This has several limitations. The first is that models 
including multiple levels in the expression of genetics information (e.g. epigenetics, 
microRNA, proteomics, metabolomics, etc.) may better represent biological complexity. 
However, current computational methods are inadequate to represent properly the 
interaction between these levels. Moreover, time course data that rely in disruptive 
sampling strategies are not true time course experiments. As the new functional genomics 
technologies develop further, as well as novel approaches to model the interaction 
between different layer of biological organisation, we expect that the efficacy of data-
driven approaches will increase further.	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3 A systems biology approach reveals a link between systemic 
cytokines and skeletal muscle energy metabolism in a rodent 
smoking model and human COPD 
	  
The	  work	  presented	  in	  this	  chapter	  represents	  a	  collaborative	  project	  between	  the	  labs	  
of	   Francesco	   Falciani,	   Joan	   Barberá	   (University	   of	   Barcelona)	   and	   Constancio	  
Gonzalez	   (University	   of	   Valladolid).	   The	   two	   Spanish	   labs	   jointly	   designed	   and	  
conducted	   the	   in	   vivo	   animal	   exposure	   experiment.	   Members	   of	   the	   Falciani	   lab	  
contributed	   to	   the	   development	   of	   the	   custom	   microarray	   platform	   used	   in	   this	  
chapter.	   I	   carried	   out	   all	   wet-­‐lab	   genomic	   analyses	   as	   well	   as	   all	   in	   silico	   analyses	  
presented	   herein.	   Josep	   Roca	   (University	   of	   Barcelona)	   provided	   the	   raw	   Affymetrix	  
microarray	  data	  as	  well	  as	  anthropometric	  characteristics	  related	  to	  the	  clinical	  COPD	  
cohort.	  
The	  work	  presented	  in	  this	  chapter	  was	  published	  in	  Genome	  Medicine	  in	  2014	  [131].	  
	  
3.1 Abstract 
Background: A relatively large percentage of patients with chronic obstructive 
pulmonary disease (COPD) develop systemic comorbidities that negatively affect 
prognosis, among which peripheral skeletal muscle wasting is particularly debilitating. 
Despite significant research effort, the pathophysiology of this important extrapulmonary 
manifestation is still unclear. A key question that remains unanswered is to what extent 
systemic inflammatory mediators might play a role in this pathology. 
Cigarette smoke (CS) is the main risk factor for developing COPD and therefore animal 
models chronically exposed to CS have been proposed for mechanistic studies and 
biomarker discovery. Although mice have been successfully used as a pre-clinical in vivo 
model to study the pulmonary effects of acute and chronic CS exposure, data suggest that 
mice may be inadequate models for studying the effects of CS on peripheral muscle 
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function. In contrast, recent findings indicate that the guinea pig (Cavia porcellus) may 
better mimic the wasting process observed in human COPD patients. 
Methods: I have used a systems biology approach to compare the transcriptional profile 
of hindlimb skeletal muscles from a guinea pig rodent model exposed to CS and/or 
chronic hypoxia to COPD patients with limb muscle wasting. 
Results: I show that guinea pigs exposed to long-term CS accurately reflect most of the 
transcriptional changes observed in dysfunctional limb muscle of severe COPD patients 
when compared to matched controls. Using network inference, I then show that the 
expression profile in whole lung of genes encoding for soluble inflammatory mediators is 
informative of the molecular state of skeletal muscles in the guinea pig smoking model. 
Finally, I show that CXCL10 and CXCL9, two of the candidate systemic cytokines 
identified using this pre-clinical model, are indeed detected at significantly higher levels 
in serum of COPD patients, and that their serum protein level is inversely correlated with 
the expression of aerobic energy metabolism genes in skeletal muscle. 
Conclusions: We conclude that CXCL9 and CXCL10 are promising candidate 
inflammatory signals linked to the regulation of central metabolism genes in peripheral 
skeletal muscle. On a methodological level, the current work also shows that a systems 
level analysis of animal disease models can be very effective at generating clinically 
relevant hypotheses. 
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3.2 Background 
Chronic obstructive pulmonary disease (COPD), one of the top five deadliest diseases 
worldwide [143], is an inflammatory condition of the lungs that predominantly affects 
people with a long history of cigarette smoking (CS) [144]. In addition to the well-
established clinical manifestations in lungs, COPD is also associated with several extra-
pulmonary manifestations. Peripheral skeletal muscle wasting and dysfunction is one of 
the most severe of these pathologies [21]. This muscular deconditioning of the limbs, 
which is partly independent of the severity of airflow limitation, is a prominent 
contributor to exercise intolerance [145] as well as being an independent predictor of 
morbidity and mortality [146]. Long-term CS exposure has a clear potential to contribute 
to the systemic effects of COPD, as similar findings have been observed in healthy 
smokers (e.g. a decrease in lean muscle mass and force reduction) [147]. However, the 
direct effects of CS on peripheral muscle function, at the molecular level, are at present 
poorly understood. 
Although we do not still fully understand the mechanisms that contribute to peripheral 
muscle dysfunction in COPD, there is evidence that multiple factors are likely to 
influence clinical outcome, such as systemic inflammation, reduced capillary density, 
tissue hypoxia and subsequent oxidative stress [148, 149]. However, it is currently not 
known to what extent increased levels of inflammatory cytokines play a role in muscle 
wasting.  
Likewise, hypoxaemia (abnormally low concentration of oxygen in the bloodstream) has 
been linked to several drivers of skeletal muscle dysfunction in COPD such as down-
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regulation of energy consuming processes (e.g. protein synthesis, mitochondrial 
respiration), impaired adult myogenesis (affecting muscle regeneration capacity), fibre 
type shifting (slow-to-fast myofiber transition) [150], and increased serum levels of 
cytokines [151], but the exact molecular mechanisms through which chronic or 
intermitted hypoxia affects muscle maintenance are currently unclear. 
Animal models, particularly mouse models, are widely used to study the effects of 
acute and chronic CS. Importantly, long-term CS exposure in rodent models may be the 
best approximation of the more acute aspects of lung responses in human COPD [152]. 
However, the current literature suggests that mice chronically exposed to CS develop 
either none or only mild peripheral muscle dysfunction [147, 153, 154]. For example, 
only two studies have to our knowledge reported a significant decrease in hindlimb 
muscle weight following long term whole-body exposure using very high smoking doses 
(≥ 20 cigarettes/day) [153, 155]. 
The guinea pig (Cavia porcellus) (GP), one of the most popular animal models to study 
infectious diseases [156], has been shown to tolerate CS exposure without the rapid 
weight loss observed in other pre-clinical models [157]. However, promisingly long-term 
CS-exposed guinea pigs fail to appropriately gain body weight compared to age-matched 
sham controls [147, 158]. Further, in accordance with previous findings in COPD 
patients [147], guinea pigs demonstrate CS-induced oxidative stress in limb muscles 
within 3 months of exposure [147, 158], potentially highlighting the relevance of the GP 
model for studying extrapulmonary comorbidities that characterise human COPD. 
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However, the GP is a rather challenging model organism to determine the molecular 
response due to the lack of a fully annotated genome. This paucity of genetic information 
is unfortunate since gene expression profiling has shown to be a very promising approach 
to formulate hypotheses on complex molecular mechanisms underlying pathology [159, 
160]. Here, we report the development of the first transcriptome-sequencing for guinea 
pigs representing lung and limb skeletal muscles, as well as the development and 
validation of a novel genome-wide microarray platform. With this novel platform, we 
profiled the transcriptional response of lung and muscle tissues chronically exposed to 
CS, hypoxia (CH) or to combined stimuli (CSCH). The overarching aim of this study was 
to assess whether GP hindlimb muscles (both oxidative and glycolytic) show a 
transcriptional response to these exposures, and whether such gene signatures can be 
correlated to the expression of lung secreted proteins. 
We discovered that indeed skeletal muscles of GP exposed to all experimental 
interventions accurately mimic the transcriptional state of human limb muscle sampled 
from COPD patients with muscle atrophy. Using a relatively simple network inference 
method we then identified systemic cytokines whose mRNA and serum protein levels are 
inversely correlated with the transcriptional state of energy metabolism pathways in GP 
and human COPD patients, respectively. 
These results provide further evidence for the utility of the GP smoking model to study 
muscle wasting in COPD and support the hypothesis that systemic inflammation plays an 
important role in altering the energy metabolic state in peripheral muscles causing them 
to dysfunction.  
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3.3 Methods 
3.3.1 Guinea pig smoking model 
Sixteen male Hartley guinea pigs were divided into four groups: one group was exposed 
to CS for 3 months (n = 4); a second group was kept in normoxia for 10 weeks and 
subsequently placed in an hypoxic environment (12% O2) for two weeks (n = 4); a third 
group (n = 4) was CS-exposed for 3 months and to chronic hypoxia the last two smoking 
weeks; finally we included a fourth group (n = 4) of sham controls remaining in 
normoxia for the whole study period. To avoid problems related to ageing, young adults 
were used (8 weeks of age), and to avoid scaling effects body mass was similar (~300 
g/animal). All procedures involving animals and their care were approved by the Ethics 
Committee of the University of Barcelona and by the University of Valladolid 
Institutional Committee for Animal Care and Use, and were conducted following 
institutional guidelines that comply with national (Generalitat de Catalunya decree 
214/1997, DOGC 2450) and international (Guide for the Care and Use of Laboratory 
Animals, National Institutes of Health, 85–23, 1985) laws and policies. 
Whole lung as well as soleus and lateral gastrocnemius hindlimb muscles were isolated 
from each animal at the end of the study period. The soleus muscle and the lateral gastro 
were selected to represent oxidative and glycolytic muscles, respectively. It should be 
noted that although the gastrocnemius as a whole is a mixed muscle, the lateral portion is 
predominantly glycolytic. 
Animals receiving CS were daily exposed to the smoke of 4 cigarettes (2R4F; Kentucky 
University Research; Lexington, KY, USA, 11 mg tar, 0.8 mg nicotine per cigarette), 5 
days/week using a nose-only inhalation system (Protowerx Design Inc; Langley, British 
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Colombia, Canada). Sham-exposure to CS was done daily by placing control animals in 
the nose-only exposure chamber for the same duration (1 hour) without cigarettes being 
lighted. In this experimental model, neither nutritional status (determined via 
measurements of plasma cholesterol, protein and lipids) nor whole-body weight gain at 
the end of the study period is significantly different between CS-exposed and sham 
animals [158]. Moreover, no changes in the proportion of Type I and Type II fibres can 
be detected between CS-exposed and shams [147]. Detailed information on exposure 
protocols, pulmonary function data and histological assessments from this study, which 
demonstrate that observations in lung function and pulmonary structural changes of 
COPD patients are indeed replicated in the CS-exposed guinea pigs, have been reported 
in two separate publications [157, 161]. 
3.3.2 RNA isolation from guinea pig samples 
Total RNA was extracted using the RNeasy Mini extraction kits (Qiagen, USA) 
according to the manufacturer’s recommendations. RNA purity and quality was evaluated 
using a NanoDrop (Thermo Scientific) and a BioAnalyzer 2100 instrument (Agilent 
Technologies), respectively. All samples had a RIN score >7. 
3.3.3 Definition of the guinea pig transcriptome by mRNA sequencing and 
microarray design 
In 2008 the GP genome was sequenced to a depth of ~7X full coverage, and last updated 
in 2010. However, because of the lack of cDNA and protein resources the GP genome is 
at present poorly annotated. Thus, in order to address this issue we performed an in-depth 
mRNA sequencing of the lung and skeletal muscles transcriptomes and used this to 
annotate the available GP genome for transcribed sequences. We then used this 
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information to design and validate the custom Agilent microarray platform used 
throughout this chapter. 
Transcriptome sequencing was performed using Illumina sequencing. Briefly, NCBI and 
Ensembl transcripts of GP were combined with transcripts constructed from Illumina 
paired end reads using the TopHat and Cufflinks algorithms [162, 163]. Microarray probe 
sequences were then chosen based on the combined transcriptome assembly. The raw 
RNA-Seq data have been deposited at the Gene Expression Omnibus (GEO) under the 
reference number GSE56099. A detailed description of the procedure is provided in 
Appendix 7.1. 
3.3.4 Guinea pig microarray gene expression profiling 
One hundred nanograms of total RNA from each sample was amplified and converted 
into labelled cRNA using Agilent’s Low Input Quick Amp Labelling Kit according to the 
manufacturer’s recommendations. Cy3-labelled cRNA (600 ng/sample) was hybridized 
to our custom Cavia porcellus oligonucleotide microarray (manufactured by Agilent) in 
randomized sample order, which generated 61,657 measures per sample (18,073 
annotated genes). Hybridization, washing and scanning of arrays were performed 
according to manufacturer’s protocol. Three samples (one from each tissue) were lost 
during the process of generating raw data. All scanned microarrays passed all eleven of 
the Agilent’s quality metrics. Capture probes that were flagged (i.e. did not pass Agilent’s 
‘well above background’ condition) on at least 80% of the chips were removed prior to 
data analysis, such that only those capture probes with a raw signal greater than 99% of 
the background population signal, for at least 20% of the samples, were retained (29,333 
probes were discarded). 
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Raw microarray data were then normalised against sham controls for each of the three 
tissues using loess in the ‘marray’ [164] and ‘limma’ [165] Bioconductor packages. 
Arrays were examined using hierarchical clustering and principal component analysis 
(PCA) to identify outliers prior to statistical analysis. 
The statistical significance of differential expression of each gene was determined using 
the Significance Analysis of Microarray (SAM) algorithm [166] with a False Discovery 
Rate (FDR) cut-off of 1%. Gene ontology (GO) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) enrichment in differentially expressed genes was examined using the 
web-based tool DAVID [167]. Disease KEGG pathways were excluded from the analysis 
to maximise biological interpretability. Therefore the analysis was restricted to KEGG 
group 1–4 (Metabolism, Genetic Information Processing, Environmental Information 
Processing, and Cellular Processes). The microarray data have been deposited in GEO 
under accession number GSE56099. 
3.3.5 RT-qPCR validation of custom GP array 
Reverse transcription of 1 µg of isolated total RNA from whole-lung tissue (same RNA 
as were used for the microarray part) was performed using the Tetro cDNA synthesis kit 
(Bioline) with random hexamer primers following the manufacturer’s instructions. The 
resulting cDNA was diluted ten-fold and 2.5 µL of this was used to perform qPCR in 
triplicate (25 µL reaction mixture volume) using the Maxima SYBR green (Thermo 
Scientific) and 300nM of primers according the manufacturer’s instructions. To adjust for 
variations in the cDNA synthesis, each gene was normalized to that of 18S ribosomal 
RNA and beta-actin mRNA, respectively. All reactions were run in singleplex on a 
StepOnePlus Real Time System (Applied Biosystems) at 95˚C for 10 min, followed by 
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40 cycles at 95˚C for 15 sec and 60˚C for 1 min. Two-fold dilution series were performed 
for all primer pairs to verify the linearity of the assay. In addition, dissociation curve 
analysis was performed after each PCR to check for unspecific signals. Quantification 
was performed using the comparative cycle threshold (2-∆∆Ct) method [168]. 
The following primers were used:  
CXCL9 fwr: 5’-AGGCACCCCAGTAATGAG-3’;  
CXCL9 rev: 5’-TGATTTCTGTTTTCTCACACG-3’;  
CXCL10 fwr: 5’-TCTGAGTGGGACTCAAGGAATACC-3’;  
CXCL10 rev: 5’-TCCAGACATCTCTTCTCCCCATTC-3’;  
beta-actin fwr: 5’-GAGGCACCAGGGAGTCATG-3’; 
beta-actin rev: 5’-AAGGTGTGGTGCCAGATCTTCTC-3’;  
18S rRNA fwr: 5’-GTACAGTGAAACTGCGAATGGCTC-3’; 
18S rRNA rev: 5’-CCGTCGGCATGTATTAGCTCTAG-3’. 
 
3.3.6 Human COPD clinical studies 
In order to assess the clinical relevance of the findings in respect to the GP dataset, we 
took advantage of a human microarray dataset we have previously published [133]. This 
defined the baseline/resting transcriptional state of the vastus lateralis muscle in severe 
COPD patients with either a normal (n = 9) or low (n = 6) body mass index (BMI) and 
healthy controls matched for age and smoking history (n = 12) (Table 3-1). In addition, 
the low BMI COPD group also had a significantly lower fat free mass index (FFMI) (on 
average 16.7 kg/m2; Figure 3-1), a clear surrogate for muscle wasting. 
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Figure 3-1 | Barplot highlighting group mean differences in mass indexes (whole-
body and fat-free, respectively) and 6-min walking distance. 







Gender (M/F) 10/2 9/0 6/0 
Age (years) 65.3±2.9 69.4±1.5 69.2±4.6 
BMI (kg/m2) 26.3±1.1 27.4±1.4 19.7±1.0**,†† 
FFMI (kg/m2) 21.0±0.8 21.5±0.7 16.7±0.9**,†† 
VE (L/min) 71.2±5.6 40.5±3.6*** 33.0±3.8*** 
FEV1 (L) 3.46±0.2 1.41±0.09*** 1.21±0.21*** 
FEV1/FVC (%) 75.9±2.4 44.0±2.7*** 39.5±4.5*** 
RV (% of pred.) 103.9±5.2 145.0±13.3 160.0±28.6* 
VO2max (l•min-1•kg-1) 22.3±1.4 13.9±1.7** 14.4±1.5** 
Peak power (W) 117±8 60±7*** 47±9*** 
6MWD (m) 584±24 469±30* 367±59*** 
BODE index 0.1±0.1 2.3±0.4** 4.0±1.0***,† 
    
    
Data are presented as mean±SEM. 
*P <0.05; **P <0.01; ***P <0.001 versus controls. †P <0.05; ††P <0.01; †††P <0.001 
versus COPD patients with a normal BMI. Comparisons were analysed using one-way 
ANOVA and Tukey’s post hoc test. 
BMI: body mass index; FEV1: forced expiratory volume in 1 s; FFMI: fat-free mass 
index; VE: lung ventilation; 6MWD: 6-min walking distance 
Table 3-1 | Baseline physiological data of the COPD patients and healthy controls.  
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All participants signed a written, informed consent approved by the Ethics Committee on 
Investigations Involving Human Subjects at the Hospital Clinic, Universitat de 
Barcelona, and the study was conducted in accordance with principles of the Declaration 
of Helsinki. Briefly, raw Affymetrix CEL files were RMA normalized following removal 
of probes that were termed ‘absent’ in more than 80% of the samples by the MAS5 
algorithm inside the ‘affy’ package (26,197 probes were discarded). Following probe 
summarization, a two-class unpaired SAM analysis was performed using the R package 
‘samr’ comparing gene expression levels between COPD patients with a muscle wasting 
phenotype and matched controls. Enrichment of KEGG terms (group 1 to 4) in the 
resulting gene lists was assessed using DAVID. Enriched terms used to define the ‘true 
response’ in the cross-species overlap analysis were defined as having an EASE score p-
value < 0.2. The raw microarray .CEL files are deposited under the reference number 
GSE27536. 
In addition, we also analysed a public microarray dataset published by the Ronald Crystal 
lab [169] examining transcriptional changes in small airway epithelium from healthy 
non-smokers (n = 47), healthy smokers (n = 58) and smokers with COPD (n = 22), 
respectively (GSE19407). Due to a clear scan date batch issue (Figure 3-2), which the 
original authors did not discover, we focused our analysis on the data generated in year 
2006 and 2007 (hence excluding the two samples scanned in 2005 as well as the 36 
samples processed in 2008). As both human studies were conducted on the Affymetrix 
U133+2 platform, the data analysis strategy of the raw CEL files representing the 
pulmonary data was identical to that of the human dataset in skeletal muscle presented in 
this paper (see above). 
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Figure 3-2 | PCA plot showing that subjects profiled in the GSE19407 dataset 
(n=127) group by the year they were scanned (30,652 probesets included). 
Particularly, a clear separation exists between samples scanned in year 2005/2008 and 
2006/2007 (see dotted black line). Noteworthy, the samples profiled in year 2006 and 
2007 are intermixed. 
 
3.3.7 Summarizing the molecular state of skeletal muscle using indices of pathway 
transcriptional activity 
In order to reduce the complexity of the genome-wide transcriptional state of GP skeletal 
muscles, thereby increasing statistical power, we computed indices of the overall 
pathway transcriptional activity [74, 170]. For each of the two GP hindlimb muscles, we 
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first mapped the thousands of individual gene expression measures onto KEGG pathways 
using DAVID [128]. We then summarized the transcriptional activity for the enriched 
pathways (FDR < 10%) by computing the first three principal components (PCs), a 
procedure that allowed us to retain between 50% and 78% of the total variance (63% on 
average). Computation of the PCs was performed using the ‘prcomp’ function within the 
statistical programming environment R. 
3.3.8 Inference of biological networks linking lung and skeletal muscles in guinea 
pigs 
An exhaustive list of genes annotated to the cytokine superfamily (n=72) was compiled 
from the SABiosciences PCR Array Web Portal (see Appendix 1.1 for the complete list). 
Such an approach has been used previously for compiling gene-lists [171]. Among these 
candidates we identified 33 genes coding for cytokines, which were differentially 
expressed in GP lung tissue (Table 3-2). These were selected for further analysis. 
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Table 3-2 | List of genes that are annotated to the cytokine superfamily AND 
differentially expressed in whole-lung tissue of treated guinea pigs compared to 
untreated controls (n=33; FDR<1%). 
Coloured cells denote non-differentially expressed. 
	  
Correlation between the expression of these cytokines and skeletal muscle pathway 
indexes were computed using the Spearman correlations coefficient, which allows the 
identification of linear and non-linear monotone relationships [108]. Resampling of 
samples (10,000 permutations) was conducted to obtain P-values for each correlation 
coefficient. Pair-wise associations within the regulatory network were defined as 
statistically significant when P < 0.01. 
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The resulting sparse network was visualised using a force-directed layout as implemented 
in the network visualization tool Cytoscape v2.8 [112]. 
3.3.9 Creating and visualizing a KEGG pathway map 
To visually represent the relationship between enriched KEGG pathways in the clinical 
dataset, we computed a pathway similarity matrix based on the Jaccards Index of overlap. 
This matrix was used as input to a hierarchical clustering procedure (average linkage). 
3.3.10 Measurement of inflammatory mediators in human serum from COPD 
patients and healthy controls and validation of the guinea pig lung-muscle 
cross-talk network 
Previously published multiplex protein profiling data from COPD serum samples (n = 
26) and healthy controls (n = 23) were included [133]. Briefly, data were log2 
transformed followed by imputation of missing values using K nearest neighbours in the 
R package ‘impute’ [172]. Finally, the full data matrix was Z-scored. 
A Mack-Skillings test with two factors (disease and training) was used to identify overall 
main effects across groups in serum protein levels (P < 0.05). A Gene Set Enrichment 
Analysis (GSEA) was used to establish statistical functional enrichment by ranking all 
Pearson correlation coefficients between serum protein levels and global muscle mRNA 
expression [84].  
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3.4 Results 
3.4.1 Sequencing of the Guinea pig transcriptome and development of a genome-
wide guinea pig microarray platform 
Illumina RNA sequencing (RNA-Seq) in this study has facilitated the construction of a 
comprehensive transcriptome for GP lung and skeletal muscles, with much higher 
coverage than attainable purely by public available data. In combination with public 
domain data, Ensemble cDNAs and Genscan gene predictions, we have generated the 
first comprehensive annotation of the genome-wide transcriptome consisting of 151,072 
transcript sequences (of which 81,074 were derived solely from the RNA-Seq data). The 
number of transcripts annotated with a RefSeq sequence, by stringent BLAST searching 
against mouse transcripts from NCBI’s RefSeq collection, was 97,822. This represented 
17,907 non-redundant mouse gene symbols. Annotated genes were classified according 
to GO categories: cellular component (CC), biological process (BP) and molecular 
function (MF). Figure 3-3 and Figure 3-4 depicts the distribution of the major GO 
categories at ‘level 1’3, for comparison we also included level 1 GO terms for the mouse 
transcriptome. Overall, the GP GO term representation is very comparable to that of the 
genes annotated in the full mouse genome, highlighting the generality of the assembled 
GP transcriptome. Only reproduction processes and extracellular region are poorly 
represented in the guinea pig transcriptome. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  Gene Ontology terms are organized hierarchically such that higher level terms are more 
general.  
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Figure 3-3 | Barplot showing level 1 Gene Ontology (GO) terms of the biological 
process category. 
Blue bars represent all functionally annotated genes from the Mus musculus species 
whereas the red bars represent all annotated genes from the guinea pig RNA-Seq 
analysis. 
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Figure 3-4 | Barplot showing level 1 Gene Ontology (GO) terms of the cellular 
component (CC) and molecular function (MF) category, respectively. 
Blue bars represent all functionally annotated genes from the Mus musculus species 
whereas the red bars represent all annotated genes from the guinea pig RNA-Seq 
analysis. 
	  
In addition, by Human ortholog identification, it was shown that the GP transcriptome 
assembled in this work contained genes included in the entire set of Human KEGG 
pathways available for download via the Broad Institute’s MSigDB Collections [173] 
(please see ‘KeggGPandMouseCounts.xlsx’ associated to the online version of 
Additional file 1). 
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Using the transcript assembly we have developed the first genome-wide microarray 
platform for the GP model species. Based on the probe performance using an initial 180K 
array, we developed a 60K custom Agilent microarray, representing 17,896 unique genes. 
Importantly, we are able to demonstrate a significant concordance between our custom 
60K array platform and RNA-Seq data (Figure 3-5 & Figure 3-6), particularly when the 
ratio between gene expression in lung and muscle tissue is compared (Figure 3-7). 
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Figure 3-5 | Scatterplot highlighting the association between signal intensity on the 
custom guinea pig microarray and normalized RNA-Seq counts using pooled RNA 
from skeletal muscles. 
The two profiling technologies show a good agreement for genes with an above-median 
level of expression. However, for transcripts with a log2 RPKM value close to zero, the 
microarray platform assigned a much wider range of intensity values (primarily from 5 to 
10 on the log2 scale). A possible cause for this reduced correlation for genes with a 
below-median expression may be related to non-specific binding to the array capture 
probes, which affect lowly expressed genes to a greater extent. To avoid taking the log 
base 2 of zero, we added 1 to each of the counts prior to taking the log2. 
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Figure 3-6 | Comparison of estimated log2 fold changes (lung/muscle) from Illumina 
RNA-Seq (y-axis) and the custom microarray platform (x-axis). 
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Figure 3-7 | Plot indicating the fractional overlap (y-axis) between profiling technologies 
in terms of genes being called muscle-specific based on the RNA-Seq data (x-axis). 
The numeric value above each triangle indicates the number of transcripts termed 
muscle-specific by RNA-Seq (at a given RPKM threshold) that overlap with genes being 
expressed above detection background in lung (blue triangles) and muscle tissue (red 
triangles), respectively, on our 60K custom microarray platform. 
	  
3.4.2 Chronic exposure to smoking and/or hypoxia induces transcriptional 
changes in both lung and skeletal muscle in guinea pigs 
To assess whether the current GP model show a transcriptional response, we used our 
newly developed microarray platform with mRNA extracted from whole lung and two 
metabolically distinct hindlimb muscles (gastro and soleus) sampled from shams and 
nose-only CS exposed animals approximately one month after a significant (P < 0.01) 
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Figure 3-8 | Guinea pig whole-body weight gain during the experimental protocol. 
 
Indeed, we were able to identify a relatively large number of genes differentially 
expressed in all three tissues from all experimental groups (Figure 3-9). Notably, both 
hindlimb muscles examined displayed a marked response, with the oxidative soleus 
muscle showing the largest number of changes following exposure to CS alone (Figure 
3-9). 
	  
	   91	  
 
Figure 3-9 | Differentially expressed genes in the Guinea pig experimental model. 
Barplot summarising the number of differentially expressed genes identified by SAM 
analysis (FDR < 1%) following long-term exposure to hypoxia (CH), chronic smoking 
(CS), or smoking followed by hypoxia (CS + CH) in whole lung and skeletal muscles 
(soleus and gastrocnemius). 
	  
3.4.3 Lung response to the different stressors is comparable in magnitude, but 
involves different subsets of functional pathways 
Having shown that both lung and skeletal muscles mount a quantitatively comparable 
transcriptional response following the different experimental challenges, we then 
compared and characterized such responses at the functional pathway level. We first 
focused on lung tissue and performed a functional enrichment analysis, which identified 
15 KEGG pathways that were enriched in genes differentially expressed in lungs, in at 
least one experimental condition (Figure 3-10). Only genes annotated to the ribosome 
pathway were significantly modulated by all three experimental conditions. Instead the 
vast majority of differentially modulated pathways were equally distributed between the 
specific exposure conditions. The six pathways (40%) unique to the CSCH group could 
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be grouped into two main functional categories: i) biosynthetic pathways, and ii) 
pathways with a strong signalling component such as ErbB- and Wnt signalling as well as 
tight junction. In contrast, all 3 pathways (i.e. cytochrome P450 drug-, glutathione-, and 
arginine & proline metabolism) enriched in genes up-regulated by long-term smoking per 
se could be associated to metabolic processes primarily involved in detoxification of 
oxidative stress. Finally, the 4 enriched terms specific to hypoxia can be broken down 
into 2 main functional classes: i) an oxygen-dependent bioenergetic component 
(Oxidative Phosphorylation) enriched in genes down-regulated by hypoxia, and ii) 
pathways with a strong signalling component also negatively affected by hypoxia (i.e. 
phosphatidylinositol signalling, inositol phosphate metabolism and gap junction). 
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Figure 3-10 | Overlap analysis of enriched KEGG pathways in Guinea pig lung 
tissue. 
Rectangles coloured in green indicate pathways unique to a specific experimental 
condition (i.e. CS, CH or CSCH). Grey-coloured rectangles indicate pathways that are 
regulated by more than one condition. 
	  
3.4.4 Glycolytic and oxidative limb muscles respond differently to either smoking 
or hypoxia 
The lateral gastrocnemius modulated a larger number of genes following hypoxia, 
whereas the soleus (an oxidative muscle) responded preferentially to the smoking 
challenge (Figure 3-9). This trend was even more evident when testing for functional 
pathway enrichment. The soleus muscle responded to CS exposure by modulating 10 of 
the 13 pathways (77%) identified as differentially regulated in at least one sample group, 
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making this muscle the most sensitive to this stressor (Figure 3-11A). Of these, eight 
were specifically modulated by CS.
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Figure 3-11 | Overlap analysis of enriched KEGG pathways in two Guinea pig 
hindlimb muscles with discrete metabolic profiles. 
Rectangles coloured in green indicate pathways unique to a specific experimental 
condition (i.e. CS, CH or CSCH). Grey-coloured rectangles indicate pathways that are 
regulated by more than one condition. Panel A is soleus muscle; Panel B represents 
gastrocnemius muscle. 
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The response to hypoxia only involved 2 pathways of which one was specific to CH 
(TGF-beta signalling). However, hypoxia has a considerable effect in the CSCH 
exposure, effectively reducing the impact of CS (only five pathways were enriched when 
both stimuli were combined). 
Consistent with the gene-level analysis, the gastrocnemius muscle primarily showed 
functional pathway enrichment in response to hypoxia (Figure 3-11B). Genes 
differentially regulated in this condition, were enriched in 15 of the 19 KEGG pathways 
(79%) modulated in this muscle in at least one of the experimental challenges. These 
could be grouped in to three main functional clusters: i) bioenergetic pathways such as 
glycolysis and TCA cycle, ii) metabolic pathways (e.g. fatty acid-, propanoate-, purine- 
and pyrimidine metabolism), and iii) pathways exerting degradative processes such as 
proteasome and ubiquitin-mediated proteolysis. Only three pathways, all with a tissue-
remodelling component, were specific to the CS group (focal adhesion, VEGF- and 
ECM-receptor signalling; Figure 3-11B). As a further contrast to the oxidative soleus 
muscle (Figure 3-11A), aerobic energy metabolism in gastro, represented by OxPhos, 
was only enriched among down-regulated genes when hypoxia was added on top of the 
CS-challenge. 
3.4.5 The guinea pig smoking model recapitulates the transcriptional changes 
observed in human COPD skeletal muscles 
Having described the pulmonary as well as extrapulmonary transcriptional response to 
long-term CS and/or hypoxia, we assessed their clinical relevance with an initial primary 
focus on peripheral skeletal muscle. This was achieved by comparing the enriched 
transcription-based functional profiles derived from the GP model with the functional 
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profile of genes differentially expressed in quadriceps skeletal muscle biopsies from 
COPD patients relative to matched healthy controls (see online Additional file 8 for the 
list of regulated transcripts as well as functional enrichment analysis; 
http://www.genomemedicine.com/content/6/8/59/additional) [132]. 
First, we defined the transcriptional signature representing muscle wasting in human 
COPD by comparing a cohort of COPD patients with low FFMI to matched healthy 
individuals. This identified 1,861 differentially regulated genes (1,416 up- and 445 down-
regulated), which represented 19 unique functionally enriched KEGG pathways (Figure 
3-12C). In order to assess which experimental challenge best mirrored human COPD, we 
performed a sensitivity and specificity analysis where ‘true response’ was defined by the 
19 KEGG terms (KEGG group 1–4) representing dysfunction human COPD muscle. This 
analysis, performed ignoring the direction of change, showed that a large percentage of 
enriched KEGG terms in GPs did overlap with the COPD pathway signature - 
irrespective of the exposure (specificity scores ranging from 91% to 98%, p < 0.01) 
(Figure 3-12A). Soleus muscle derived from CS-exposed GP showed the highest 
sensitivity, with 13 out of 19 (68%) KEGG pathways in common (Figure 3-12A). The 
gastro muscle from hypoxic guinea pigs followed by a short measure with a sensitivity of 
53% and 10 KEGG pathways in common. The pathway overlap was statistically 
significant in all six experimental conditions (P < 0.01). 
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Figure 3-12 | Muscle specific pathway-level comparisons between the guinea pig 
model and a clinical COPD study (GSE27536). 
The figure displays the result of the sensitivity and specificity analysis for each of the six 
experimental conditions at the KEGG pathway level, where “true response” is defined by 
the 19 enriched KEGG pathways in the vastus lateralis of muscle-wasted COPD patients 
when compared to matched healthy controls. Panel A is a plot where the x-axis 
represents the experimental conditions in the GP model. The two y-axes represent i) the 
true positive rate as a fraction, and ii) the actual number of overlapping pathways with the 
human COPD cohort. In this panel specificity and sensitivity is computed without 
considering the direction of change in expression (up- and down-regulation). Panel B 
represents the equivalent of the plot in Panel A where specificity and sensitivity is 
computed taking into consideration the direction of change. The grey-colored crosses 
indicate the sensitivity values from the undirected approach presented in Panel A. Panel 
C represents the specific pathways regulated in the GP model (column 2–4) when 
contrasted against COPD patients with a muscle-wasting phenotype (column 1). Green-
coloured cells indicate enrichment among down-regulated transcripts; red-coloured cells 
indicate enrichment among the up-regulated transcripts; and yellow-coloured cells 
indicate enrichment for transcripts enriched in both directions. 
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The same comparison, this time only considering those KEGG pathways that were 
enriched in genes with the same direction of regulation as the human dataset (Figure 
3-12B), still revealed a significant overlap with the human dataset for 5 out of 6 
experimental challenges (only CSCH-exposed gastro had a P > 0.01). On average the 
sensitivity only decreased by 14%, indicating that most of the response is in the same 
direction. 
We conclude that the transcriptional response of GP limb muscle to long-term CS 
accurately reflects the transcriptional state of dysfunctional limb muscles in COPD 
patients. From a biological standpoint, many of the KEGG pathways in common between 
the GP model and human COPD relate to (Figure 3-12C): 
1) increased tissue remodelling (VEGF signalling, focal adhesion, apoptosis) 
2) altered energy metabolism (oxidative phosphorylation, glycolysis) 
3) increased proteolysis 
Thus, we demonstrate the validity of the GP smoking model as the basis for further 
mechanistic investigation, to facilitate better clinical therapy. 
Noteworthy, a similar approach comparing GP and human lungs from healthy and COPD 
smokers highlighted a less striking, albeit significant response (p < 0.05) (Figure 3-13). 
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Figure 3-13 | specific pathways regulated in the GP model (column 3–5) when contrasted 
against COPD patients (column 1) and healthy chronic smokers (column 2). 
Green-coloured cells indicate enrichment among down-regulated transcripts; red-
coloured cells indicate enrichment among the up-regulated transcripts; and yellow-
coloured cells indicate enrichment for transcripts enriched in both directions 
Of the 2,584 genes regulated in small airway epithelium from smokers with COPD 
compared to healthy non-smokers (832 up- and 1,752 down-regulated; FDR<5%), which 
represented 20 unique functionally enriched KEGG pathways (see 1st column in Figure 
3-13), only 6 pathways (30%) where in common with the CSCH group in our GP model. 
Whereas this animal model does capture the CS-induced oxidative stress response (i.e. 
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glutathione metabolism and metabolism of xenobiotics by cytochrome P450 are both 
induced), our functional gene-level comparison indicates a “metabolic gap” in the current 
GP smoking model, which is particularly pronounced for amino acid metabolism (Figure 
3-13). 
A significant fraction (60%) of the enriched pathways in smokers with COPD are also 
modulated in healthy smokers without COPD. Of the pathways regulated in healthy 
smokers compared to non-smokers, 3 pathways (25%) overlapped with the smoking GP 
model (i.e. glutathione metabolism, pentose phosphate- and the proteasome pathways) 
(Figure 3-13). 
3.4.6 Gene expression of lung soluble inflammatory mediators correlate with 
skeletal muscle gene expression 
Having demonstrated that the transcriptional state of GP hindlimb muscles following CS 
exposure represents that of dysfunctional COPD muscle well, we then determined 
whether we could reverse engineer [108] the structure of a gene regulatory network, 
linking mRNA abundance of inflammatory mediators expressed in GP lung tissue to 
indices of the overall KEGG pathway activity in GP hindlimb muscles (see Section 3.3.7 
for how these indices were calculated). 
Thirty-three of the 72 genes annotated to the cytokine superfamily (46%) were 
differentially expressed in lung tissue in at least one of the three experimental groups 
compared to sham-exposed controls and hence used as nodes in the reverse engineering 
procedure (Table 3-2). We next computed the Spearman correlation coefficients between 
the profile of expression of each of the 33 candidate factors in lung tissue and indexes of 
KEGG pathway activity in skeletal muscles. After removing all correlations with P > 
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0.01, the union of the soluble factors neighbourhoods was visualised using a force driven 
layout (Figure 3-14). 
. 
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Figure 3-14 | Networks representing the transcriptional coupling between lung and 
skeletal muscle in the GP smoking model. 
Correlation network linking the expression of soluble factors in GP lung with the 
transcriptional activity of enriched KEGG pathways in gastrocnemius (Panel A) and 
soleus (Panel B) muscles, respectively. Each network edge (grey line) represents the 
correlation with a given principal component, representative of several genes in each 
function/KEGG term. Some of the genes will be correlated positively and others will 
show a negative correlation. Only edges with a bootstrapped P-value < 0.01 are shown in 
this figure. Hexagons represent KEGG terms, and circles represent soluble factors that 
are secreted by lungs. Each circle has been divided into three sectors, representing the 
CS, CSCH and CH groups. A red sector indicates that the cytokine is significantly up-
regulated; a blue sector indicates significant down-regulation; and a grey-coloured sector 
indicates that the transcriptional level is not significantly affected by the experimental 
condition. 
Analysis of the gastro network (Figure 3-14A) revealed two cytokines each with six 
edges (i.e. Cntf and Cxcl10), indicating that these hub genes could exert an effect on 
multiple pathways within the network. The topological analysis also revealed a dense 
connected area within the network that was enriched of energy metabolism pathways 
(OxPhos, TCA cycle and glycolysis). Interestingly, Cxcl10, whose expression level was 
significantly increased in both the CSCH and CH groups (observed with both microarray 
and qPCR technology; Figure 3-15), was connected to both members within this energy 
metabolism dense area of the network that comprised aerobic respiration (i.e. OxPhos and 
TCA cycle). Noteworthy, Cxcl9, which targets the same receptor as Cxcl10, also linked 
to both oxidative phosphorylation and glycolysis. 
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Figure 3-15 | Validation of selected microarray results by real-time RT-PCR. 
CXCL9  (Panel A) and CXCL10 (Panel B) mRNA levels in lung tissue of sham controls, 
cigarette smoke-exposed, hypoxic and to combined stimuli. Values (means ± SE) in the 
treated groups are presented as relative to the untreated sham controls (basal level = 1.0). 
* Significantly different from the control group (p<0.05). (*) tends to be significantly 
different among treated (0.05 > P < 0.1). 
 
Visual inspection of the soleus network (Figure 3-14B) revealed that Cxcl9 was still 
linked to bioenergetic processes via the glycolysis pathway. Notably, Cxcl10 was now 
unconnected to energy metabolism pathways. Instead, this cytokine among others linked 
to the ribosome component within the network, which had the highest number of 
connections (11 edges)(Figure 3-14B). 
We may thus hypothesise that some of the cytokines we have identified in the GP may 
also act as systemic signals in COPD patients and be responsible for reducing energy 
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3.4.7 Serum cytokine profiling in human COPD patients confirms the predictions 
of the guinea pig model 
Having shown a remarkable similarity between the transcriptional state of GP and human 
COPD muscles, we next assessed whether the link between expression of selected 
pulmonary cytokines and the transcriptional activity of enriched KEGG pathways in 
peripheral GP muscles was of clinical relevance. For this analysis we took advantage of 
relevant measures from a COPD serum profiling dataset (i.e., CXCL9, CXCL10, CCL4, 
CCL5, CCL11, IL1beta and VEGF) used in a previous publication from our group [133] 
in order to test whether i) serum cytokine protein levels were affected by disease and/or 
prolonged endurance training, and ii) if they were correlated with skeletal muscle gene 
expression. Of the 7 cytokines included, we could indeed verify that the serum protein 
level of both CXCL9 and CXCL10 were significantly modulated in COPD patients, 
irrespective of their FFMI, compared to healthy controls (Figure 3-16). 
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Figure 3-16 | Heatmap visualization of the protein expression of 7 serum cytokines 
among healthy controls and COPD at baseline and post training (trained). 
Each row represents a cytokine, whereas each column represents a human subject. Red 
colours mean increased expression whereas green colours mean decreased expression 
(relative to the average across subjects).  An asterix denotes significance at p<0.05 for the 
disease factor (Mack-Skillings test).	  
More specifically, CXCL10 human serum protein levels were higher in COPD patients. 
This elevated expression was consistent with the observed up-regulation of Cxcl10 
mRNA in lung tissue from smoke and hypoxia exposed GPs compared to shams (see 
Table 3-2). However, the increase in CXCL9 human serum protein levels (Fig 3-16) only 
fit with the increase in Cxcl9 mRNA levels in GP lungs exposed to CH compared to 
shams (Table 3-2). 
3.4.8 Training did not modulate any of the tested cytokines 
We next correlated all mRNA transcripts expressed above background (12,783 genes) in 
skeletal muscle in the same cohort with serum cytokine levels and tested whether specific 
	  
	   108	  
KEGG pathways were significantly enriched between the positively or negatively 
correlated genes. Encouragingly, these results were remarkably similar to the GP 
correlation networks shown in Figure 3-14. The similarity was particularly evident in 
respect to the inverse correlation between CXCL9 and CXCL10 serum protein levels and 
the expression of aerobic energy metabolism genes in muscle (OxPhos and TCA cycle) 
(Figure 3-17). 
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Figure 3-17 | Network representing the correlation between serum cytokine levels and 
skeletal muscles gene expression in the human COPD study. 
Panel A shows the force-directed network representation linking the serum level of 
selected chemokines/cytokines (round nodes) with enriched KEGG pathways (yellow 
hexagons). Each circular node has been divided into two sectors, representing COPD 
patients with i) a normal FFMI and ii) a low FFMI. A red sector indicates that the cytokine 
level is significantly higher compared to matched controls, and a grey-coloured sector 
indicates that the serum protein level is stable between groups. Blue edges mean negative 
correlation, whereas red edges mean positive correlation. 
Panels B-C are scatterplots representing the association between serum levels of CXCL9 
(x-axis) and muscle mRNA expression (y-axis) of examples of genes involved in oxidative 
phosphorylation (Panel B) and ribosomal biogenesis (Panel C). 
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Importantly, these strong negative associations to aerobic energy metabolism genes were 
still present if we ignored the control samples, demonstrating that VO2max difference is 
not a main component of the correlations (Figure 3-18 & Figure 3-19). 
 
Figure 3-18 | Correlation between standardised CXCL9 serum protein levels and 
the transcriptional abundance of ATP5J, a gene encoding for a protein in the fifth 
protein complex of oxidative phosphorylation. 
A) All three patient groups were plotted (R=46; p=0.001). B) When we removed the 
healthy control samples we still see a significant linear association (p=0.01) between 
CXCL9 and ATP5J expression.
	  




Figure 3-19 | Correlation between standardized CXCL10 serum protein levels and 
the transcriptional abundance of COX8A, a gene encoding for a protein in the forth 
protein complex of oxidative phosphorylation. 
A) All three patient groups were plotted (R=37; p=0.008). B) When we removed the 
healthy control samples we still see a significant linear association (p=0.03) between 
CXCL10 and COX8A expression. 
Finally, we found a statistically significant negative association between CXCL9 and 
CXCL10 serum protein levels and the distance walked in 6 minutes, an objective measure 
of functional exercise capacity. 
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Figure 3-20 | Scatterplots highlighting the clinical association (Spearman correlation) 
between distance walked in 6-min and serum levels of CXCL9 (Panel A) and CXCL10 
(Panel B), respectively 
3.5 Discussion 
The most important finding of this study is the discovery that mRNA levels in CS-
exposed GP lungs, as well as human serum protein levels of CXCL9 and CXCL10, are 
significantly inversely correlated to the expression of aerobic energy metabolism genes in 
skeletal muscles. In addition, we demonstrate that the GP smoking model can mimic 
many of the transcriptional changes observed in limb muscle of atrophic COPD patients, 
making this an extremely useful in vivo experimental model. 
3.5.1 The role of systemic inflammatory cytokines in controlling the molecular 
state of skeletal muscles 
Several human studies have demonstrated that COPD is associated not only to 
inflammation of the lungs, but also with increased levels of circulating pro-inflammatory 
cytokines [174, 175]. Notably, there is a clear trend toward significant induction of TNF-
α plasma levels of CS-exposed guinea pigs, suggestive of a similar systemic 
inflammatory process in this model organism [158]. Although elevated levels of pro-
	  
	   113	  
inflammatory cytokines have previously been linked to skeletal muscle dysfunction 
[176], until now it was unclear whether they are the primary factor driving muscle 
wasting. 
The analyses we have performed provide the first evidence that expression of systemic 
cytokines significantly correlates with expression of energy metabolism genes 
(represented by the OxPhos, TCA and glycolytic pathway) in limb muscles (Figure 3-14 
& Figure 3-17). This is consistent with the previous observation that dysfunctional limb 
muscle of COPD patients are unable to co-ordinate the expression of energy metabolism 
genes [133]. 
Importantly, there is strong evidence that most of the candidates we have identified in the 
GP model are also modulated in COPD patients. For example, it has previously been 
shown that serum levels of CCL24, CSF1 and IL1A (among others) are significantly 
higher in COPD patients compared to matched controls [177]. Our own validation of 
selected model predictions demonstrated that serum protein levels of two CXCR3 
chemokines (CXCL9 and CXCL10) are significantly higher in the same COPD cohort 
used for muscle mRNA profiling, and their levels negatively correlate with the 
expression of energy metabolism genes in human COPD skeletal muscle (see hos and 
TCA cycle) (Figure 3-17). 
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A). Consistent with this observation (see also [178]) we found a statistically significant 
negative association between CXCL9 and CXCL10 serum protein levels and the distance 
walked in 6 minutes (Figure 3-20). 
Noteworthy, exercise training did not modulate serum levels of these chemokines, 
indicating that differences in the level of physical activity overall will not affect serum 
levels of these chronic inflammatory mediators. 
Overall, this strongly suggests that systemic inflammation plays a major role in 
promoting skeletal muscles dysfunction in both smoking GP and human COPD patients. 
3.5.2 Biological significance of the transcriptional response to smoking and/or 
hypoxia in lungs and muscles 
In accordance with the (pre)clinical literature, we identified a massive transcriptional 
response in whole lung tissue (Figure 3-9). As anticipated, the result of the functional 
enrichment analysis suggests that long-term CS-exposure induces pathways related to the 
antioxidant defence system (i.e. glutathione and cytochrome P450 drug metabolism), 
most likely in order to try and cope with the increased ROS production. Such responses 
are consistent with the changes observed in the human airway transcriptome of chronic 
smokers [179, 180] (Figure 3-13). 
Interestingly, the two skeletal muscles showed a distinct pattern of response both at the 
gene and pathway level, likely reflecting differences in fibre type composition, and hence 
metabolic profile, between these two hindlimb muscles. Soleus is a postural, primarily 
oxidative muscle, with a high Type I fibre content, whereas the gastrocnemius is a phasic 
muscle of mixed Type II composition that is predominantly glycolytic. 
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Our data suggest that CS per se primarily affects the soleus (Figure 3-9) similar to a 
recent finding in C57 mice, where contractile properties were selectively affected in 
soleus following chronic CS exposure using a nose-only device [154]. Furthermore, only 
the soleus showed a tendency towards lower muscle mass after mice had been whole-
body exposed to CS for 6 months [153]. 
The result of the pathway level analysis in GP soleus clearly suggests that long-term 
smoking modulates the activity of the MAPK pathway as induced signalling pathways 
(i.e. ErbB signalling and apoptosis) represent components of this pathway. This agrees 
with a recent human study in which several key members of the MAPK pathway were 
up-regulated at the mRNA level in vastus lateralis of patients with COPD [181]. In 
addition, aerobic energy metabolism is also clearly hit in the CS-group, which is also 
consistent with findings in skeletal muscle of human COPD patients [182]. 
One puzzling finding in the current study is that hypoxia appears to exert a ‘protective’ 
transcriptional effect in the soleus, as only a few enriched pathways were found when the 
hypoxic challenge was added to the CS intervention. A density plot of fold-changes 
revealed that CS as a single factor exerts a greater transcriptional effect than either of the 
two other experimental conditions where CH is present, among the transcripts with an 
absolute fold-change above 1.4. The reason for this is not clear and highlights the need 
for further research in this area. 
In addition to the demonstrated agreement with published human transcriptional data, we 
also addressed the clinical relevance of the present animal model by comparing the 
transcription-based functional profiles related to each experimental challenge with the 
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functional signature derived from stable yet severe COPD patients when compared to 
healthy age matched controls. In accordance with results from our gene-level analysis 
and phenotypic data from the mouse smoking model, the response of the soleus to long-
term smoke exposure best mimics expression signatures linked to the effects of COPD in 
human limb muscle, with 68% KEGG terms in common (Figure 3-12A). However, 
exposure to CH in gastro also yielded a highly statistically significant overlap with the 
clinical dataset as highlighted by a 53% functional overlap. 
3.5.3 Gene expression profiling as a tool to assess animal model relevance of 
human disease 
Most pre-clinical models of CS-induced COPD have for obvious reasons focused on the 
lung component of the disease [183]. However, with the increasing awareness of the 
clinically important extrapulmonary manifestations linked to COPD, a number of studies 
have now begun to try to elucidate the mechanisms governing skeletal muscle 
dysfunction, whether or not accompanied by loss of muscle mass. Consistent with COPD, 
previous studies have shown marked reduction in body weight gain [157, 158] as well as 
increased oxidative stress [147] in GP hindlimb muscles following only 3 months of daily 
CS exposure. In contrast, macroscopic data suggest that mouse models poorly reproduce 
the systemic effects of human COPD. For example, long-term exposure to CS only 
induce mild effects in selected skeletal muscles, as defined by fibre redistribution and 
altered oxidative enzyme activity [153, 154], despite both studies using much longer 
exposure protocols than that of the present study. 
It may be important to assess and compare the relevance of the current GP model with 
that of other rodent CS models such as the mouse. Although an extensive microarray 
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analysis of such model has not been published, we have been able to retrieve a dataset 
from the GEO database (GSE18033). In order to comment on the suitability of this 
dataset to address this important issue, I analysed this data using the same approach 
described in this paper (see Appendix 7-3 for the full data analysis). 
The experiment performed was limited to the gastrocnemius, which our analysis in the 
guinea pigs suggests is not the most representative of human COPD. However, before 
any comparison could be made, our analysis only identified 24 genes that were 
differentially modulated by chronic CS-exposure (24 weeks) in hindlimb gastrocnemius 
muscle compared with time-matched sham controls at a reasonable statistical threshold 
(FDR < 15%). Only by raising the statistical cut-off to 30%, which increased the number 
of regulated transcripts to 1,020 (Table 3 in Appendix 7-3), could we detect biologically 
relevant functions, although the maximum sensitivity of 0.11 was substantially lower 
than any of the experimental conditions involving CS-exposure in the current GP model 
(Figure 3-12A). Although further analysis of the mouse model is required for reaching 
any definitive conclusion, these results indicate poor transcriptional response following 
smoking exposure in mice. 
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4 Using an integrative framework combining association data with 
skeletal muscle gene expression predicts endurance training-induced 





Up to now, this thesis has focused on identifying genes and molecular pathways involved 
in mammalian peripheral skeletal muscle wasting. Exercise training is essential to 
skeletal muscle performance and represents a promising intervention strategy. 
However, of great medical importance, clinical trials have clearly highlighted a 
heterogeneous ability among participants to physiologically adapt to exercise training 
(despite being fully standardized and monitored). 
A major challenge in the analysis of genomic data is to develop predictive statistical 
models [75]. The next two chapters attempt to address this important clinical aspect. 
 
The work presented in this chapter represents a collaborative project between the labs of 
Francesco Falciani and Claude Bouchard (Pennington Biomedical Research Center, 
US). The Bouchard lab provided the raw GWAS SNP and mRNA microarray data as well 
as anthropometric characteristics for all subjects in the HERITAGE exercise training 
cohort. I have solely conducted all in silico analyses presented throughout the chapter. 
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4.1 Introduction 
Endurance exercise training is a strong physiological stimulus that plays a large role in 
skeletal muscle homeostasis. It leads to a multitude of functional improvements when 
performed regularly (i.e. training). These include substantial health benefits such as 
prevention and/or treatment of onset of Type II diabetes [184, 185] by increasing tissue 
responsiveness to circulating insulin. 
Skeletal muscle contraction and peripheral insulin action are highly inter-twined [186]. In 
fact, up to eighty per cent of the in vivo insulin-mediated glucose disposal occurs in 
skeletal muscle [187], making it a quantitatively important organ. 
However, we and others have demonstrated that healthy individuals show a marked 
heterogeneous ability to improve their peripheral insulin sensitivity (SI) in response to 
endurance exercise training (∆SI). Notably, a significant percentage of individuals 
(~20%) show no change in SI and some even demonstrate an adverse response [188, 
189]. 
The molecular mechanisms underlying this heterogeneous ability to improve SI through 
regular exercise, which likely includes a substantial genetic component [190], are 
currently not well understood. In support of a molecular basis of this heterogeneous 
effect, we previously found that sex- and age-matched healthy individuals with high and 
low SI responses to endurance exercise training have different skeletal muscle gene 
expression patterns at baseline [188]. 
These observations led to the hypothesis that training-induced changes in SI may in part 
be determined by genetic factors. Here, we address this question by applying a 
computational framework aimed at identifying the chain of events linking genetic 
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variation in the form of single nucleotide polymorphisms (SNPs) to skeletal muscle gene 
expression and to phenotypic response (∆SI). 
Remarkably, our integrative approach revealed that common genetic variants in close 
proximity to genes representing calcium signalling and carbohydrate metabolism 
associate with basal mRNA abundance that are quantitatively predictive of ∆SI. We also 
demonstrate that a significant proportion of the transcriptional variation linked to 
responder status can be explained by an overall basal difference in the activity of the 
MEF2 calcium-dependent transcription factor, a well known regulator of skeletal muscle 
metabolism.  
In conclusion, our results provide the first plausible hypothesis on a molecular 
mechanism underlying the heterogeneous ability to improve SI with training. Moreover, 
we also provide an independently validated quantitative model, based on a specific 
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4.2 Research Design and Methods 
	  
4.2.1 HERITAGE Family Study 
Participants. The study design and exercise training protocol of the HERITAGE Family 
Study have been described elsewhere [191]. Briefly, 834 subjects from 218 families of 
Blacks and Whites were recruited to participate in an endurance exercise training study. 
Among them, 483 adults from 99 families of European descent were defined as 
completers. Blacks are not considered in this and the following chapter. Parents were 65 
yr of age or less while offspring ranged in age from 17 to 41 years. Participants were 
sedentary at baseline, normotensive or mildly hypertensive (<160/<100 mm Hg) without 
medications for hypertension and dyslipidemia [191]. Most subjects were normoglycemic 
at baseline but 55 were defined as having impaired fasting glucose (100 mg/dL or 5.6 
mmol/L and more but less than 126 mg/dL or 7.0 mmol/L), and 4 were in the diabetic 
range with fasting glucose of 126 mg/dL or 7.0 mmol/L and more. None of the subjects 
were on hypoglycemic medications.  The study protocol was approved by the 
Institutional Review Boards at each of the five participating centers of the HERITAGE 
Family Study consortium. Written informed consent was obtained from each participant. 
 
Exercise training program. Each volunteer in HERITAGE exercised three times per 
week for 20 weeks on cycle ergometers controlled by direct heart rate (HR) monitoring. 
Details of the exercise program can be found elsewhere [191]. Briefly, subjects exercised 
at the HR associated with 55% of baseline maximal oxygen uptake (VO2max) for 30 
minutes per session for the first 2 weeks.  The duration and intensity were gradually 
increased every 2 weeks, until reaching 50 minutes and 75% of the HR associated with 
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baseline VO2max.  This level was maintained for the final 6 weeks of training. The 
protocol was standardized across all clinical centers and supervised to ensure that the 




Intravenous glucose tolerance test (IVGTT) protocol. A frequently sampled IVGTT was 
performed in all participants after an overnight fast (12 h), at baseline and post-
intervention (24-36h after the last exercise bout). In premenopausal women, the test was 
scheduled to coincide with the follicular phase of the menstrual cycle. The protocol 
previously defined by Walton et al. was followed for the IVGTT [192]. The protocol did 
not include an injection of insulin or tolbutamide.	  From the IVGTT data, an SI index (mU 
/ [L×min]), which measures the ability of an increment in plasma insulin to enhance the 
net disappearance of glucose from plasma and is used as a measure of insulin sensitivity, 
was derived using the MINMOD Millennium software [193]. Percent changes in SI (∆SI) 
were calculated as follows: ([SIpost – SIpre]/SIpre) x 100. 
	  
4.2.2 GWAS analysis: 
SNP genotyping (~325,000 SNPs, Illumina Human CNV370-Quad v3.0 BeadChips) on 
genomic DNA from permanent lymphoblastoid cells was done as previously described 
[194].  
SNPs used in association analyses were filtered according to the following criteria: (a) 
minor allele frequency (MAF) less than 5%, (b) violated Hardy-Weinberg equilibrium (p-
value > 0.1), (c) missing values in >10% of individuals, (d) located more than 20kb away 
from a gene coding sequence, (e) SNP associated gene not expressed in human skeletal 
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muscle (see below for more details), and (f) redundant SNPs due to strong pairwise 
linkage disequilibrium (R2>0.8; PLINK v1.07 [195]). These criteria reduced the list of 
candidate SNPs to 68,595 (a 79% reduction).  
Genome location of each SNP is based on the latest build in dbSNP (GRCh38/hg38) 
 
SI training response was adjusted for age, weight-adjusted VO2max, and baseline SI 
within sex-by-generation subgroups. Associations between the normalized trait residuals 
and SNP genotypes were analysed using additive linear mixed effect models that 
accounted for within family correlations (function lme of the ‘nlme’ R package). 
 
4.2.3 RNA extraction & global gene expression profiling: 
Muscle biopsies were taken before and after (~96 h after final training session) exercise 
training intervention using a percutaneous needle. Skeletal muscle RNA extraction as 
well as reverse transcription were done as previously described [196]. Affymetrix 
U133+2 arrays were used to quantitate global mRNA expression levels. The raw 
microarray CEL files are deposited in the public Gene Expression Omnibus (GEO) 
database [197] under accession number GSE47874. 
 
4.2.4 Microarray analysis: 
Raw CEL files were Robust Multichip Average (RMA) normalized following removal of 
probes that were termed ‘absent’ in more than 80% of the samples by the MAS5 
algorithm inside the ‘affy’ package (26,151 probesets discarded) [198]. 
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Quality control plots of the polyA-control RNAs (spike-ins added right after RNA 
purification) highlighted a batch issue/problem that was resolved by applying the 
ComBat software [79]. 
 
The JetSet R package was used to select a single ‘optimal’ probeset to represent each 
gene based on specificity, robustness against mRNA degradation and MAS5 present call 
rate [63].  
 
Validation exercise training dataset: 
We tested our findings in an independent training study, for which Affymetrix Gene 1.1 
ST microarray data are publically available (accession: GSE53598), consisting of 15 
overweight to obese normoglycemic middle-aged men that underwent 12 weeks of mixed 
exercise training (2 days/wk aerobic, 1 day/wk resistance training). Demographic data on 
the subjects as well as the exercise training protocol have been previously described 
[199]. Whole-body SI was measured using the hyperinsulinemic-euglycemic clamp 
technique (40 mU/m2 per min), as previously described [200]. 
Raw microarray data were downloaded from GEO and .CEL files were RMA normalized 
for ‘core’ transcripts using the Bioconductor ‘oligo’ package (v. 1.28.3) [201]. RefSeq 
IDs corresponding to the affy probes were obtained using the 
‘hugene11sttranscriptcluster.db’ annotation library in R (v. 8.3.1). 
 
4.2.5 Pathway-level analyses: 
Biological pathway information was obtained from the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database [128], and downloaded from the Molecular Signatures 
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Database collection (www.broadinstitute.org/gsea/msigdb/index.jsp) [173]. To maximise 
biological interpretability, as previously described [131], the analysis was restricted to 
KEGG group 1-4 (Metabolism, Genetic Information Processing, Environmental 
information Processing and Cellular Processes) as well as Endocrine and Circulatory 
system pathways in group 5. In addition, gene sets with <20 or >200 genes were excluded 
to protect against spurious associations from very small pathways or the lack of sufficient 
specificity from very large pathways [202]. A total of 110 pathways were included. 
 
GSEA Pre-ranked analysis: 
The entire skeletal muscle transcriptome was ranked by individually regressing their 
basal expression against ∆SI, with age, gender and type 1 fiber composition included as 
covariates. 
Based on this ranking (Student’s t-statistic) we performed a pre-ranked gene set 
enrichment analysis (GSEA; v2.0.12) [84], using the default parameters, to identify 
candidate gene-sets significantly enriched in genes that are significantly associated with 
∆SI (either towards the top or bottom). The a priori defined gene-set collections used 
were transcription factor targets (c3.tft.v4.0symbols.gmt) and KEGG pathways, 
respectively (see above). 
 
4.2.6 Data analysis: 
In order to link gene expression to ∆SI we used a regression-based modelling approach 
allowing for pairwise interactions (function lm of the ‘stats’ R package). More precisely, 
we define: 
 
∆𝑆𝐼 = 𝑎𝜃! + 𝑏𝜃! + 𝑐𝜃! + 𝑑𝜃!𝜃! + 𝑒𝜃!𝜃! + 𝑓𝜃!𝜃! + 𝑠𝑒𝑥 + 𝑉𝑂2!"# + 𝜀 
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where mRNA abundance are represented by θ and ε is the noise model component. 
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4.3 Results 
 
4.3.1 Overview of the analysis strategy: 
Identification of prognostic exercise-sensitive biomarkers, ideally of circulating factors, 
that can tell who will demonstrate the largest improvement in SI is a challenging task. 
As outlined in Figure 4-1, this study addresses this issue by applying a proof-of-principle 
multi-step data mining approach. Due to the multi-omics nature of the HERITAGE study, 
we took on the challenge of overlaying an individual’s genetic background with the 
tissue-specific gene expression profile against the improvements in whole-body insulin 
sensitivity to develop a robust muscle-derived RNA-based classifier. 
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Figure 4-1 | Flowchart highlighting the analysis strategy. 
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4.3.2 Improvement potential in SI has a clear heritable component: 
The overarching objective of this study is based on the assumption that molecular 
mechanisms underlying individual variation in ΔSI have a genetic component. We tested 
this hypothesis by using the HERITAGE Family study, one of the largest endurance 
training studies to date. Our analysis revealed that 29% of the variance associated to ΔSI 
is accounted for by family membership (Figure 4-2). Moreover, the ANOVA model 
estimated that there was 40% more variance between families than within families 
(p=0.02), providing first time evidence that the changes in SI in response to exercise 
training are characterized by a significant genetic component. 
	  
Figure 4-2 | Training-induced change in insulin sensitivity plotted against Caucasian 
family rank (i.e. families ranked by family mean) in the HERITAGE study.  
Only families with at least 3 members are shown (94 families in total); family average 
was 4.3 members. Each vertical box represents the range of training responses across all 
family members (parents and offspring). Red horizontal reference line denotes family 
mean. The F-value from the ANOVA indicates that there is 40% more variance between 
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4.3.3 Functional GWAS identifies an association between ∆SI, carbohydrate 
metabolism and calcium signalling pathways: 
Having demonstrated that changes in SI following endurance training show evidence of a 
genetic component, we set to identify the specific pathways enriched in genetic variants 
(in the form of SNPs) associated to ∆SI. We approached this challenge using a validated 
analysis technique (functional GWAS), which has been shown to be particularly effective 
in studies with a relatively small sample size (N=424) [203]. This methodology, which 
considers the effects of multiple SNPs jointly (both within a gene as well as between 
genes within a pathway), tests whether SNPs that are most associated to ∆SI are enriched 
in specific functional pathways. 
Nine KEGG pathways were significantly (Padj<0.05) associated with SI improvement 
potential (Table 4-1 and Figure 4-3 for an example). Overall, the enriched pathways 
represent three functional categories: calcium signalling, carbohydrate metabolism, and 
cell communication (see Table 4-1).  
 
 







Cardiac muscle contraction 77 639 <0.001 Calcium 
Inositol phosphate metabolism 57 463 0.017 Calcium 
Arachidonic acid metabolism 59 200 0.023 Calcium 
Galactose metabolism 27 130 <0.001 Carbohydrate 
Starch and sucrose metabolism 55 140 0.002 Carbohydrate 
Pentose phosphate pathway 27 132 0.017 Carbohydrate 
Fructose and mannose metabolism 36 207 0.017 Carbohydrate 
Focal adhesion 200 1575 0.023 Cell 
communication 
Adherens junction 73 658 0.026 Cell 
communication 
Table 4-1 | KEGG pathways enriched for DNA variants associated with ∆SI. 
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Figure 4-3 | Histogram of the p-value distribution for SNPs flanking genes 
annotated to the ‘cardiac muscle contraction’ KEGG pathway. 
The red line is a fitted density curve. 
 
As nearly 90% of all GWAS loci fall outside of protein-coding regions, we sought to 
identify SNPs that associate with basal mRNA abundance (so-called ‘expression SNPs’) 
among the subset of White HERITAGE participants (n=47) for which global gene 
expression data is available using the method detailed by Schadt et al. [204]. To refine 
the interpretation, all 1,280 nominally associated eSNPs (Kruskal-Wallis p<0.01) were 
mapped to genes with KEGG pathway annotation. As shown in Figure 4-4A, 19 out of 
110 KEGG pathways tested had more significant eSNPs associated to them than expected 
by chance (p<0.01), indicating that mRNA abundance of a significant subset of genes (up 
to 27%) within these enriched pathways is associated to common DNA sequence variants 
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with potential regulatory effects. Noteworthy, calcium signaling and vascular smooth 
muscle contraction were the most enriched pathways.  
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Figure 4-4 (see previous page) | Panel A: histogram showing the observed number of 
SNPs associated with basal mRNA abundance for each KEGG pathway. The red line 
represents 3 standard deviations from the permutation-based null distributuion. Since 
KEGG gene-sets are not independent, the overlaps between significant ones were 
assessed using the Jaccard’s index of similarity. From Panel B it is clear that many of the 
enriched gene-sets can be grouped into three overall functional categories: carbohydrate 
metabolism, cell communication, and calcium signalling. It is of note that multiple terms 
within ‘cell communication’ have a strong calcium signalling component such as gap 
junction, vascular smooth muscle contraction and Wnt signalling  
 
Based on the results presented in Table 4-1 and Figure 4-4A we decided to focus on 
calcium signalling as it represents the most upstream component of the pathways 
discovered by the functional GWAS analyses. Initially, we constructed an integrated 
pathway that connected the calcium-related pathways in Table 4-1 at the gene level. We 
then mapped all SNPs to genes within this high-level pathway (Figure 4-5). Visual 
inspection of the resulting diagram was fully consistent with the result of the GWAS 
analysis, showing that ∆SI-associated genetic variants cluster around the cascade of 
events that link calcium mobilization to the transcriptional response mediated by 
transcription factor targets of calmodulin-dependent protein kinases (e.g. MEF2s, 
HDACs; see	  Figure 4-5).  
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Figure 4-5 | Diagram representing the detailed relationships between the calcium-
related KEGG pathways identified in Table 4-1. 
Genes with an orange background contain DNA variants (within a 20-kb flanking 
window on either side of the gene) significantly associated to ∆SI. Further, the basal 
mRNA abundance of genes with a red font are significantly associated with DNA 
variants. 
 
Interestingly, we also discovered that SNPs identified by our functional GWAS analysis 
were significantly associated with gene expression variability (p<0.05), suggesting that 
these have a true regulatory role (Figure 4-5 and Figure 4-5). 
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4.3.4 The calcium-dependent MEF2A transcription factor drives the 
transcriptional signature associated to ∆SI 
The functional pathways enriched in ∆SI-associated SNPs represent the initial molecular 
events that eventually may influence and drive phenotypic response. It is reasonable to 
expect that downstream events, including changes in mRNA expression/abundance, may 
be involved in this process. We therefore set to identify transcription factors for which 
the basal expression of a significant proportion of their target genes is correlated to the 
percent change in SI post-training. More specifically, by using the transcript abundance 
of sets of transcription factor (TF) target genes (i.e. group of genes sharing a specific TF 
binding site in the promoter region) we sought to infer the activity of a compendium of 
TFs at baseline using a GSEA approach. 
The gene targets of two transcription factor families, namely splicing factor 1 
(V$SF1_Q6) and myocyte enhancer factor (MEF)-2 (V$MEF2_04), were positively 
associated with ∆SI (FDR < 5%), highlighting that individuals exhibiting high 
responsiveness of SI to training have an overall higher basal expression of genes co-
regulated by SF1 and MEF2, respectively, compared to those demonstrating an adverse 
response (see Appendix 7.4 for a comprehensive overview of the GSEA).  
Interestingly, MEF2 has been extensively studied in muscle cells as it is known to 
directly regulate transcription of multiple muscle-enriched genes (e.g. myogenin and 
troponin I) [205]. Moreover, MEF2 is activated by contraction-induced calcium 
signalling [206], a pathway whose gene activity overall is under significant regulatory 
genetic control (see Figure 4-5). We therefore hypothesised that MEF2 could be a key 
driver of the pleiotropic transcriptional response linked to ∆SI.  
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In order to test this hypothesis we first defined the global transcriptional signature 
associated to MEF2 knockdown and then asked whether this MEF2-dependent signature 
can recapitulate the transcriptional signature correlated to ∆SI.  
Recently, Wales et al. reported a comprehensive list of both direct and indirect MEF2A 
mammalian target genes using isoform-specific short interference RNA (siRNA) 
knockdown in differentiating C2C12 myotubes [207]. Notably, despite the four-
membered MEF2 protein family sharing a high sequence homology in their DNA binding 
domains, genes distinctly sensitive to the A isoform play roles in calcium signalling 
[208]. 
Of the 1,280 dysregulated genes reported by Wales et al. (828 being down-regulated), we 
identified human orthologs for 990 (77%) [209]. We then performed a custom GSEA 
using up- and down-regulated MEF2A gene targets, respectively, as gene sets. 
Intriguingly, as shown in Figure 4-6, genes down-regulated by knockdown of MEF2A, 
which overall relate to ‘muscle function’ [207], were highly enriched (FDR<1%) 
amongst the most positively associated genes to ∆SI in HERITAGE. In addition, the 2nd 
gene-set containing up-regulated MEF2A target genes, was highly enriched (FDR<1%) 
amongst the most negatively associated genes to ∆SI. 
It is of note that the genes within the calcium-signalling pathway are enriched (p=0.02) 
towards the positive end of the ranked gene-list (Figure 4-6B, middle panel). 
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Figure 4-6 | (A) Using small interfering RNA (siRNA), Wales et al. [207] recently 
defined the global transcriptional signature associated with MEF2A modulation in 
differentiating C2C12s. Corresponding human orthologs for the dysregulated genes were 
identified using the Mouse Genome Informatics (MGI) database (72% mapping success). 
 (B) All skeletal muscle expressed genes in HERITAGE were ranked according to their 
association to ∆SI (grey panel in middle). GSEA revealed that the custom geneset 
containing gene targets up-regulated by MEF2A knockdown was enriched in the negative 
end of the ranked gene list (left panel), whereas the geneset containing down-regulated 
MEF2A targets was enriched in the positive end (right panel). The green curves 
correspond to the running sum of the enrichment score that reflects the degree to which 
the MEF2A-associated signatures (represented by black horizontal lines) are 
overrepresented at the top or bottom of the ranked list. 
	   
4.3.5 Basal mRNA abundance of MEF2A interacting targets is predictive of ∆SI: 
The above in vitro validation of the in silico framework prompted us to ask whether we 
could develop robust statistical models linking the basal mRNA abundance of MEF2A 
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targets to ∆SI. Since our aim was to develop a predictive model that included direct 
targets of MEF2A⎯rather than the pleiotropic gene expression signature⎯we used the 
STRING database to focus the analysis around physically-functionally interacting 
MEF2A targets (n=46; see Appendix 7.5 for an exhaustive list) [210]. As most genes do 
not act in isolation but interact with each other collectively, we developed all possible 
multivariate linear regression models based on the combination of three MEF2A targets, 
including pairwise interaction components: 
46!
46− 3 ! (3!) = 15,180  𝑚𝑜𝑑𝑒𝑙𝑠 
 
Interestingly, the most predictive statistical model that consisted of HDAC4, as well as 
the delta and gamma chain of the calmodulin-dependent protein kinase (CaMK) II 
enzyme complex (i.e. CAMK2D and CAMK2G), was able to explain nearly half (48%) of 
the variance of ∆SI in the HERITAGE study (F-value=6.4, p<0.001; Table 4-2). 
Consistent with the established heteromultimeric nature of CaMKII, the model reports a 
highly significant interaction between the two isoforms CAMK2D and CAMK2G. 
Regression diagnostics confirmed conformity of the residuals to the assumptions of 
normality, linearity and homoscedasticity. 
	  







VO2max -0.03 0.004 -0.68 0.50 
Gender -2.15 0.83 -2.59 0.013 
CAMK2D 40.73 27.98 1.46 0.15 
CAMK2G 74.78 32.04 2.33 0.02 
HDAC4 -34.94 22.37 -1.56 0.13 
CAMK2D: 
CAMK2G 
-12.08 3.41 -3.54 0.001 
CAMK2D: 
HDAC4 
6.94 1.63 4.27 <0.001 
CAMK2G: 
HDAC4 
-0.40 2.90 -0.14 0.89 
Table 4-2 | Result of the multivariate regression model for SI training response in 
HERITAGE (n=47). 
Gender and aerobic capacity adjusted for body size were included as covariates in the 
model. Notably, the abundance of these transcripts was not responsive to the training 
intervention, but rather higher basal expression levels were associated with greater gains 
in SI. CAMK2D: 228555_at; CAMK2G: 212757_s_at; HDAC4: 228813_at 
 
To examine the general applicability of this predictive gene signature, as all 
HERITAGE samples were used for developing models, we took advantage of a 
previously published Affymetrix gene expression dataset from a smaller independent 
mixed exercise training cohort [199]. Importantly, this cohort also spanned a broad range 
in terms of the training-induced change in SI (-65% to +86%). Intriguingly, as shown in	  
Figure 4-7 below, the multi-gene RNA signature was able to explain 37% of the ∆SI 
among the healthy middle-aged male participants (n=15), a value comparable to the 
estimated heritability of ∆SI (see Figure 4-2). A resampling procedure in which 1,000 
random multivariate models were developed confirmed the significance of the regression 
model (p=0.05), despite the differing gene-chip technology between cohorts (i.e. 3’-based 
versus the newer whole transcript based methodologies). 
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Figure 4-7 | Plot of experimentally determined (observed) versus predicted values of 
training-induced change in insulin sensitivity (derived from euglycaemic 
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4.4 Discussion 
Having established that the SI training response in part is genetically regulated, we have 
overlaid an individual’s genetic background with the skeletal muscle specific gene 
expression profile to achieve an integrated view of the SI training response at the 
molecular level. Notably, such a tandem-omics approach enabled us to develop a 
quantitative multi-gene predictor of ∆SI, which was validated in an independent training 
cohort. The present analysis thereby extends the notion that transcriptomic profiling 
captures critical information and process prognostic information about complex 
physiological processes [24, 211–213]. 
4.4.1 Predicting changes in insulin sensitivity from gene expression profiling 
The multi-gene predictor was developed using the HERITAGE cohort, a well-
characterized, demographically heterogeneous cohort. Due to the study-design induced 
interindividual heterogeneity (e.g. sex, BMI, VO2max), the RNA signature should be of 
broader applicability (i.e. less sensitive to environmental factors). In support of this, we 
were indeed able to validate the predictor in an independent training cohort of similar 
ancestry ⎯ despite the weekly cycling duration, a primary factor controlling SI training 
response [214], differed significantly. It remains to be established whether the RNA 
signature also works across other intervention regimes  (e.g. interval-based). 
Notably, all three predictor genes have many splice variants (between 14 and 17) 
[215]. However, as the most representative probeset for each gene was selected using the 
well established JetSet algorithm [63], both the specificity and splice isoform coverage 
are very high among the predictor probesets. The high coverage is likely also the main 
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reason behind the successful independent validation, which used exon arrays for profiling 
(a newer Affymetrix chip generation). 
 
The RNA expression levels of most genes in the KEGG calcium signalling pathway (as 
well as the actual predictor signature) are stable to the training intervention, which is in 
accordance with the published ‘training-responsive transcriptome’ database [24]. Hence, 
the reported genotype/RNA associations within this pathway (see Figure 4-4) appear to 
be driven by exercise-independent factors. 
 
4.4.2 Is there a relationship between changes in SI and myofiber 
interconvertibility? 
It is well established that physical activity (i.e. muscle contraction) induces the calcium 
signalling pathway, leading to activation of MEF2 (among others) via CaMKs (CaMKII 
in particular), evoking a muscle-specific transcriptional response [10]. The non-biased 
informatics analyses presented here clearly point towards an involvement of genetic 
variations within the calcium signalling pathway affecting the ability to improve 
peripheral SI via MEF2. If this hypothesis is true, then it would not be unreasonable to 
assume that high responders in terms of ∆SI would show the biggest training-induced 
fast-to-slow myofiber transformation, given the key role of MEF2 in adult oxidative type 
I myofiber formation [216]. Although controversial, multiple clinical studies have in fact 
reported an increase in type I content following endurance training interventions [217–
219]. 
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As age and sex have been shown to significantly affect muscle myofiber composition [11, 
220], the analysis was restricted to men under 40 as they made up the largest contribution 
to the HERITAGE subcohort (~40%). 
The result was striking: the group of ‘younger’ males that increased their SI with at least 
40% (n=8) showed a significant training-induced increase in Type I myofiber 
composition (6.5% median increase; p=0.04) (Figure 4-8). In contrast, those with a 
modest or even negative potential (<9% increase in SI; n=8) showed a very 
heterogeneous myofiber adaptation and hence failed as a group to increase their type I 
content (0.8% median increase; p=0.23); this was evident despite the marked influence of 
an outlier with an abnormally high absolute increase of 29% post-intervention (67% Type 
I fibers). 
	  
Figure 4-8 | Column scatter plot showing training-induced change in Type I 
myofiber content within the two defined responder groups (change in whole-body 
insulin sensitivity; ∆SI). 
Horizontal lines represent the mean value. 
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4.4.3 Conclusion 
Whole-body SI is likely the most important physiological property that can be 
manipulated by lifestyle intervention in order to prevent cardiometabolic diseases [221, 
222]. Promisingly, muscle RNA abundance can easily be quantified due to the 
development of pain-free micro-needle biopsy sampling [223, 224]. Further, one-step 
multiplex real-time RT-PCR assays are a rapid, sensitive and cheap diagnostics option. 
For these reasons, we believe that our predictive RNA signature potentially—if 
successfully validated in bigger independent endurance training cohorts--has clinical 
health implications. This is even more critical as skeletal muscle insulin resistance is one 
of the earliest hallmarks of the development of type 2 diabetes. All of this emphasizes the 
importance of developing evidence-based personalized exercise prescription to maximize 
the health-promoting benefits of a physically active lifestyle. 
I would like to point out the importance of the independent validation in order to gain 
more confidence in the predictor signature put forward in this chapter. Hence, further 
research is urgently needed to replicate and further test these findings in independent 
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5 Combining genomic and transcriptomic predictors of plasma 
triglyceride response to exercise training: a genome-wide approach 
	  
	  
The	  work	  presented	  in	  this	  chapter	  represents	  a	  collaborative	  project	  between	  the	  labs	  
of	  Francesco	  Falciani	  (University	  of	  Liverpool)	  and	  Prof.	  Claude	  Bouchard	  (Pennington	  
Biomedical	  Research	  Center).	  The	  Bouchard	   lab	  provided	   the	  raw	  mRNA	  microarray	  
data	   as	   well	   as	   all	   clinical	   readouts.	   Dr.	   Mark	   Sarzynski	   from	   the	   Bouchard	   lab	  
conducted	   the	   GWAS	   analysis.	   I	   conducted	   all	   transcriptomic	   and	   pathway-­‐based	  
analyses.	  
The	  results	  presented	  in	  this	  chapter	  were	  very	  recently	  accepted	  in	  British	  Journal	  of	  
Sports	  Medicine	  [226].	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5.1 Introduction 
Triglycerides (TG) are the major constituent of dietary fats/lipids, composed of a glycerol 
esterified to three FA chains of varying composition and length. TGs are transported in 
the blood stream within globular molecular complexes know as lipoproteins. Notably, 
these circulating lipoproteins differ in size, density and lipid composition (Table 5-1). 
 % of 
Lipoprotein class TG ChoL 
Chylomicrons 90 3 
VLDL 65 15 
LDL 10 45 
HDL 5 20 
Table 5-1 | Major classes of lipoproteins in human plasma 
 
Normal resting values of TG are below 150 mg/dL in serum; levels above this threshold 
constitute hypertriglyceridemia. Very high levels of TGs are defined as serum levels of 
500 mg/dL or greater [227]. Epidemiological studies have associated chronic elevated 
serum TG levels with an increased risk of cardiovascular disease (CVD) [228–230], the 
leading cause of death in developed countries [231]. Notably, Mendelian randomization 
studies of genetic variants affecting TG serum levels suggests a causal role of TG on 
CVD and all-cause mortality [232, 233]. Common secondary causes of raised serum TG 
levels are obesity, physical inactivity, excess alcohol intake and uncontrolled T2DM. 
 
Regular physical activity (e.g. fast walking, out-door games) is considered a major target 
for therapeutic lifestyle changes in the prevention and treatment of elevated TG [234]. 
Evidence from the existing sports literature highlights a favorable reduction in serum TG 
levels ranging from 4 to 38 mg/dL follow exercise training [235]. However, we and 
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others have observed a large inter-individual variation in the magnitude of changes in 
serum TG levels following endurance training. For example, in the HERITAGE Family 
Study, the changes in TG after 20 weeks of highly standardized and fully supervised 
exercise training ranged from a decrease of 163 mg/dL (1.8 mmol/L) to an increase of 
207 mg/dL (2.3 mmol/L) among Caucasians (Figure 5-1). 
	  
Figure 5-1 | Histogram highlighting the individual differences in training-induced change 
in serum triglyceride levels among Caucasians in the HERITAGE study. 
 
In HERITAGE, the heritability estimate for exercise-induced changes in serum TG 
has been estimated to reach 29% among Caucasians [236]. However, at present the DNA 
variants predisposing for interindividual variation in TG response remain to be 
determined. 
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A limited number of candidate gene studies have provided evidence of the association of 
DNA sequence variants with TG response to lifestyle and exercise interventions, with 
nominal associations found for variants in the APOE, LIPC, and PGS1 genes [237, 238]. 
However, these candidate genes explain only a small percentage of the variance in serum 
TG response to exercise training. Thus, currently there is a clear need for unbiased data-
driven approaches in the search for the genes and DNA sequence variants contributing to 
serum TG response to regular exercise. 
 
Our collaborators, lead by Prof. Bouchard, have demonstrated in 2010 that global 
mRNA profiling of resting skeletal muscle combined with targeted SNP genotyping can 
increase the explanatory power of a multi-gene RNA signature for exercise adaptability 
[24]. Notably, such an approach dramatically improves statistical power and thus allows 
smaller cohorts of carefully characterized subjects to be studied. Therefore, the overall 
aim of this chapter is to perform both SNP and mRNA microarray profiling in order to 
identify a multivariate SNP-based gene signature that accurately predicts the 
responsiveness of serum TG levels to chronic endurance training. 
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5.2 Methods 
	  
5.2.1 Determination of plasma lipids 
Blood samples for plasma lipid assays were obtained from an antecubital vein into 
Vacutainer tubes containing EDTA in the morning after a 12-hour fast with participants 
in a semi-recumbent position. The blood samples were collected twice at baseline (on 
separate days), and again at 24- and 72-hours after the last exercise session. TG levels 
were determined in plasma by enzymatic methods using a Technicon RA-500 Analyzer 
(Bayer Corporation Inc, Tarrytown, NY). The reproducibility of TG measurements in 
HERITAGE has been previously examined, with a coefficient of variation of 21.8, 
intraclass correlation of 0.79, and technical error of 0.21 (mmol/L). The response to 
exercise training was computed as the difference between the average post-exercise 
training TG measures and the average baseline TG measures. 
5.2.2 GWAS SNP genotyping 
See Section 4.2.2 for more details. 
 
5.2.3 GWAS statistical analyses 
See online manuscript4, as I didn’t contribute to this part. 
5.2.4 Affymetrix microarray analysis 
Please refer to Section 4.2.4. 
	  
5.2.5 Baseline RNA gene signature 
We used GALGO, an R package for multivariate variable selection based on a genetic 
algorithm (GA) methodology [99], to derive a multivariate regression model of ΔTG in 
HERITAGE using baseline mRNA expression levels. In brief, this computational search 
procedure tries to find the best subset of genes for maximizing the fitness of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  http://www.ncbi.nlm.nih.gov/pubmed/?term=26491034 
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regression model (defined by R2). The fitness function was implemented as a linear 
model containing three genes with sex as an additional parameter. The fitness value for 
model selection was set to R2≥0.7 (this particular cutoff was chosen based on thorough 
parameter estimation in accordance with the GALGO manual). Hence, a GA search is 
termed ‘successful’ once a model, through generations of evolution, has reached a fitness 
greater than or equal to the specified goal fitness. To reduce the risk of overfitting, a GA 
search had to reach the goal fitness within 300 generations in order for it to be selected. 
During the GA search procedure ¾ of the samples (N=37) were used for training whereas 
the remaining 12 samples were completely omitted and used for model validation. In 
order to better estimate the accuracy of each developed model (due to the modest number 
of profiled samples) the training dataset was split in 100 different training and test sets. 
The GA procedure was allowed to run 4,000 successful simulations (i.e. developed 4,000 
regression models with an R2≥0.7). 
Due to variability in the model performance across the splits (likely caused by inter-
individual differences), I chose to focus on the subset of models (N=512) that performed 
well in most splits (i.e. low overall deviation and high accuracy) (Figure 5-2).  
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Figure 5-2 | Chromosome goal fitness distribution across all 100 splits for A) all 4,000 
predictive models, and B) the subset (n=512) that performed well in most splits (i.e. low 
overall deviation and high accuracy). 
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5.2.6 SNP summary score 
	  
A SNP ‘summary score’ for ΔTG was constructed using the GWAS SNPs that accounted 
for all of the estimated heritability in the conditional heritability analyses (N=4: 
rs222158, rs2722171, rs1906058, rs2593324) along with the top SNPs from the RNA-
based classifier genes (N=4: rs1043968, rs3793336, rs594461, rs11646610). The four 
latter SNPs were included as the heritability estimate reported herein (i.e. 29%) is 
subjected to uncertainty (±13%; see [236]) because of relatively modest number of 
Whites included in the HERITAGE study (n<500). Hence, the true ∆TG heritability 
could potentially be significantly higher. 
Each SNP was re-coded to reflect the number of positive or favorable response to regular 
exercise alleles (e.g. positive defined as a decrease in TG) in the following manner: 0 for 
no copy of the positive response allele, 1 for one copy and 2 for two copies of the 
positive response allele. The sum of the re-coded SNPs was used as the SNP summary 
score. Associations between SNP summary score and TG response to exercise training in 
HERITAGE Whites (N=476) were analyzed using general linear models. Covariates in 
the models included age, sex, baseline BMI, and baseline TG.  
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5.3 Results 
The basic characteristics, including mean lipid values at baseline and in response to exercise 
training, of HERITAGE White participants with valid GWAS or gene expression data are 
shown in Table 5-2. On average, HDL-C and lipoprotein lipase activity increased with regular 
exercise, while TG and hepatic lipase activity decreased.	  
	  
 
Subjects with GWAS Data  
(N = 478) 
Subsample with 
Gene Expression 
Data (N = 49) 







Age, yrs 35.9 (14.5) 
 




BMI, kg/m2      
• Baseline  25.9 (5.0) 
 




• Response to 
exercise training -0.09 (0.7) 
-0.15 to 










• Baseline  1.4 (0.8)  0.4 to 6.3 1.4 (0.8)  
• Response to 
exercise training -0.02 (0.4) 
-0.06 to 
0.02 -1.8 to 2.3 







• Baseline  1.0 (0.3)  0.5 to 2.0 1.1 (0.2)  
• Response to 
exercise training 0.04 (0.1) 
0.03 to 










• Baseline  3.0 (0.8)  0.9 to 6.0 2.8 (0.8)  
• Response to 
exercise training -0.004 (0.4) 
-0.04 to 





Table 5-2 | Descriptive data, including pre- and post-training values for lipid, lipoprotein 
and lipase measurements, for HERITAGE Whites with valid GWAS (left) and gene 
expression (right) data, respectively. 
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5.3.1 GWAS associations for TG response to exercise training 
39 SNPs showed associations of p<1x10-4 (Appendix 7.6). The strongest evidence of 
association with ΔTG was detected at rs2396190 (P=3.3x10-7) located 90kb from DOCK10 
(2q36.2), followed by rs222158 (P=1.8x10-6) located in CYYR1 (21q21.2). In the final forward 
regression model, the top 10 SNPs explained 32.0% of the variance in ΔTG (Appendix 7.6). 
CYYR1 rs222158 was the strongest independent predictor of ΔTG in the model, explaining 
5.5% of the total variance, followed by GLT8D2 rs2722171, which explained 4.1% of the 
variance. 
As shown in the last column of Appendix 7.6, the top four SNPs were shown to be sufficient to 
account for the genetic component of TG response to exercise training in White HERITAGE 
families. These four SNPs were retained for the ΔTG SNP summary score. 
 
Pathway analysis of GWAS associations. The result of the pathway-based SNP analyses 
using the 2nd-best p-value and Stouffer’s method, respectively, can be found in Appendix 7.7. 
Briefly, the glycosphingolipid biosynthesis gene set was enriched using both approaches. 
Glycosphingolipid biosynthesis-related gene sets were the 2nd, 5th, and 6th most enriched 
positive gene sets using the 2nd-best p-value method (FDR: 0.07-0.32), while it was the 3rd 
ranked gene set using the Stouffer method (FDR=0.30). The most enriched positive gene set 
using the 2nd-best p-value method was the heparan sulfate glycosaminoglycan biosynthesis gene 
set (FDR=0.097), while cell adhesion molecules was the most enriched negative gene set 
(FDR=0.12). 	  
	  
	   156	  
5.3.2 RNA expression-based gene signature of TG response to exercise training 
Having shown that genetic variants in lipid biosynthesis pathways are linked to changes in TG 
levels, we set to test whether and mRNA signature could predict this important clinical variable. 
We therefore developed statistical models predictive of ∆TG based on a multi-gene RNA 
signature. The method we used, developed by the Falciani lab, is based on a true multivariate 
variable selection procedure designed to optimize the prediction of the response variable by 
means of the smaller number of gene expression profiles available. 
By means of forward stepwise regression, ranking Affymetrix probesets by their selection 
frequency (high to low) in the different GA-derived predictor models, an 11-gene linear 
regression model was developed (Table 5-3). 
Variable Beta SE t-value P-value 
Gender 0.21 0.17 1.1 0.27 
DYX1C1 0.59 0.11 5.6 9.9x10-6 
ZNF30 -0.01 0.12 -0.09 0.93 
BTG2 0.21 0.12 1.7 0.10 
MACROD1 0.10 0.20 0.5 0.62 
UBE2L3 0.16 0.15 1.1 0.29 
C21orf88 -0.14 0.13 -1.1 0.28 
EEF2K 0.21 0.10 2.1 0.05 
NCBP2 0.22 0.16 1.5 0.15 
FASTK 0.39 0.15 2.5 0.02 
C2orf69 -0.03 0.12 -0.3 0.80 
NSA2 -0.28 0.10 -2.8 0.009 
Table 5-3 | Results of the RNA-based multivariate regression model with forward 
selection for TG response to exercise training in HERITAGE Whites (N=37). 
 
This model was able to explain 80% of the variance in the training set (F-value=13.2, 
p<0.0001). We next evaluated the model performance on the remaining 12 HERITAGE 
samples that were completely omitted from the GA search procedure (so-called ‘test set’). As 
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shown in Figure 5-3, the predictor model was able to explain 27% of the variance. Importantly, 
the test set spanned a broad range in terms of the training-induced changes in TG (range: -40 to 
+20%).	  
	  
Figure 5-3 | Performance of the RNA-based regression model derived from the training set 
(N=37, gray dots) in the test set (N=12, red dots) for the prediction of exercise training-induced 
changes in serum triglycerides in HERITAGE. 
 
In order to examine the general applicability of the molecular signature, we took 
advantage of a previously published Affymetrix gene expression dataset from an independent 
exercise-training cohort (the same cohort used in Chapter 4). As the gene-chip technology 
significantly differed between cohorts (i.e. 3’-based versus the newer whole transcript based 
methodologies), we performed all possible subsets regression. We found that the model 
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containing six genes (BTG2, C2orf69, C21orf88, DYX1C1, NSA2, UBE2L3) performed the best, 
as this model (F-value=3.7, P=0.03) explained 48% of the variance in TG changes in the 
independent dataset, while also having the lowest Bayesian Information Criterion (BIC) score 
(Figure 5-4). Further, a resampling procedure in which 10,000 random multivariate models 
were developed confirmed the significance of the 6-gene model in terms of R2 performance. 
	  
Figure 5-4 | All possible subset regression. 
(A) Performance of regression models testing subsets of genes from one gene to all 11 genes for 
ability to predict TG change with exercise training in the independent dataset. (B) Comparison 
of model performance based on Bayesian Information Criterion (BIC), R2, and p-values for 
each model. Ideally, the goal is to select the model with the lowest BIC and p-value that 
explains the most variance, which in this case is the model that includes 6 genes. (C) Results of 
the forward regression model for changes in TG with exercise training in the independent 
dataset containing six genes. 
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The association of SNPs (N=498), in or near (± 20kb) the 11 predictor genes, with ΔTG was 
tested in all HERITAGE Whites (N=481). Only SNPs from four genes (NSA2, FASTK, 
MACROD1, and EEF2K) showed nominal (p<0.05) associations with ΔTG (see online 
Supplementary, Tables S5-S8). The top associated SNP from each of the four genes 
(rs1043968, rs3793336, rs594461, rs11646610) was used in the SNP summary score. 
 
Pathway analysis of mRNA predictor models. We evaluated the enrichment of pathways among 
genes in the subset of 512 predictive models using Ingenuity Pathways Analysis (IPA). We 
found that mitochondrial energy metabolism pathways were enriched, including pathways 
related to mitochondrial dysfunction and oxidative phosphorylation (Figure 5-5). 
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Figure 5-5 | Results of the Ingenuity Pathway Analysis (IPA) on a subset of the baseline 
gene expression predictor models (N=512). Horizontal bars represent the p-value for the top 
12 canonical pathways enriched in genes within the most predictive GALGO models (see 
Figure 5-2B) and are expressed as -1 times the log of the p-value. The black vertical line 
represents the probability threshold at P=0.05. The orange line represents the ratio of the 
number of GALGO model genes in a particular pathway divided by the total number of genes 
that make up that pathway. 
 
5.3.3 Association of SNP score and ΔTG 
The SNP score was created by combining the four top SNPs from the GWAS analysis 
(rs222158, rs2722171, rs1906058, rs2593324) and the four top SNPs from the targeted SNP 
analysis of the RNA-predictor genes (rs1043968, rs3793336, rs594461, rs11646610). The SNP 
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score values ranged from 2 to 12 in HERITAGE Whites. The adjusted mean decrease in TG in 
subjects with 11 or 12 favorable alleles (N=18) was -18.2 mg/dL (-0.21 mmol/L), while those 
with 4 or less favorable alleles (N=284) experienced an adjusted mean increase of 38.1 mg/dL 
(0.43 mmol/L) after exercise training (Figure 5-6). 
 
	  
Figure 5-6 | Adjusted mean ΔTG across eight SNP summary score categories in 
HERITAGE Whites. 
Values were adjusted for age, sex, baseline BMI, and baseline triglyceride level. Number of 
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5.4 Discussion 
	  
The present work highlights that selected genes and common SNP variants are associated 
to the pronounced interindividual training-induced variation in serum TG levels. A novel 
finding is that an 11-gene muscle-derived molecular signature predicted 27% of TG 
exercise response in HERITAGE; importantly I was able to validate the response 
predictor model an independent training cohort. 
The result of the SNP-derived summary score showcases how parsimonious panels of 
candidate SNPs from multiple omics platforms potentially can be used as a priori 
predictors of phenotype response. 
 
Pathway-based analysis of the SNP data highlighted that the genetic effect of TG 
response to regular exercise may be exerted through specific biological pathways related 
to heparan sulfate glycosaminoglycan and glycosphingolipid biosynthesis and cell 
adhesion molecules (see Appendix 7.7). 
Heparan sulfate has several biological functions, including cell adhesion and notably cell 
surface binding of lipoprotein lipase (LPL). As such, several studies have shown that 
heperan sulfate glycosaminoglycan modified proteoglycans act in the hydrolysis of 
triglyceride-rich lipoproteins [239].	   In HERITAGE, LPL activity significantly increased 
with exercise training, concomitant with decreases in TG levels (r= -0.21, P<0.001). 
Glycosphingolipids mediate and modulate intercellular coordination in multicellular 
organisms [240]. Glycosphingolipids cluster in lipid rafts, which are enriched in 
cholesterol and sphingolipids such as sphingomyelin. Lipid rafts are involved in many 
cellular processes, including membrane sorting and trafficking, cell polarization, and 
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signal transduction processes. As such, the specialized structure of lipid rafts may play a 
critical role in the trafficking of lipids between lipoproteins and cells. However, it is 
unknown how exercise affects lipid rafts and glycosphingolipids.  
  Pathway-based analysis of the transcriptomic predictor models revealed that 
mitochondrial dysfunction and oxidative phosphorylation pathways were enriched in 
relation to TG response to exercise training. Mitochondrial dysfunction has been linked 
to fat storage abnormalities, including accumulation of TG in various tissues such as 
muscle and adipose. Additionally, defects in mitochondrial oxidation and 
phosphorylation are associated with insulin resistance, Type II diabetes, and ectopic TG 
accumulation (e.g., intramyocellular and intrahepatic lipids), among others. Exercise is 
known to improve insulin sensitivity and risk of diabetes, while the effects of exercise on 
intramyocellular and intrahepatic lipids are less clear.	   
In summary, our bioinformatics analysis suggests that different subsets of pathways 
are enriched when variants from genomic and transcriptomic data are interrogated for 
their association with TG response to exercise. These analyses inform on the potential 
mechanisms involved in TG changes with regular exercise, with the transcriptomics data 
possibly representing muscle-specific mechanisms. 
 This study is the first to test systematically whether the TG GWAS loci identified 
from the most recent meta-analysis	  modify the response of TG to regular exercise. We 
did not find any associations between the SNPs associated with TG GWAS loci and the 
response of TG to regular exercise. Thus, our results suggest that the genes most 
important in modifying changes in TG in response to regular exercise are likely different 
from the loci contributing to variation in population TG levels. It is not clear how many 
	  
	   164	  
of the markers and genes identified here are functionally related to the response to regular 
exercise of TG, but, if confirmed in independent studies, they could inform the biology of 
plasma TG and their adaptation to regular exercise. Given the estimated effect sizes 
observed in HERITAGE Whites, some of these genomic regions deserve further 
investigation, such as GLT8D2.  
5.4.1 Study limitations 
This study is based on a relatively small sample size compared to commonly accepted 
standards of GWAS. Thus, it is not surprising that we did not find SNPs reaching 
genome-wide significance. However, it is important to appreciate that human 
experimental studies are by definition characterized by much smaller sample sizes than 
epidemiological and observational studies, but are also less likely to be negatively 
impacted by any number of uncontrolled confounders. HERITAGE remains the largest 
fully controlled exercise intervention study thus far. The family structure and well-
defined and twice-measured phenotypes in HERITAGE help to minimize the influence of 
confounding factors. Moreover, since one component of the environment (i.e., exercise) 
has been rigorously controlled in HERITAGE, we had predicted larger effect sizes than is 
commonly seen in observational studies. Thus, we concluded that it would be useful to 
undertake hypothesis-free and unbiased GWAS explorations for the response of TG to 
regular exercise, as it could generate hypotheses and candidate genes deserving further 
research. Furthermore, our global microarray data from a subset of HERITAGE 
participants complements our GWAS results and provides a separate unbiased 
exploration of the genes involved in TG exercise response. We acknowledge that there is 
still a possibility of false discovery and that the parsimonious SNP score associated with 
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ΔTG in HERITAGE is likely to overfit our data, possibly resulting in biased conclusions 
about the strength of the findings. Therefore, there is an obvious need to replicate our 
results in other samples and studies.	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6 Concluding Remarks and Research Perspective. 
 
There are clearly many types of data in a complex biological system that one could 
choose to quantitate in order to generate a biomarker (signature); ideally of clinical 
relevance. 
I personally believe that alterations in RNA abundance currently are more tightly linked 
to true biological variation as compared to DNA or tissue-based proteomics approaches. 
For example, protein abundance (the readout of most proteomic technologies) is often a 
poor surrogate for genuine protein activity due to the many post-translational 
modifications, effecting its location⎯and thereby function⎯within the 
compartmentalized eukaryotic cell [241]. Proteomics technology also suffers from the 
inability to detect accurately low-abundance proteins [242]. 
In further support of my (admittedly controversial) claim, commercially available 
personal genetic screening tests are currently too imprecise, highlighted by the recent ban 
of 23andMe company products (www.23andMe.com) by the US Food and Drug 
Administration (FDA).  
 
In support of RNA as a good class of molecules for developing personalized medicine: 
using omics technologies, particular gene expression microarrays, there have been 
advances in predicting therapeutic outcomes ⎯ especially in the field of cancer 
chemotherapy [243–246]. This success is in part based on the clear-cut genetic 
aberrations that can drive tumor growth and aggression. So for example, a given tumor 
may lose a piece of genomic DNA, producing an unambiguous loss of gene expression in 
the gene-chip profile for those genes located in the lost DNA region [247]. 
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In the field of metabolic traits/cardiovascular diseases, it is understood that phenotypes 
are much more complex (i.e. polygenic); thus ‘single-gene’ DNA analyses will most 
likely not, alone, be sufficient to predict susceptibility or treatment responsiveness. In 
addition, variation in gene expression can be very subtle [24]⎯yet consistent⎯and 
therefore multiple gene markers are needed to provide a more robust diagnostics. 
 
While altered physiological status and altered protein-coding sequence feedback to 
impact on mRNA abundance, it is certainly also very likely that DNA sequence and 
epigenetic modifications contribute to this process. Hence it is obvious to conclude that 
the more of the biological system that is measured (ideally on a global scale) the easier it 
will be to discern important intracellular pathways etc [248]. In Chapter 4, I took 
advantage of this concept by combining genomic and transcriptomic data to develop the 
first RNA signature that can predict whether an individual has a high or low potential for 
improving whole-body insulin sensitivity. 
 
As highlighted in the Introduction of this thesis, NGS technology is able to provide the 
customer with a lot more quantitative information including splice variants, DNA 
sequence variations (e.g. SNPs) as well as non-protein coding RNA species (e.g. 
microRNAs and long-non-coding RNAs). 
More and more evidence indicates that microRNAs can regulate mRNA stability in cells, 
thus ultimately affecting gene product abundance [249, 250]. In vivo in humans, however, 
it would appear that microRNAs may impact on protein synthesis rather than mRNA 
stability [251]. Irrespective of the mechanism of action, non-coding RNA species 
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represent yet another level of biological variance. Capturing microRNA expression 
profiles AND integrating them with mRNA profiles should, in theory, allow for the 
development of more complex statistical models of human metabolic physiology. 
Certainly, as the cost continues to decrease, NGS will be used more and more in clinical 
research as a tool for complex biomarker discovery. 
 
Currently, several EU-funded projects are focusing on the development of personalized 
medicine. In the context of human skeletal muscle biology, the multi-center EU FP7 
funded project ‘Metapredict’ (www.metapredict.eu) is aiming to develop robust 
predictors for the personalized clinical response to exercise training. Core to the success 
of this project is the integration of sufficient multi-level omics data (hence the multi-
center nature of the project) [225] ⎯ with exon array profiling being a vital component!  
 
Epigenetic modifications to DNA bases also convey important biological 
information. For example, as pointed out by Zierath et al. in a recent perspective in Cell 
Metabolism, the interplay between genes and environment may alter our epigenome, 
which ultimately could impact on health [225]. As NGS depend on PCR amplification, 
all epigenetic information is lost during sequencing (i.e. both 5-methylcytosine and 5-
hydroxymethylcytosine are treated as cytosine by the enzymes involved in PCR). 
Hence, in the more distant future, targeted DNA sequencing and epigenetic modification 
profiling using ‘third’ generation sequencing technology platforms may likely become 
clinically applicable. Currently, the Pacific Biosciences third generation sequencing 
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system for example allows for the identification of >20 different types of DNA 
modifications directly without any chemical or enzymatic reactions. 
However, besides the creation of a multi-layered expression map on the systems level, 
sample size is obviously a very important aspect when developing robust predictors of 
complex phenotypes. Hence, further research is needed to replicate and further test the 
RNA-based signatures that I have presented in Chapters 4 and 5 in independent studies 
and other populations and exercise programs. 
Further, the people behind the HEIRTAGE study are currently doing metabolomics 
profiling. Hence, by integrating this additional layer of information in the analysis 
framework put forward in Chapter 4, we might come up with new and improved 
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7 Appendices 
	  
7.1 RNA sequencing analysis and the development of a guinea pig microarray 
platform 
	  
1.0	  Developing	  the	  Guinea	  Pig	  transcriptome	  
Although GP is a model species, at the time of writing there were only 464 genes found 
in the Reference sequence project database. To better understanding the transcriptional 
response of GP in response to smoking, a high coverage transcriptome was constructed 
using novel RNAseq data derived from lung and skeletal muscle tissues. This was 
combined with public domain data, Ensembl cDNAs and Genscan gene predictions. The 
transcript assembly was used to make a comprehensive custom GP microarray for 
hypoxia and smoking analysis. 
 
1.1	  RNAseq	  transcriptome	  assembly	  
There is a genome sequence available for GP 
(http://www.ensemble.org/Cavia_procellus/Info/Index) and this was used in conjunction 
with the TopHat [162, 252] and Cufflinks algorithms [163] to assemble transcripts based 
on genome alignments from the RNAseq data. The first stage was to align reads to the 
genome with TopHat, which requires the insert size of the RNAseq fragments to be 
known prior to mapping. This was determined using the SMALT alignment tool with the 
sampling option [253], aligning reads to publicly available transcript data. Table 1 lists 
the number of reads for each tissue and a summary of the fragment size distributions, 
which were verified using the final assembly. 
 
Table	  1	  |	  Number	  of	  RNAseq	  reads	  and	  fragment	  sizes	  






Fragment size Fragment size 
standard deviation 
Muscle 113,438,469 101 173 104 
Lung 56,466,360 101 169 92 
 
TopHat v1.3.3 was then used to align the paired-end reads of lung and muscle to the 
Cavia_porcellus.cavPor3.64 genome assembly, executed with the following options: 
insert size, closure-search, butterfly-search and coverage-search. The resulting TopHat 
genome binary alignment files were separately inputted to Cufflinks v1.1.0 to assemble 
tissue specific transcriptomes. The multiple read correction, upper quartile normalization 
and fragment bias correction options were used. Lung and muscle transcriptomes were 
subsequently combined using the cuffcompare algorithm, which produced an RNAseq 
transcriptome consisting of 81,074 sequences. A control step was performed to ensure 
that maximum transcriptome coverage was attained. Unique exon positions from the 
cufflinks assembly GTF files were extracted and compared to the cuffcompare output. A 
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number of sequences were not included in the cuffcompare output and these were added 
into the assembly. 
 
1.2	  Combining	  RNAseq	  and	  public	  data	  
A search on the NCBI Entrez system for the species Cavia porcellus, found 19,975 
sequences [254]. The Cap3 software program [255] was used to cluster these public 
domain sequences and 1,762 contigs and 9,569 singletons were obtained. Added to these 
were the Ensembl GP cDNA and non-coding RNA sequences, from the download files 
Cavia_porcellus.cavPor3.64.cdna.all and Cavia_porcellus.cavPor3.64.ncrna.fa [256]. 
Finally, Ensembl Genscan predictions [257] were downloaded and compared to the 
RNAseq and public data with BLAST [258]. Any Genscan prediction with <= 99% 
coverage was added into the assembly. The final transcriptome to be used in array design 
consisted of 151,072 transcripts. Table 2 presents a breakdown of the different sources of 
transcripts. 
 
Table	  2	  |	  a	  numerical	  breakdown	  of	  all	  the	  sequences	  





RNAseq data Cufflinks cuffcompare assembled 
transcriptome sequences from GP lung 









a set of transcript sequences based on 












Ensembl abinitio Genscan gene 
predictions based on genome 
alignments 
53,615 30,667 
NCBI data Public GP gene, mRNA and EST 
sequences, clustered with Cap3 
19,975 11,331 
 
1.3.	  New	  transcriptome	  statistics	  and	  annotation	  
A bullet point summary of the transcriptome statistics is provided below. This is an initial 
transcriptome that was used to design a custom 180K Agilent microarray. An N50 
statistic provides a base pair sequence length (a weighted median value) where 50% of 
the entire transcriptome sequences are contained within this value, with lengths equal or 
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greater than this value (www.broadinstitute.org/crd/wiki/index.php/N50). The N50 of the 
full transcript assembly was 3.2Kb.  
• Total transcripts = 151,072 
• Longest transcript = 53,613bp 
• Shortest transcript = 36bp 
• N50 statistic = 3,247bp 
• N90 statistic = 902bp 
• Mean size = 1,894bp 
Annotation of the full transcriptome prior to selection of microarray probes was 
performed using a BLAST search against the mouse Reference sequence project 
databases (Refseq) [259]. The number of transcripts annotated with a Refseq sequence 
were 97,822, consisting of 17,907 non-redundant mouse gene symbols. For the final 60K 
Agilent microarray design, a re-annotation was carried out due to the delay between full 
annotation and publication. This was done for the 86,044 transcripts that were 
represented on the final array, and the Refseq mouse data used was of August 2013. From 
the 80,044 transcripts of clusters that were mapped to the final array, 40,625 of them 
were annotated with a mouse gene. In terms of probes, 18,072 of the 60,984 probes on 
the final array were annotated with a mouse gene. This represents 17,676 non-redundant 
mouse genes. The Refseq mouse annotation of both the full transcriptome and the final 
array are accessible online: 
http://pcwww.liv.ac.uk/~herberjm/Davidson_et_al/Additional_file6.zip 
(“Davidsen_et_al_Refseq_annotation.xlsx”). Note that 235 probes match transcript 
clusters that hit more than one mouse gene (the probes matched all transcripts in a cluster 
but different transcripts of the cluster matched multiple mouse genes). These are 
highlighted in red in the “ProbeAnnotation” sheet of the file 
Davidsen_et_al_Refseq_annotation.xlsx (also accessible online5).  
 
1.4.	  Viewing	  of	  transcripts	  and	  probes	  in	  the	  Guinea	  pig	  genome	  
A genome overview of both the GP transcripts and microarray probes (see below for 
details on the development for the development of the microarray platform) has been 
provided and can be viewed via the University of California Santa Cruz genome browser 
[260, 261]. This can be done by visiting the GP genome browser page at 
http://genome.ucsc.edu/cgi-bin/hgTracks?db=cavPor3 and uploading the custom track 
file (Davidsen_et_al_UCSC_genome_browser_custom_tracks.txt) provided in the 
online supporting material1. Figure 1 shows an overview of the TMEM64 ortholog gene, 
with new transcripts displayed in red, and microarray probes in green (the top two 
tracks).  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5	  Supporting material is accessible online at 
http://pcwww.liv.ac.uk/~herberjm/Davidson_et_al/Additional_file6.zip 
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1.5.	  Differential	  gene	  expression	  and	  a	  Gene	  Set	  Enrichment	  Analysis	  of	  the	  
RNAseq	  data	  
Single samples of lung and muscle were subject to RNAseq analysis to identify genes 
that distinguish between these two tissues. Because of the lack of biological replicates, 
transcript expression was contrasted using log2 fold change between lung and muscle. To 
derive the fold change, the level of expression was measured using the Fragments Per 
Kilobase of exon model, per Million fragments mapped (FPKM) to the genome, which is 
the metric calculated by the Cuffdiff program, from the Cufflinks package. This 
expression is based on genome alignments of RNAseq reads. For a comparison, 
expression was also measured using the eXpress package [262], which measures Reads 
Per Kilobase of exon model, per Million reads mapped. eXpress measures levels of reads 
mapping to the transcriptome and accounts for variation in fragment length distributions, 
read errors and fragment bias. The log2 fold change measurements were used to make 
two ranked list of genes. The correlation of log2 fold changes between the two methods 
of measuring RNAseq expression was 0.8. Transcripts were assigned mouse gene 
symbols based on similarity searching with BLAST.   
A Gene Set Enrichment Analysis (GSEA) was carried out using the Broad Institutes 
command line java tool [84, 263]. This analysis was done using two genesets from the 
Molecular Signatures Database representing KEGG pathways [128, 264] and Gene 
Ontology biological processes [265]. The human orthologs of the mouse gene annotation 
was derived from Homologene [266]. For both KEGG and GO biological process, 
significant enrichment scores were found. Table 3a and Table 3b display the most 
enriched ontologies and pathways for lung and muscle RNAseq data. Figure 2 overviews 
examples of the enrichment within the ranked lists, with lung enrichment on the left hand 
panels and muscle on the right. The results of the GSEA for both gene ontology and 
KEGG suggest that the muscle sample is enriched for muscle related processes such as 
muscle respiration, metabolism and contraction. Biological relevance is also found in 
lung enrichments, showing evidence of immune response, defence and inflammation 
reactions. 
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Table	  3A	  |	  Gene	  Set	  Enrichment	  Analysis	  of	  the	  RNAseq	  data	  (KEGG)	  






REACTOME_COMPLEMENT_CASCADE 0.84 0 lung 
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING 0.81 0 lung 
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOK
INES 
0.8 0 lung 
KEGG_GRAFT_VERSUS_HOST_DISEASE 0.79 0 lung 
KEGG_AUTOIMMUNE_THYROID_DISEASE 0.78 0 lung 
KEGG_ALLOGRAFT_REJECTION 0.78 0 lung 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADE
S 
0.75 0 lung 
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUB
STRATE_TYPE 




0.7 0 lung 
REACTOME_INTERFERON_GAMMA_SIGNALING 0.7 0 lung 
    
REACTOME_CITRIC_ACID_CYCLE_TCA_CYCLE -0.94 0 muscle 
KEGG_CITRATE_CYCLE_TCA_CYCLE -0.9 0 muscle 




-0.88 0 muscle 
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTR
ON_TRANSPORT 
-0.86 0 muscle 
REACTOME_MUSCLE_CONTRACTION -0.83 0 muscle 
REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_A
CID_TCA_CYCLE 
-0.83 0 muscle 
KEGG_PARKINSONS_DISEASE -0.81 0 muscle 
KEGG_OXIDATIVE_PHOSPHORYLATION -0.8 0 muscle 














Table	  3B	  |	  Gene	  Set	  Enrichment	  Analysis	  of	  the	  RNAseq	  data	  (GO, biological 
process) 




CALCIUM_INDEPENDENT_CELL_CELL_ADHESION 0.78 0 lung 
DEFENSE_RESPONSE_TO_BACTERIUM 0.71 0 lung 
RESPONSE_TO_BACTERIUM 0.7 0 lung 
REGULATION_OF_T_CELL_ACTIVATION 0.67 0 lung 
LOCOMOTORY_BEHAVIOR 0.66 0 lung 
CELLULAR_DEFENSE_RESPONSE 0.64 0 lung 
T_CELL_ACTIVATION 0.64 0 lung 
RESPONSE_TO_VIRUS 0.62 0 lung 
RESPONSE_TO_OTHER_ORGANISM 0.6 0 lung 
CELL_ACTIVATION 0.6 0 lung 
LEUKOCYTE_ACTIVATION 0.6 0 lung 
DEFENSE_RESPONSE 0.58 0 lung 
INFLAMMATORY_RESPONSE 0.58 0 lung 
LYMPHOCYTE_ACTIVATION 0.58 0 lung 
    
CELLULAR_RESPIRATION -0.88 0 muscle 
AEROBIC_RESPIRATION -0.88 0 muscle 
ENERGY_DERIVATION_BY_OXIDATION_OF_ORGANIC_COMPOUNDS -0.83 0 muscle 
REGULATION_OF_MUSCLE_CONTRACTION -0.79 0 muscle 
FATTY_ACID_OXIDATION -0.75 0.003 muscle 
ENERGY_RESERVE_METABOLIC_PROCESS -0.73 0.023 muscle 
GENERATION_OF_PRECURSOR_METABOLITES_AND_ENERGY -0.66 0 muscle 
SKELETAL_MUSCLE_DEVELOPMENT -0.66 0.006 muscle 
MITOCHONDRIAL_TRANSPORT -0.66 0.03 muscle 
REGULATION_OF_HEART_CONTRACTION -0.64 0.029 muscle 
MUSCLE_DEVELOPMENT -0.61 0 muscle 
STRIATED_MUSCLE_DEVELOPMENT -0.6 0.019 muscle 
GLUCOSE_METABOLIC_PROCESS -0.59 0.06 muscle 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS -0.57 0.027 muscle 
ELECTRON_TRANSPORT_GO_0006118 -0.56 0.027 muscle 
CELLULAR_PROTEIN_CATABOLIC_PROCESS -0.52 0.053 muscle 
PROTEIN_CATABOLIC_PROCESS -0.5 0.054 muscle 
CELLULAR_CARBOHYDRATE_METABOLIC_PROCESS -0.47 0.05 muscle 
CELLULAR_CATABOLIC_PROCESS -0.45 0.05 muscle 
CATABOLIC_PROCESS -0.45 0.051 muscle 
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1.6.	  Grouping	  of	  transcripts	  and	  evidence	  of	  novel	  transcript/gene	  discovery	  
An investigation into transcript redundancy, potential isoforms and if the RNAseq data 
provides new data was carried out. There is evidence that the February 2008 Cavia 
porcellus draft assembly (Broad Institute cavPor3) contains duplicated regions of 
chromosomes on different scaffolds. This is shown by the fact that some transcripts map 
to multiple scaffolds with exactly the same high quality alignment statistics. This seems 
biologically unlikely, as some polymorphism differences would be expected between 
genuine paralogs. One example is the transcript lung_muscle_trans_00000002 that maps 
to 13 different scaffolds with 100% identity, over the full length of the 943 base pair 
sequence. This sequence does not span a known repeat. This provides good evidence of 
redundancy within the genome assembled transcriptome. The full assembly contained 
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151,072 transcripts and a subset of 86,044 was used in the design of 60,984 probes for 
the final custom 60K Agilent microarray. The full transcriptome sequences 
(Davidsen_et_al_full_transcriptome.txt) are accessible in the online material: 
http://pcwww.liv.ac.uk/~herberjm/Davidson_et_al/Additional_file6.zip.  
To find potential isoforms of the same gene and to reduce redundancy within the 
transcriptome, two approaches were taken;  
1) Uclust from the Usearch algorithm was used to cluster sequences in a de-novo process 
[267]. This resulted in a set of 93,902 non-redundant transcripts, which represent the 
centroid sequence of clusters and any singletons. This was performed using a 90% 
identity threshold. A set of non-redundant sequences can be found in the online file 
Daviden_et_al_uclust_sequences.txt and the online file 
Davidsen_et_al_Uclust_Bedtools_domains_genes.xlsx contains sequence identifiers of 
clusters6. 
2) Potential isoform groups were attained by genome position, by utilizing the BEDTools 
[268] cluster algorithm that assigns overlapping transcripts in the genome to locus 
clusters. The resulting clusters and the transcripts they contain can also be found in the 
online supporting material as “Davidsen_et_al_Uclust_Bedtools_domains_genes.xlsx”.  
From the BEDTools loci, there is evidence that the RNAseq data has identified novel 
genes or transcripts. From the 33,797 total distinct loci, the numbers of potential novel 
loci are as follows;  
• Total no. of BEDTools cluster loci = 33,797 
• No. of loci that contain an Ensembl cDNA = 16,392 
• No. of loci that contained either an Ensembl cDNA or a Genscan prediction = 
27,374 
• No. of loci that contained purely public EST and/or mRNA data = 686 
• No. of potential novel loci originating from the RNAseq data (if it contained at 
least one RNAseq data transcript but no Ensembl cDNAs) = 7,685 
• No. of potential novel loci originating from the RNAseq data (i.e. it contained at 
least one RNAseq transcript and no Ensembl cDNAs or Genscan gene 
predictions) = 5,737 
This provides evidence that the RNA 2nd generation sequencing data has produced a more 
comprehensive GP transcriptome when compared to Ensembl cDNAs and Genscan 
predictions. This has enabled a more robust investigation into the effects of smoking 
using this model. A set of 5,737 novel transcript loci were found and are labelled as 
“RNAseq_Novel” in the BEDTools file 
(Davidsen_et_al_Uclust_Bedtools_domains_genes.xlsx) available online. 
 
1.7	  Novel	  functional	  domains	  added	  to	  the	  transcriptome	  
Further evidence for RNAseq novelty was found using a comparison of functional 
domain content between the RNAseq transcriptome data and Ensembl cDNA sequences. 
This was performed using the Hmmer package [269] with the Pfam protein families 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6	  Supporting material is accessible online at 
http://pcwww.liv.ac.uk/~herberjm/Davidson_et_al/Additional_file6.zip 
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database A [270]. Initially, open reading frames from all six translation frames of each 
sequence was derived using the Sixpack tool of EMBOSS, lifted from the Iprscan suite 
[271, 272]. An expectation value of 1e-6 threshold was employed running hmmsearch. 
There were 26,129 Ensembl cDNA transcripts in the cavPor3.64 genome, which 
consisted of 5,397 non-redundant Pfam A functional domains. In contrast, the number of 
transcripts built from the RNAseq data alone was 82,945 and these transcripts contained 
5,478 distinct functional domains. This showed 81 potentially new functional domains as 
compared to the public data. However, the RNAseq data was derived from two distinct 
tissues of lung and muscle and some transcripts within the Ensembl cDNA data could be 
preferentially expressed in other tissues. This was evident when intersect and specific 
domain frequencies were taken. The number of domains specific to Ensembl cDNAs was 
38 and 119 were specific to RNAseq data, with an intersect count of 5,359. A union total 
number of domains were 5,516 and all domains and classes can be viewed in the 
Domains sheet in Davidsen_et_al_Uclust_Bedtools_domains_genes.xlsx available 
online7. 
 
1.8	  New	  representations	  of	  mouse	  orthologs	  from	  RNAseq	  transcripts	  
From the full transcriptome, prior to custom array design, transcripts were assigned 
mouse orthologs using blastx. 19,867 of 26,129 Ensembl cDNAs were assigned a mouse 
ortholog and this amounted to 16,537 distinct mouse genes. In comparison, from the 
82,945 RNAseq derived transcripts, 52,513 were assigned a mouse ortholog and the 
number of non-redundant mouse genes was 17,347.  The union, intersect and specific 
frequencies were as follows: 
• Total mouse orthologs (union) of Ensembl cDNA and RNAseq data = 17,441 
• Ensembl cDNA specific mouse orthologs = 94 
• RNAseq specific mouse orthologs = 904 
• Intersection between Ensembl cDNA and RNAseq mouse orthologs = 16,443 
From this analysis, 904 potential new GP genes were found due to RNAseq sequencing. 
The actual gene symbols for each of the classes can be seen in the 
“MouseOrthologs_RNAseq_v_Ensembl” sheet in the Excel file 
Davidsen_et_al_Uclust_Bedtools_domains_genes.xlsx available in the online 
supporting material. 
 
2.0 Development of a 60K Custom Microarray Design  
A total of 116,623 60-mer oligonucleotide probes were designed from the 151,072 
transcript sequences summarised in Table 2 using the Agilent eArray software. These 
were used to design an initial 180K custom Agilent microarray in order to test the 
performance of this large set of capture probes. Pooled mRNA from GP lung and muscle 
samples (see Method section) were hybridised to these arrays. 
The selection of probes for the final 60K array design was based on an assessment of the 
reliability of each probe compared to the sequence read counts in both tissues of interest. 
This was performed using a two-step process. For each tissue, sequencing read counts 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7	  Supporting	  material	  is	  accessible	  online	  at	  
http://pcwww.liv.ac.uk/~herberjm/Davidson_et_al/Additional_file6.zip	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(reads per kilobase of transcripts per million (RPKM) transformed) and microarray probe 
intensities were LOESS normalised to generate a ratio representing the relative difference 
in signal intensity between both platform technologies. The ratios for each probe in lung 
& muscle were then compared by fitting a linear model (lm, R software), and the residual 
for each probe was calculated. The residuals represent an overall measure of the probe 
reliability when compared in both tissues, regardless of signal intensity. This approach 
assumes that the relationship between sequence counts and probe intensity is not 
proportional. Probes with similar differences between signal intensity and read counts in 
lung and muscle, even if this difference is relatively large, were still able to detect 
relative changes in mRNA concentrations between experimental groups. For each gene 
symbol mapped to the sequencing data, the selection of a probe to include on the final 
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7.3 ANALYSIS OF SKELETAL MUSCLE TRANSCRIPTIONAL RESPONSE 
IN A MOUSE SMOKING MODEL 
 
SUMMARY 
In order to assess whether the extrapulmonary transcriptional response observed in 
guinea pigs exposed to smoking was conserved in the popular mouse smoking model, we 
analysed a publicly available microarray dataset representing the temporal transcriptional 
changes in the gastrocnemius muscle of nose-only CS or clean air (sham controls) 




In brief, 4 month old female C57/BL6 mice received nose-only exposure of 4% 
mainstream CS or clean air for 2 hours/day, 5 days a week for 2 (n=6), 12 (n=6) or 24 
(n=6) weeks, respectively. Twenty hours following the final smoke/air exposure, mice 
were anesthetized with isoflurane, exsanguinated by cardiac puncture, and the 
gastrocnemius muscle was collected. For more information on RNA isolation as well as 
the labelling and hybridization protocols, see GEO accession: GSE18033.  
 
Data processing and Analysis 
Data processing of the raw Affymetrix CEL files was undertaken using Bioconductor in 
R. The arrayMvout package in R [273], which is based on dimension reduction of diverse 
established quality metrics, identified 8 of the 38 arrays relevant for the cross-species 
comparison as technical outliers at a nominal outlier flagging rate of α = 0.05 
(GSM450983, GSM450998, GSM451003, GSM451006, GSM451012, GSM451013, 
GSM451014, GSM451018). Hence, these eight samples were removed prior to RMA 
normalization (‘affy’ R package). Microarray data were then de-noised by removing 
probes for which 75% or more of the samples were flagged as ‘absent’ by the MAS5 
algorithm (13,051 probes removed). 
 
RESULTS 
Transcriptional regulation in response to prolonged CS exposure can only be 
detected at a high False Discovery Rate threshold 
In order to assess if exposure to long-term CS induced a significant transcriptional 
response, we set to identify differentially expressed genes. In order to identify genes 
linked to both time and experimental intervention (i.e. CS versus sham controls) we used 
a two-factor ANOVA (Table 1). While we could identify thousands of genes changing 
across time, only 14 genes were differentially expressed between shams and CS-exposed 
mice at a standard FDR cut-off (FDR<15%) (Table 1). By increasing the cut-off to 
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FDR<30% we could identify 303 modulated transcripts. These were subdivided in 129 
and 174 genes up- and down-regulated, respectively, based on hierarchical clustering 
(Figure 2). We then  performed a functional enrichment analysis on these 303 genes 
using the web based tool DAVID [274]. 
 
Factor: 5% FDR 15% FDR 30% FDR 
Group 5 14 303 
Time 1,774 3,769 6,217 
Interaction 0 14 375 
	  
Table 1. Number of differentially expressed genes at various 
statistically thresholds identified via a two-way ANOVA in R. 
 
	  
Figure 2. Heatmap of the 303 genes that are differentially expressed between shams 
and smoke-exposed mice at a FDR < 30%. Clustering on the genes clearly identified 
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Functional enrichment analysis of the up- and down-regulated genes, respectively, 
highlighted several statistically significantly (FDR<10%) enriched ontological processes 
of biological relevance (Table 2). 
 
 
GO terms Number of genes FDR 
Down-regulated genes (Cluster A)   
GO:0006935~chemotaxis 6 4.49 
GO:0016331~morphogenesis of 
embryonic epithelium 5 7.88 
GO:0008283~cell proliferation 8 9.98 
   
Up-regulated genes (Cluster B)   
GO:0044257~cellular protein catabolic 
process 12 0.24 
GO:0007167~enzyme linked receptor 
protein signalling pathway 7 5.61 
GO:0000165~MAPKKK cascade 4 31.07 
   
	  
Table 2. Biological processes enriched in genes modulated by the ANOVA Group factor 
(FDR<30%) within each of the two main gene clusters. 
 
We then decided to analyse each time point (i.e. week 2, 12 and 24 after first exposure to 
CS) separately using SAM analysis [166]  (Table 3). This analysis only identified 24 
genes as being differentially expressed at a reasonable FDR cut-off (FDR<15%) 
following daily CS exposure for 24 weeks. Only by increasing the statistical cut-off to 
30%, which yielded 1,020 regulated transcripts (Table 3), could we detect functional 
enrichment using the web-based tool DAVID (Table 4). Notable, both 2 and 12 weeks of 
exposure, respectively, did not cause any transcriptional changes in the mouse limb 
muscle (FDR<15%). For the cross-species functional comparison (see Figure 4 in 
manuscript) we relied on the SAM analysis (Table 3) using a FDR cut-off of 30%. 
 
Duration: 5% FDR 15% FDR 30% FDR 
2 weeks 0 0 5 
12 weeks 0 0 4 
24 weeks 0 24 (21 ↑) 1020 (300 ↑) 
 
Table 3.  Number of differentially expressed genes identified by a two-class unpaired 
SAM analysis. The number inside the parenthesis indicates how many genes were up-
regulated by cigarette smoking. 
	  










Down-regulated genes    
Jak-STAT signalling 10 0.05 42% 
TGF-beta signalling 7 0.05 47% 
Insulin signalling 8 0.14 82% 
VEGF signalling 6 0.09 65% 
Phosphatidylinositol signalling 7 0.03 28% 
Acute myeloid leukemia 5 0.10 71% 
Endometrial cancer 5 0.08 61% 
Neurotrophin signalling 8 0.11 74% 
Glycerophospholipid metabolism 5 0.15 86% 
    
Table 4.  Selected KEGG pathways that are enriched among the differentially expressed 
genes at week 24 of CS-exposure (FDR<30%). 
 
CONCLUSIONS 
We conclude that the gastrocnemius muscle of C57 mice exposed to long-term CS (up to 
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7.4 Pre-ranked GSEA using transcription factor targets 
	  
Positive	  end	  of	  ranked	  gene	  list	  (top	  60	  gene	  sets	  shown)	  
	  






Negative	  end	  of	  ranked	  gene	  list	  (top	  60	  gene	  sets	  shown)	  
	  




7.5 MEF2A interacting targets as defined in the STRING database (confidence 
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7.6 List of GWAS SNPs associated with serum triglyceride response to exercise 
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7.7 Result of pathway-based analysis of GWAS associations 
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GSEA report for top 20 gene sets with negative enrichment scores for ΔTG using 2nd-
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